



EMORY UNIVERSITY AND ITS SUBSIDIARIES

Independent Auditors' Reports as Required by the Uniform
Guidance and State of Georgia and Related Information

Year Ended August 31, 2024

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Table of Contents

	Page
Independent Auditors' Report	1
Consolidated Financial Statements – Years ended August 31, 2024 and 2023	3
Notes to Consolidated Financial Statements	8
Independent Auditors' Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With <i>Government Auditing Standards</i>	42
Supplementary Schedules	
Supplementary Schedule of Expenditures of Federal Awards	44
Supplementary Schedule of Cash Receipts and Expenditures of State of Georgia Awards	96
Notes to Supplementary Schedules of Expenditures of Federal Awards and Cash Receipts and Expenditures of State of Georgia Awards	97
Uniform Guidance Reports	
Independent Auditors' Report on Compliance for Each Major Federal Program; Report on Internal Control Over Compliance; and Report on Supplementary Schedules of Expenditures of Federal Awards Required by the Uniform Guidance and Cash Receipts and Expenditures of State of Georgia Awards	100
Schedule of Findings and Questioned Costs	103



KPMG LLP
Suite 2000
303 Peachtree Street, N.E.
Atlanta, GA 30308-3210

Independent Auditors' Report

The Board of Trustees
Emory University:

Report on the Audit of the Consolidated Financial Statements

Opinion

We have audited the consolidated financial statements of Emory University and its subsidiaries (the University) which comprise the consolidated statements of financial position as of August 31, 2024 and 2023, and the related consolidated statements of activities, and cash flows for the years then ended, and the related notes to the consolidated financial statements. In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the University as of August 31, 2024 and 2023, and the changes in its net assets and its cash flows for the years then ended in accordance with U.S. generally accepted accounting principles.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America (GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are required to be independent of the University and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with U.S. generally accepted accounting principles, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the University's ability to continue as a going concern for one year after the date the consolidated financial statements are issued.

Auditors' Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the consolidated financial statements.



In performing an audit in accordance with GAAS and *Government Auditing Standards*, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the University's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the consolidated financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the University's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated December 18, 2024 on our consideration of the University's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the University's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the University's internal control over financial reporting and compliance.

KPMG LLP

Atlanta, Georgia
December 18, 2024

EMORY UNIVERSITY

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

AUGUST 31, 2024 AND 2023 (Dollars in thousands)

	August 31, 2024	August 31, 2023
ASSETS:		
Cash and cash equivalents	\$ 845,459	\$ 779,690
Patient accounts receivable, net	769,299	709,009
Student accounts receivable, net	19,886	20,466
Loans receivable, net	14,524	15,143
Contributions receivable, net	150,498	178,701
Other receivables, net	389,184	338,762
Prepaid expenses, deferred charges, and other assets	517,116	428,498
Investments	11,678,888	11,093,857
Interests in perpetual funds held by others	2,013,211	1,716,576
Operating lease right-of-use assets	180,933	211,581
Property and equipment, net	4,707,332	4,682,100
Total assets	\$ 21,286,330	\$ 20,174,383
LIABILITIES AND NET ASSETS:		
Accounts payable and accrued liabilities	\$ 1,211,079	\$ 1,104,301
Deferred revenue	360,164	458,510
Interest payable	53,624	46,338
Liability for derivative instruments	32,604	39,664
Bonds and notes payable	3,304,279	3,343,281
Accrued liabilities for benefit obligations and professional liabilities	791,494	662,502
Operating lease liabilities	206,925	239,029
Finance lease liabilities	16,498	17,378
Funds held in trust for others	1,183,408	1,109,200
Annuities payable	13,737	13,245
Government advances for federal loan programs	13,281	13,834
Asset retirement obligations	97,167	93,520
Total liabilities	7,284,260	7,140,802
Net assets without donor restrictions, controlled by Emory	6,171,010	5,824,675
Net assets without donor restrictions related to noncontrolling interests	119,822	116,878
Net assets without donor restrictions	6,290,832	5,941,553
Net assets with donor restrictions	7,711,238	7,092,028
Total net assets	14,002,070	13,033,581
TOTAL LIABILITIES AND NET ASSETS	\$ 21,286,330	\$ 20,174,383

See accompanying notes to consolidated financial statements.

EMORY UNIVERSITY

CONSOLIDATED STATEMENTS OF ACTIVITIES

YEAR ENDED AUGUST 31, 2024 (WITH SUMMARIZED COMPARATIVE INFORMATION FOR AUGUST 31, 2023) (Dollars in thousands)

	Net Assets without Donor Restrictions	Net Assets with Donor Restrictions	Total August 31, 2024	Total August 31, 2023
OPERATING REVENUE				
Tuition and fees, net of scholarship allowance	\$ 532,165	-	\$ 532,165	\$ 522,206
Sales and services of auxiliary enterprises, net of scholarship allowance	83,169	-	83,169	78,507
Endowment spending distribution	280,141	-	280,141	245,478
Distribution from perpetual funds	49,094	-	49,094	44,830
Other investment income designated for current operations	112,778	-	112,778	93,082
Gifts and contributions for current use	51,402	10,750	62,152	72,506
Grants and contracts	793,137	-	793,137	704,398
Indirect cost recoveries	235,529	-	235,529	213,104
Net patient service revenue	6,258,326	-	6,258,326	5,332,513
Medical services	359,413	-	359,413	292,244
Independent operations	23,695	-	23,695	19,221
Other revenue	676,976	-	676,976	653,956
Net assets released from restrictions	46,178	(16,133)	30,045	18,217
Total operating revenue	9,502,003	(5,383)	9,496,620	8,290,262
OPERATING EXPENSES				
Salaries	4,672,130	-	4,672,130	4,313,737
Fringe benefits	1,080,649	-	1,080,649	935,867
Student financial aid	24,248	-	24,248	22,604
Other operating expenses	3,213,549	-	3,213,549	2,846,097
Interest on indebtedness	110,286	-	110,286	92,896
Depreciation and amortization	398,179	-	398,179	359,420
Total operating expenses	9,499,041	-	9,499,041	8,570,621
NET OPERATING ACTIVITIES	2,962	(5,383)	(2,421)	(280,359)
NONOPERATING ACTIVITIES, NET				
Investment return	276,743	278,944	555,687	(17,513)
Change in undistributed income from perpetual funds held by others	-	285,135	285,135	22,918
Gifts and contributions for capital and long-term investment	9,127	104,187	113,314	141,097
Other losses	(2,844)	-	(2,844)	(1,032)
Gain on retirement of debt	5,982	-	5,982	-
Change in fair value of derivative instruments	(12,361)	-	(12,361)	47,602
Net periodic benefit cost other than service cost	(5,443)	-	(5,443)	(3,599)
Changes in pension and other postretirement obligations	5,808	-	5,808	23,104
Other nonoperating items, net	50,105	5,572	55,677	13,853
Net assets released from restrictions	19,200	(49,245)	(30,045)	(18,217)
Total nonoperating activities, net	346,317	624,593	970,910	208,213
CHANGE IN NET ASSETS	349,279	619,210	968,489	(72,146)
Less change in net assets related to noncontrolling interests	2,944	-	2,944	(3,857)
CHANGE IN NET ASSETS CONTROLLED BY EMORY	346,335	619,210	965,545	(68,289)
BEGINNING NET ASSETS	5,941,553	7,092,028	13,033,581	13,105,727
ENDING NET ASSETS	\$ 6,290,832	7,711,238	\$ 14,002,070	\$ 13,033,581

See accompanying notes to consolidated financial statements.

EMORY UNIVERSITY

CONSOLIDATED STATEMENT OF ACTIVITIES

YEAR ENDED AUGUST 31, 2023 (Dollars in thousands)

	Net Assets without Donor Restrictions	Net Assets with Donor Restrictions	Total August 31, 2023
OPERATING REVENUE			
Tuition and fees, net of scholarship allowance	\$ 522,206	-	\$ 522,206
Sales and services of auxiliary enterprises, net of scholarship allowance	78,507	-	78,507
Endowment spending distribution	245,478	-	245,478
Distribution from perpetual funds	44,830	-	44,830
Other investment income designated for current operations	93,082	-	93,082
Gifts and contributions for current use	63,507	8,999	72,506
Grants and contracts	704,398	-	704,398
Indirect cost recoveries	213,104	-	213,104
Net patient service revenue	5,332,513	-	5,332,513
Medical services	292,244	-	292,244
Independent operations	19,221	-	19,221
Other revenue	653,956	-	653,956
Net assets released from restrictions	31,750	(13,533)	18,217
Total operating revenue	8,294,796	(4,534)	8,290,262
OPERATING EXPENSES			
Salaries	4,313,737	-	4,313,737
Fringe benefits	935,867	-	935,867
Student financial aid	22,604	-	22,604
Other operating expenses	2,846,097	-	2,846,097
Interest on indebtedness	92,896	-	92,896
Depreciation and amortization	359,420	-	359,420
Total operating expenses	8,570,621	-	8,570,621
NET OPERATING ACTIVITIES	(275,825)	(4,534)	(280,359)
NONOPERATING ACTIVITIES, NET			
Investment return	40,479	(57,992)	(17,513)
Change in undistributed income from perpetual funds held by others	-	22,918	22,918
Gifts and contributions for capital and long-term investment	21,891	119,206	141,097
Other losses	(1,032)	-	(1,032)
Change in fair value of derivative instruments	47,602	-	47,602
Net periodic benefit cost other than service cost	(3,599)	-	(3,599)
Changes in pension and other postretirement obligations	23,104	-	23,104
Other nonoperating items, net	7,898	5,955	13,853
Net assets released from restrictions	495,604	(513,821)	(18,217)
Total nonoperating activities, net	631,947	(423,734)	208,213
CHANGE IN NET ASSETS	356,122	(428,268)	(72,146)
Less change in net assets related to noncontrolling interests	(3,857)	-	(3,857)
CHANGE IN NET ASSETS CONTROLLED BY EMORY	359,979	(428,268)	(68,289)
BEGINNING NET ASSETS	5,585,431	7,520,296	13,105,727
ENDING NET ASSETS	\$ 5,941,553	7,092,028	\$ 13,033,581

See accompanying notes to consolidated financial statements.

EMORY UNIVERSITY

CONSOLIDATED STATEMENTS OF CASH FLOWS

YEARS ENDED AUGUST 31, 2024 AND 2023 (Dollars in thousands)

	August 31, 2024	August 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:		
Change in net assets	\$ 968,489	\$ (72,146)
Adjustments to reconcile change in net assets to net cash provided by (used in) operating activities:		
Contributions and pledge payments restricted for long-term investment and capital projects	(96,173)	(114,837)
Contributions of donated securities	(37,991)	(36,369)
Proceeds from sale of donated securities	5,051	5,006
Equity in gains of joint ventures	(1,535)	(2,049)
Net realized and unrealized gains on investments	(817,537)	(224,559)
Loss on disposal of property and equipment	2,844	1,070
Change in undistributed income from perpetual funds held by others	(285,135)	(22,918)
Depreciation and amortization	395,537	355,588
Amortization of bond premiums and issuance costs	(27,110)	(22,625)
Amortization of right-of-use assets	37,062	39,857
Change in pension and other postretirement	448	(18,470)
Change in fair value of derivative instruments	(7,060)	(47,602)
Change in operating assets:		
Accounts and other receivables, net	(110,132)	(123,518)
Contributions receivable for operations	12,133	(6,863)
Prepaid expenses, deferred charges, and other assets	(88,618)	(47,836)
Interests in perpetual funds	6,000	5,984
Change in operating liabilities:		
Accounts payable, accrued liabilities, and interest payable	102,511	57,660
CARES Act accrued liabilities	-	(69,811)
Asset retirement obligations	3,647	3,918
Accrued liabilities for benefit obligations and professional liabilities	128,544	56,066
Lease liabilities, net	(36,840)	(37,631)
Deferred revenue	(98,346)	37,770
Net cash provided by (used in) operating activities	55,789	(284,315)
CASH FLOWS FROM INVESTING ACTIVITIES:		
Distributions from partnerships	500	13,407
Disbursements for loans to students	(1,874)	(2,050)
Repayment of loans from students	2,493	3,322
Proceeds from sales and maturities of investments	11,665,594	30,567,426
Purchases of investments	(11,349,851)	(30,654,884)
Purchases of property, plant, and equipment	(412,389)	(652,127)
Decrease in funds held in trust for others	(28,921)	(43,412)
Net cash used in investing activities	\$ (124,448)	\$ (768,318)

EMORY UNIVERSITY

CONSOLIDATED STATEMENTS OF CASH FLOWS

YEARS ENDED AUGUST 31, 2024 AND 2023 (Dollars in thousands)

	August 31, 2024	August 31, 2023
CASH FLOWS FROM FINANCING ACTIVITIES:		
Contributions and pledge payments restricted for long-term investment and capital projects	\$ 94,743	\$ 107,310
Proceeds from sale of donated securities restricted for long-term investment and capital projects	32,940	31,363
Proceeds from bonds payable, including commercial paper	350,000	791,751
Principal repayments of bonds payable, including commercial paper	(361,450)	(371,345)
Payments on finance lease obligations	(1,194)	(1,715)
Change in annuities payable	492	(706)
Debt issuance costs	(442)	(1,946)
Change in government advances for federal loan programs	(553)	1,947
Net cash provided by financing activities	114,536	556,659
Net change in cash, cash equivalents, and restricted cash	45,877	(495,974)
Cash, cash equivalents, and restricted cash at beginning of year	965,645	1,461,619
Cash, cash equivalents, and restricted cash at end of year (Note 2a)	\$ 1,011,522	\$ 965,645
Supplemental disclosures:		
Cash paid for interest	\$ 112,703	\$ 111,765
Accrued liabilities for property, plant, and equipment purchases	11,765	25,316

See accompanying notes to consolidated financial statements.

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2024 AND 2023

(1) Organization

Emory University (the University or Emory) is a private, coeducational, not-for-profit institution, located in Atlanta, Georgia. Founded in 1836, Emory owns and operates educational, research, and healthcare facilities to support its mission. Emory provides educational services to approximately 8,400 undergraduate students and 7,800 graduate and professional students within its nine schools and colleges. Included within the University is the Emory Healthcare System (Emory Healthcare), Emory Medical Care Foundation, and Emory Innovations, LLC.

Emory Healthcare consists of Emory Healthcare, Inc. (EHC) and its controlled operating companies, including Emory University Hospital Midtown (EUHM), Emory University Hospital (EUH), Emory Saint Joseph's Hospital (ESJH), EHCA Johns Creek Hospital, LLC (EJCH), Emory Rehabilitation Hospital (ERH), DeKalb Medical Center, Inc. (DMC), Decatur Health Resources, Inc. (DHR), DeKalb Medical Center Foundation (DMCF), The Emory Clinic, Inc. (TEC), Emory Specialty Associates, LLC (ESA), Emory Specialty Associates – Joint Operating Company (ESA-JOC), Wesley Woods Center of Emory University, Inc. (WWC), and Clifton Casualty Insurance Company, Ltd. (CCIC). EUHM, EUH, ESJH, EJCH, ERH, DMC, and DHR are sometimes referred to herein, collectively, as “the Hospitals.”

The consolidated financial statements include the University and all other entities in which Emory has a significant financial interest and control. All significant inter-entity accounts and transactions have been eliminated in consolidation.

(2) Summary of Significant Accounting Policies

The consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (GAAP).

Net assets and revenue, gains, and losses are classified based on the existence or absence of externally imposed restrictions. Accordingly, net assets of the University are classified and reported as follows:

Net assets without donor restrictions – Net assets that are not subject to donor-imposed stipulations.

Noncontrolling interests in net assets are reported in the accompanying consolidated statements of financial position as a separate component of net assets without donor restrictions.

Net assets with donor restrictions – Net assets that are subject to donor-imposed stipulations that will or may be met either by

actions of the University and/or the passage of time. These net assets include donor-restricted endowments, unconditional pledges, split-interest agreements, and interests in perpetual trusts held by others. Generally, the donors of these assets permit the University to use all, or part, of the income earned and net appreciation on related investments for general or specific purposes.

Revenue is reported as an increase in net assets without donor restrictions unless its use is limited by donor-imposed restrictions. Expenses are reported as decreases in net assets without donor restrictions. Gains and losses on investments and other assets or liabilities are reported as increases or decreases in net assets without donor restrictions unless restricted by explicit donor stipulation or by law. Expirations of restrictions on net assets (i.e., the donor-stipulated purpose has been fulfilled and/or the stipulated time period has elapsed) are reported as net assets released from restrictions and shown as reclassifications among the applicable classes of net assets.

The University considers the following items to be nonoperating activities: gifts and contributions for capital and long-term investment and the related net assets released from restrictions, investment return, change in fair value of derivative instruments, pension and postretirement related changes and net periodic benefit cost other than service cost, and other activities, net.

(a) Cash, Cash Equivalents, and Restricted Cash

Cash and cash equivalents consist primarily of bank balances and short-term money market mutual funds and treasury bills with original maturities generally three months or less that are not invested as part of the long-term investments. These amounts are carried at cost, which approximates fair value. Cash and cash equivalents that are part of the long-term pool are shown within investments as those funds generally are not used for daily operating purposes. For purposes of the statements of cash flows, activity related to liabilities with original maturities of three months or less is presented net.

Restricted cash consists of cash on hand that is restricted for a specific purpose under various capital financing arrangements or cash held for others and, therefore, not available to Emory for immediate or general business use. Restricted cash appears separately from the cash and cash equivalents on the University's accompanying consolidated statements of financial position.

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2024 AND 2023

The following table is a reconciliation of cash, cash equivalents, and restricted cash reported within the accompanying consolidated statements of financial position to the amounts shown in the accompanying consolidated statements of cash flows as of August 31 (in thousands):

	2024	2023
Cash and cash equivalents	\$ 845,459	\$ 779,690
Restricted cash included in investments	166,063	185,955
Total cash, cash equivalents, and restricted cash	\$ 1,011,522	\$ 965,645

Included within the 2024 and 2023 cash and cash equivalents balance is \$52.3 million and \$192.5 million of bond proceeds, respectively (note 12).

(b) Contributions Receivable, Net

Contributions to be received after one year, net of an allowance for uncollectible amounts, are discounted to their present value at credit-adjusted rates. Amortization of discounts is recorded as additional contribution revenue. An allowance for uncollectible contributions receivable is recorded to reduce the contributions receivable balance to the amount reasonably expected to be collected and is based on management's judgment, considering such factors as prior collection history, type of contribution, relationship with donor, and other relevant factors.

(c) Loans Receivable, Net

Loans receivable represents the outstanding loan balance due under Emory-funded and various federal government loan programs offered to graduate and undergraduate students less allowances for bad debt. Loans to students are carried at the estimated net realizable value. Interest earned on these loan programs is recognized as operating revenue in the accompanying consolidated statements of activities. Loans receivable from students under certain government loan programs, carried at cost, can only be assigned to the federal government or its designees. In addition to federal direct loans (which are not reported in the accompanying consolidated financial statements), loans to qualified students are funded principally with government advances to Emory under the Perkins, Nursing, and Health Professions Student Loan Programs.

(d) Student Accounts and Other Receivables, Net

Student accounts and other receivables are recorded at net realizable value and include receivables from students, sponsors, other organizations, and reinsurers. Allowances for uncollectible amounts are recorded based on management's assessment of expected net collections considering historical trends and current economic factors.

(e) Investments

Investments are reported at fair value. Investments in securities and listed funds are valued using quoted prices in active markets if available; otherwise, if the market is inactive, fair value is determined by the University in accordance with its valuation policy.

Investments in alternative investment fund structures are valued using the net asset value (NAV) per share of the investment (or its equivalent), as a practical expedient, if (a) the underlying investment manager's calculation of NAV is fair value based and (b) the University does not currently have plans to sell the investment for an amount different from NAV. Valuations provided by the general partners and investment managers are evaluated by Emory Investment Management as of August 31, 2024 and 2023.

Investments are exposed to several risks, which may include (but are not limited to) interest rate, liquidity, tax, regulatory, currency, market, and credit risks. The University attempts to manage these risks through diversification, ongoing due diligence of fund managers, and monitoring of economic conditions, though it is at least reasonably possible that changes in the values of investments will occur in the near term and that such changes could materially affect the amounts reported in the University's consolidated financial statements.

Investment transactions are accounted for on a trade-date basis. Dividend income is recognized on the ex-dividend date, and interest income is recognized on an accrual basis. Investment return, including realized and unrealized gains and losses, is recognized when earned and reported in the accompanying consolidated statements of activities, net of external and direct internal investment expenses. Investment return, if restricted, is reported in the accompanying consolidated statements of activities as increases or decreases in net assets with donor restrictions until amounts have been appropriated and the donor-imposed or statutory time restrictions have been satisfied.

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2024 AND 2023

(f) Fair Value Measurements

The University uses valuation approaches that maximize the use of observable inputs and minimize the use of unobservable input to the extent possible. The University determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:

Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.

Level 2 – Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.

Level 3 – Unobservable inputs for the asset and liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.

(g) Split-Interest Agreements

The University's split-interest agreements with donors consist primarily of gift annuity agreements and irrevocable charitable remainder trusts for which the University serves as trustee. Assets held in the trusts are included in investments. Contribution revenue is recognized when trusts (or annuity agreements) are established, after recording liabilities for the present value of the estimated future payments to be made to beneficiaries. The liabilities are adjusted annually for changes in the value of assets, accretion of the discount, and other changes in the estimates of future benefits.

(h) Interests in Perpetual Funds Held by Others

The University is also the beneficiary of certain perpetual funds held and administered by others. The value of the funds' net assets (or Emory's share when there are other beneficiaries) is considered a reasonable estimate of the present value of the estimated future cash flows from these funds and is recognized in change in undistributed income from perpetual funds held by others and as contribution revenue at the date such funds are established. The carrying value of Emory's interest in such perpetual funds is adjusted for changes in fair value.

(i) Property and Equipment, Net

Land, buildings, and equipment are recorded at cost at the date of acquisition or fair value at the date of gift to the University. Depreciation expense is based on the straight-line method over the estimated useful lives of the assets. Useful lives are as follows: buildings – 10 to 60 years, land improvements and infrastructure – 5 to 40 years, movable equipment – 3 to 20 years, fixed equipment – 3 to 30 years, software and enterprise systems – 3 to 10 years, leasehold improvements – term of the lease, and library books – 10 years. Certain assets totaling \$128.6 million and \$124.3 million, such as art, museum assets, and rare books, are included in property and equipment, net, as of August 31, 2024 and 2023, respectively, but are not depreciated.

If circumstances require property and equipment to be tested for impairment, the University compares undiscounted cash flows expected to be generated by the property and equipment to its carrying amount. If the carrying amount exceeds the undiscounted cash flows, an impairment is recognized to the extent that the carrying amount exceeds its fair value. There were no asset impairments for fiscal years 2024 or 2023.

(j) Health Insurance Plan

The University is self-insured for employee and student health insurance costs, with losses insured in excess of a maximum amount on both a per claim and annual aggregate claim amount. The self-insurance liability is based on claims filed and an estimate of claims incurred but not yet reported. Self-insurance claims are reported as net of insurance premiums collected from employees and students.

(k) Patient Accounts Receivable and Concentrations

Patient accounts receivable are reported at the estimated net realizable amounts due from patients, third-party payors, and others for services rendered, including estimated retroactive adjustments due to future audits, reviews, and investigations. Retroactive adjustments are considered in the recognition of revenue on an estimated basis in the period the related services are rendered, and such amounts are adjusted in future periods as adjustments become known or as years are no longer subject to such audits, reviews, and investigations.

Emory Healthcare analyzes contractually due amounts and provides an allowance for implicit price concessions. Accounts receivable are written off after collection efforts have been undertaken in accordance with Emory's policies.

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2024 AND 2023

The mix of net receivables from patients and third-party payors for the years ended August 31 is as follows:

	2024	2023
Managed care and other third-party payors	62%	63%
Medicare	30	28
Medicaid	4	5
Patients	4	4
	100%	100%

(l) Leases

The University determines whether an arrangement is a lease (operating or finance) at inception by evaluating whether the contract conveys the right to use an identified asset and whether Emory obtains substantially all of the economic benefits from and has the right to control the asset. Right-of-use (ROU) assets represent the University's right to use an underlying asset for the lease term and lease liabilities represent the University's obligation to make lease payments arising from the lease. Operating and finance lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term discounted using the interest rate implicit in the lease agreement or Emory's relevant incremental borrowing rate. The University's current discount rates range from 0.5% to 5.6% depending on the term of the arrangement.

(m) Income Taxes

The University is recognized as a tax-exempt organization as defined in Section 501(c)(3) of the U.S. Internal Revenue Code of 1986, as amended (the Code), and is generally exempt from federal income taxes on related income pursuant to Section 501(a) of the Code. The University is, however, subject to federal and state income tax on unrelated business income and provision for such taxes is included in the accompanying consolidated statements of activities.

The Tax Cuts and Job Acts (the Act) imposes an excise tax on net investment income and excess compensation for certain organizations and establishes rules for calculating unrelated business income. Emory has reflected the tax assets and liabilities in the accompanying consolidated financial statements based on reasonable estimates. The University also has a net operating loss carryforward related to unrelated business income aggregating \$170.9 million, for which a valuation allowance of \$117.0 million is recorded as of August 31, 2024. As of August 31, 2023, the

University had a net operating loss carryforward of \$179.9 million, with a valuation allowance of \$151.8 million.

The University regularly evaluates its tax positions and as of August 31, 2024 and 2023, does not believe it has any material uncertain tax positions that require disclosure or adjustment to the consolidated financial statements.

(n) Derivative Instruments

Certain investment strategies used by the University and its investment managers incorporate various derivative financial instruments to reduce volatility, manage market risk, and enhance investment returns. Such instruments are reflected at fair value and included in either investments or liability for derivative instruments within the accompanying consolidated statements of financial position. Changes in the fair value of investment-related derivative instruments are included in investment return on the accompanying consolidated statements of activities. The University also utilizes interest swap agreements to hedge interest rate market exposure of variable rate debt. The difference between amounts paid and received under such agreements is reported in interest expense. Changes in the fair value of these swap agreements or any gains or losses that result from the termination of these swap agreements are recognized as nonoperating activities in the accompanying consolidated statements of activities.

(o) Pension and Postretirement Benefit Plans

The University recognizes the funded status of its defined-benefit pension and postretirement benefit plans as an asset or liability and recognizes changes in funded status during the year in which the changes occur as changes in net assets without donor restrictions.

(p) New Accounting Pronouncements

In fiscal year 2024, Emory adopted Accounting Standards Update (ASU) No. 2016-13, *Financial Instruments – Credit Losses (Topic 326) Measurement of Credit Losses on Financial Statements*. ASU No. 2016-13 introduces an approach based on expected losses to estimate credit losses on certain types of financial instruments. The amendments of ASU No. 2016-13 are intended to provide financial statement users with more decision-useful information related to expected credit losses on financial instruments and other commitments to extend credit by replacing the current incurred loss impairment methodology with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to determine credit loss estimates. The adoption of

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2024 AND 2023

this ASU did not materially impact the consolidated financial statements and related disclosures.

(q) Use of Estimates

The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets, liabilities, revenue, and expenses, as well as disclosure of contingent assets and liabilities. Actual results could differ from those estimates.

Significant items in the University's consolidated financial statements subject to such estimates and assumptions include valuations for certain investments without readily determinable fair values, the determination of the allowances for price concessions for medical services, reserves for employee and student healthcare and workers' compensation claims, accrued professional and general liability costs, estimated third-party settlements, and actuarially determined benefit liabilities.

(r) Conflict of Interest Policies (Related Parties)

University trustees, directors, principal officers, and key employees may periodically be directly or indirectly associated with companies doing business with the University. The University requires annual disclosure of significant financial interests in, or employment or board service with, entities doing business with the University. The annual disclosures cover these key officials and their immediate family members.

When such relationships exist, measures are taken to appropriately manage the actual or perceived conflict. The written conflict of interest policy for the University requires, among other things, that no member of a governing board may participate in any decision in which he or she (or an immediate family member) has a material financial interest.

(s) Investments in Joint Ventures

Emory accounts for certain operating investments in joint ventures over which it has significant influence but not a controlling interest, using the equity method. Investments in joint ventures are generally included in investments in the accompanying consolidated statements of financial position and equity income/loss is recorded within other nonoperating activities in the accompanying consolidated statements of activities. One of these joint ventures owns a medical office tower that was funded by an \$83.0 million loan, which is secured by the constructed building. Emory, which owns a 50% investment, and its joint venture partner, jointly and severally fully guaranty the

loan obligations of the company in the event of the company's bankruptcy, insolvency or related circumstances. The loan is due June 1, 2032.

(3) Contributions Receivable

Contributions receivable as of August 31 consist of the following (in thousands):

	2024	2023
UNCONDITIONAL PROMISES EXPECTED TO BE COLLECTED IN:		
Less than one year	\$ 67,999	\$ 93,170
One year to five years	94,816	92,854
Over five years	3,563	9,051
Gross contributions receivable	166,378	195,075
Less:		
Allowance for uncollectible amounts	(5,638)	(5,747)
Discount to present value	(10,242)	(10,627)
Contributions receivable, net	\$ 150,498	\$ 178,701

At August 31, 2024 and 2023, the five largest outstanding donor pledge balances represented 37.0% and 55.0%, respectively, of Emory's total contributions receivable, net. Contribution receivables are discounted at rates ranging from 4.15% to 4.25%.

As of August 31, 2024, the University had received bequest intentions and conditional promises of approximately \$21.0 million. These intentions to give are not recognized as assets or revenue and, if received, will generally be restricted for purposes stipulated by the donor.

(4) Revenue Recognition

(a) Net Tuition and Fees

Tuition and fees revenue is derived from degree programs and continuing education programs. Tuition and fees are recognized in the fiscal year in which the academic programs are provided. Revenue is reflected in the accompanying consolidated statements of activities for the portion of the program or service that is completed by the end of the fiscal year. The remaining performance obligation that will be completed in the following fiscal year remains a liability and is recorded within deferred revenue on the accompanying consolidated statements of financial position.

Most undergraduate students receive institutional financial aid based upon academic promise and demonstrated financial need. Graduate students often receive tuition support in connection

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2024 AND 2023

with research assistant, teaching assistant, and fellowship appointments. Student financial aid provided by the University for tuition and fees is reflected as a reduction of tuition and fees revenue from published rates. Institutional resources provided in excess of amounts owed by the students to Emory are recorded as scholarship expenses.

(b) Sales and Services of Auxiliary Enterprises

An auxiliary enterprise is a nonacademic entity that exists predominantly to furnish goods and services to students, faculty, and staff. Auxiliary enterprises revenue primarily includes residential services, parking, and bookstore. Residential services and parking revenue is recognized over time, as the services are performed. Sales of goods occur as a point-of-sale transaction, and the revenue is recognized as the sale occurs. Any discounts are factored into the selling price at the point of sale.

The following table provides the components of tuition and fees and student-related auxiliary enterprises revenue for the year ended August 31, 2024 (in thousands):

		Tuition and Fees	Auxiliary Enterprises	Total
Undergraduate programs	\$	515,423	56,986	572,409
Graduate and professional programs		373,749	1,418	375,167
Total at published rates		889,172	58,404	947,576
Less institutional aid for undergraduate programs		(181,101)	(10,262)	(191,363)
Less institutional aid for graduate and professional programs		(184,688)	(298)	(184,986)
Tuition and fees and auxiliary enterprises, net of institutional aid		523,383	47,844	571,227
Other academic programs		8,782	—	8,782
Total tuition and fees and auxiliary enterprises	\$	532,165	47,844	580,009

The following table provides the components of tuition and fees and student-related auxiliary enterprises revenue for the year ended August 31, 2023 (in thousands):

		Tuition and Fees	Auxiliary Enterprises	Total
Undergraduate programs	\$	477,470	53,829	531,299
Graduate and professional programs		384,663	1,441	386,104
Total at published rates		862,133	55,270	917,403
Less institutional aid for undergraduate programs		(167,251)	(8,131)	(175,382)
Less institutional aid for graduate and professional programs		(182,115)	(282)	(182,397)
Tuition and fees and auxiliary enterprises, net of institutional aid		512,767	46,857	559,624
Other academic programs		9,439	—	9,439
Total tuition and fees and auxiliary enterprises	\$	522,206	46,857	569,063

(c) Gifts and Contributions Revenue

Contributions, including unconditional promises to give, are recognized as revenue in the period the contribution is received, or in the period in which the unconditional promise was made. Unconditional promises to give, with payments due in future periods, are recorded as increases in net assets with donor restrictions at the estimated present value of future cash flows, net of an allowance for uncollectible pledges. Contributions of assets other than cash are recorded at their estimated fair value at the date of the gift.

Donor-restricted contributions are reported as revenue with donor restrictions, which increases this net asset class. If the donor stipulation is met in the year of the gift, the contribution is reflected in net assets without donor restrictions. Restrictions on gifts to acquire long-lived assets are considered met in the period when the asset is placed in service. Conditional promises to give are not recognized until they become unconditional.

(d) Grants and Contracts Revenue

Emory receives funding from federal, state, corporate, and private foundations (sponsors). The agreement with the sponsor may take the form of a contract, grant, or cooperative agreement. If resource providers do not receive commensurate benefit (only indirect benefit because the research findings serve the general public), such grants and contracts are considered contributions.

Most Emory nonexchange, sponsored research agreements are conditional contributions as the agreements include both a right

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2024 AND 2023

of return or release of assets and a barrier that Emory must overcome to be entitled to the consideration. The University recognizes revenue associated with these sponsored agreements as qualifying allowable expenses are incurred or a measurable performance-related barrier is achieved in accordance with the terms and conditions of the agreements. Conditional agreements with sponsor-imposed restrictions that expire simultaneously with the satisfaction of the specified conditions are reported as net assets without donor restrictions. Deferred revenue is recognized when cash is received from sponsors in advance of revenue being earned. Amounts recorded in other receivable, net are for services rendered or expenditures incurred in advance of the receipt of funds.

Emory considers revenue from most clinical trial agreements to be exchange transactions where revenue is recognized as services are performed, billed, and the University has contractual right to consideration. Revenue related to clinical trial agreements included in grants and contracts revenue in the accompanying consolidated statements of activities for the years ended August 31, 2024 and 2023 totaled \$71.6 million and \$68.4 million, respectively.

Indirect cost recoveries are based on negotiated rates with grantor agencies and represent recoveries of facilities and administrative costs incurred under grant and contract agreements.

The following table presents Emory's sources of grants and contracts revenue (including indirect cost recoveries) for the years ended August 31 (in thousands):

	2024		2023	
	Grants	Contracts	Grants	Contracts
Federal government \$	784,397	2,829	\$ 700,164	5,703
Other government	2,967	—	2,104	5
Corporate	23,984	59,634	26,655	49,215
Private institutions	145,761	9,094	120,174	13,482
Total	\$ 957,109	71,557	\$ 849,097	68,405

As of both August 31, 2024 and 2023, Emory had unexpended grant awards of \$1.0 billion for which revenue will be recognized when conditions have been met or performance obligations have been satisfied.

(e) Royalties Revenue

The University recognizes revenue from nonrefundable, up-front fees allocated to a license at a point in time when the license is transferred to the licensee and the licensee is able to use and benefit from the license. Sales-based royalties revenue, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, is recognized over the licensing agreement.

(f) Medical Services and Other Revenue

Medical services revenue is recognized as services are performed and the customer receives and uses the benefits of the services. The University has contractual agreements with Grady Memorial Hospital where practicing interns and medical residents of the Emory School of Medicine receive clinical training and faculty provide teaching, medical care, and hospitalization services. The School of Medicine is reimbursed for expenses incurred for interns and medical residents based on the costs for labor and reimbursed for the faculty teaching, administrative, and clinical services based on the number of interns and residents trained and time spent performing clinical and administrative services.

The University also has affiliation and administrative services agreements with Children's Healthcare of Atlanta and the Emory + Children's Pediatric Institute, where it provides various administrative services. Revenue is recognized over time and is recorded as other revenue in the accompanying consolidated statements of activities.

Retail pharmaceutical sales are recognized at a point in time when the customer receives the product.

The major components of other sources of operating revenue for the years ended August 31 are as follows (in thousands):

	2024	2023
Retail pharmaceutical sales	\$ 360,145	\$ 300,058
FEMA funds	13,967	—
Royalties	64,785	96,190
Other	238,079	257,708
Other revenue	\$ 676,976	\$ 653,956

(g) Independent Operations Revenue

Independent operations are activities independent of its mission, including an externally managed conference center, hotel, and fitness center. Fee charges are based on market rates for the

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2024 AND 2023

services provided and revenue is recognized at a point in time or over time as the services are rendered.

(h) Net Patient Service Revenue

Emory Healthcare has agreements with government and other third-party payors that provide for reimbursement to Emory Healthcare at amounts different from established rates.

Revenue is recognized as performance obligations are satisfied. Performance obligations are determined based on the nature of the services provided. Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected (or actual) charges. Emory Healthcare believes that this method provides a faithful depiction of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation. Generally, performance obligations satisfied over time relate to patients in Emory Healthcare's hospitals receiving inpatient, outpatient, or emergency services. Emory Healthcare measures the performance obligation from admission, or the commencement of an outpatient service, to the point when it is no longer required to provide services to that patient, which is generally at the time of discharge or completion of the outpatient services. Revenue for performance obligations satisfied at a point in time is generally recognized when services are provided to Emory Healthcare's patients.

Emory Healthcare determines the transaction price based on standard charges for goods and services provided, reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients in accordance with Emory Healthcare policy, and implicit price concessions provided to patients. Emory Healthcare determines its estimates of contractual adjustments and discounts based on contractual agreements, its discount policies, and historical experience.

Emory Healthcare provides care to patients regardless of their ability to pay. Emory Healthcare has determined it has provided implicit price concessions to uninsured patients and patients with other uninsured balances (e.g., co-pays and deductibles).

The implicit price concessions included in estimating the transaction price represent the difference between amounts billed to patients and the amounts Emory Healthcare expects to collect based on its collection history with those patients considering business and economic conditions, trends in healthcare coverage, and other collection indicators. Periodically, management assesses the adequacy of the allowance for implicit price

concessions based upon historical write-off experience by payor category and adjusts the allowance as appropriate.

Patient service revenues, net of contractual adjustments, implicit price concessions, and other discounts recognized from major payor sources for the years ended August 31 is as follows (in thousands):

	2024	2023
Medicare	\$ 2,070,112	\$ 1,595,229
Medicaid	250,520	237,420
Managed care and other third-party payors	3,848,254	3,425,311
Patients	89,440	74,553
Net patient service revenue	\$ 6,258,326	\$ 5,332,513

Included within Medicare revenue is a \$75.4 million payment from the Centers for Medicare and Medicaid Services to compensate for an invalid payment rate utilized during the period from 2018 to 2022 for drugs acquired under Section 340B of the Public Health Service Act.

The composition of net patient service revenue based on the Emory Healthcare lines of business for the years ended August 31 is as follows (in thousands):

	2024	2023
Services lines:		
Hospital – inpatient	\$ 2,571,358	\$ 2,258,790
Hospital – outpatient	2,404,706	1,939,516
Physician services	1,282,262	1,134,207
Net patient service revenue	\$ 6,258,326	\$ 5,332,513

Emory Healthcare provides care to patients who meet certain criteria under its financial assistance policy without charge or at amounts less than their established rates and such amounts are not included in net patient service revenue.

Data is maintained to identify and monitor the level of charity care provided, including the amount of charges foregone and actual costs for services furnished under its charity and indigent care policies.

The cost of charity care provided totaled \$160.9 million and \$147.1 million for the years ended August 31, 2024 and 2023, respectively. Emory Healthcare estimated these costs by applying a ratio of cost to gross charges to the gross uncompensated charges associated with providing care to the charity patients.

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2024 AND 2023

(5) Liquidity and Availability

Emory regularly monitors the liquidity required to meet its operating needs and other contractual commitments, while also maximizing the investment of its available funds.

For purposes of analyzing resources available to meet general expenditures over a 12-month period, the University considers all expenditures related to its ongoing mission-related activities as well as the conduct of services undertaken to support those activities to be general expenditures.

In addition to financial assets available to meet general expenditures over the next 12 months, the University operates with a balanced budget and anticipates collecting sufficient revenue to cover general expenditures not covered by donor-restricted resources.

As of August 31, 2024 and 2023, the following financial assets could readily be made available within one year of the statements of financial position date to meet cash needs for general expenditures (in thousands):

	2024	2023
TOTAL ASSETS	\$ 21,286,330	\$ 20,174,383
Less:		
Property and equipment, net	(4,707,332)	(4,682,100)
Interest in perpetual trusts held by others	(2,013,211)	(1,716,576)
Donor-restricted and board-designated endowment funds	(8,088,842)	(7,493,960)
Other investments	(3,290,671)	(3,122,417)
Prepaid expenses, deferred charges, and other assets	(517,116)	(428,498)
Operating lease right-of-use assets	(180,933)	(211,581)
Contributions receivable, net	(150,498)	(178,701)
Loans receivable, net	(14,524)	(15,143)
Add:		
Endowment payout in following year	257,306	232,276
Contributions receivable due within one year for operations	67,999	93,170
Financial assets	\$ 2,648,508	\$ 2,650,853

The University has \$2.6 billion of financial assets as of August 31, 2024 to meet cash needs for general expenditures, consisting of cash and cash equivalents of \$845.5 million, accounts receivable of \$1.2 billion, contributions receivable, less than one year of \$68.0 million, unrestricted payout on endowment funds

of \$257.3 million, and other operating investments of \$299.7 million.

(6) Investments

The following table summarizes investments as of August 31 (in thousands):

	2024	2023
Short-term investments and cash equivalents ^(a)	\$ 458,413	\$ 792,257
Public equity ^(b)	3,903,838	3,625,278
Absolute return/fixed income ^(c)	2,691,485	2,046,404
Private equity/venture capital ^(d)	3,714,144	3,667,516
Real assets ^(e)	911,097	911,800
Derivative instruments ^(f)	(898)	50,293
Total investments at fair value	11,678,079	11,093,548
Joint ventures (equity method)	809	309
Total investments	\$ 11,678,888	\$ 11,093,857

^{a)} Includes short-term U.S. and non-U.S. Treasury securities with original maturities of less than one year, as well as funds that invest in these types of investments.

^{b)} Includes domestic and international stocks, as well as interests in funds that invest in both long only and long/short equity-based strategies; certain investments in funds may be subject to restrictions that limit the University's ability to withdraw capital until (i) certain "lock-up period" has expired or (ii) until certain underlying investments designated as "illiquid" or "side pockets" are sold. In addition, fund investments in this category may be subject to restrictions limiting the amount the University is able to withdraw as of a given redemption date. Certain fund investments in this category may not be eligible for redemptions and instead issue distributions received through liquidation of the funds' underlying assets, which is expected to occur over the next eight years.

^{c)} Includes directly-held actively traded global fixed-income securities (such as government bonds and corporate bonds) or commingled funds holding such securities of \$1.8 billion and \$1.1 billion and investments in multistrategy or credit funds, as well as opportunistic absolute return funds intended to enhance diversification and reduce correlation to public equity of \$881.0 million and \$909.0 million as of August 31, 2024 and 2023, respectively; certain fund investments included in this category may hold marketable securities and be subject to redemption terms governed by the respective fund agreement or may contain illiquid investments and, therefore, offer no liquidity over the fund life. Such funds holding illiquid

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2024 AND 2023

investments are expected to yield liquidating distributions over the next four years.

- d) Includes illiquid investments in private and public companies, both domestically and internationally; the majority of these investments are held through funds and also include buyout, venture capital, private debt, high yield, and subordinated debt strategies. The nature of the investments in this category is such that distributions are received through liquidation of the funds' underlying assets, which are expected to occur over the next 15 years.
- e) Includes investments in oil and gas, commodities, timber, and real estate, the majority of which are held through funds. The nature of the investments in this category is such that distributions are received through liquidation of the underlying assets of the funds, which are expected to occur over the next 9 years.
- f) Includes investments in foreign exchange contracts valued at fair value of each underlying investments

As of August 31, 2024, the related unfunded commitments of the University's alternative investments valued using the practical expedient and limitations and restrictions on the University's ability to redeem or sell are summarized as follows (in thousands):

		Unfunded Commitments	Redemption Frequency (if currently eligible)	Redemption Notice Period
Absolute return	\$	515,468	0 - 90 days or not eligible	0 - 92 days
Private equity/ venture capital		1,198,357	360 days or not eligible	90 days
Public equity		9,931	0-360 days or not eligible	0-180 days
Real assets		326,030	not eligible	not eligible
	\$	2,049,786		

Unfunded commitments are generally expected to be called by funds within five years of fund inception.

(7) Endowment Net Assets

The University's endowed assets (the Endowment) consist of approximately 2,500 individual funds established for various purposes, including with donor restriction endowment funds and without donor restrictions funds designated by the Board of Trustees to function as endowments. The Endowment provides stable financial support to a wide variety of programs and activities in perpetuity, playing a critical role in enabling the University to achieve its mission. Net assets associated with these endowment funds are classified and reported based on the existence or absence of donor-imposed restrictions.

(a) Interpretation of Relevant Law

The University follows the State of Georgia's Uniform Prudent Management of Institutional Funds Act (UPMIFA), which provides standards for managing investments of institutional funds and spending from endowments. The University classifies as donor-restricted historical value net assets (a) the original value of gifts donated to the permanent endowment, (b) the original value of subsequent gifts to the permanent endowment, and (c) accumulations to the permanent endowment made under the direction of the applicable donor gift instrument at the time the accumulation is added to the fund.

The remaining portion of the donor-restricted endowment fund is classified as restricted appreciation until those amounts are appropriated for expenditures by the University in a manner consistent with the standard of prudence prescribed by UPMIFA. Per UPMIFA, the University considers several factors in deciding to appropriate or accumulate donor-restricted endowment funds, including the duration and preservation of the fund, the purposes of the fund, general economic conditions, the possible effect of inflation and deflation, the expected total return from income and the appreciation of investments, other resources of the University, and the investment policies of the University. The endowment funds subject to UPMIFA are true endowments and do not include perpetual funds held by others, long-term investments, annuity funds, funds held in trust for others, and miscellaneous investments. As of August 31, 2024, 69.3% of the investments described in note 6 are classified as endowed net assets.

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2024 AND 2023

Endowment funds are categorized in the following net asset classes as of August 31 (in thousands):

	2024			2023		
	Without Donor Restrictions	With Donor Restrictions	Total	Without Donor Restrictions	With Donor Restrictions	Total
Donor-restricted endowment funds						
Appreciation	\$ —	4,089,078	4,089,078	\$ —	3,819,395	3,819,395
Historical value	—	1,389,120	1,389,120	—	1,306,808	1,306,808
Total donor restricted	—	5,478,198	5,478,198	—	5,126,203	5,126,203
Funds functioning as endowments or board-designated	2,610,644	—	2,610,644	2,367,757	—	2,367,757
Total endowment net assets	\$ 2,610,644	5,478,198	8,088,842	\$ 2,367,757	5,126,203	7,493,960

The following table represents endowment net asset composition by purpose as of August 31 (in thousands):

	2024			2023		
	Without Donor Restrictions	With Donor Restrictions	Total	Without Donor Restrictions	With Donor Restrictions	Total
Academic and research ⁽¹⁾	\$ 1,719,946	5,366,490	7,086,436	\$ 1,571,221	5,002,930	6,574,151
Capital maintenance, infrastructure, and real estate	890,698	111,708	1,002,406	796,536	123,273	919,809
Total endowment net assets	\$ 2,610,644	5,478,198	8,088,842	\$ 2,367,757	5,126,203	7,493,960

⁽¹⁾ Academic and research includes endowment net assets for student financial aid of \$2.2 billion as of August 31, 2024 as well as program support.

Changes in endowment funds by net asset classification for the years ended August 31 are summarized as follows (in thousands):

	Without Donor Restrictions	With Donor Restrictions	Total
Balance as of August 31, 2022	\$ 2,205,380	5,105,457	7,310,837
Endowment investment return, net	64,185	153,946	218,131
Gifts and additions to endowment, net	192,647	81,204	273,851
Withdrawal of board-designated funds for strategic initiatives	(5,177)	(986)	(6,163)
Endowment spending distributions	(89,278)	(213,418)	(302,696)
Balance as of August 31, 2023	\$ 2,367,757	5,126,203	7,493,960
Endowment investment return, net	231,168	502,217	733,385
Gifts and additions to endowment, net	124,382	82,312	206,694
Withdrawal of board-designated funds for strategic initiatives	(10,504)	—	(10,504)
Endowment spending distributions	(102,159)	(232,534)	(334,693)
Balance as of August 31, 2024	\$ 2,610,644	5,478,198	8,088,842

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2024 AND 2023

(b) Funds with Deficiencies

From time to time, the fair value of assets associated with individual donor-restricted endowment funds may fall below the level of the donor's original contribution. Deficiencies of this nature were \$1.6 million and \$6.3 million as of August 31, 2024 and 2023, respectively.

(c) Return Objectives and Risk Parameters

The University has adopted investment and spending policies for endowment assets that attempt to provide a predictable stream of funding to programs supported by its endowment and seek to maintain the purchasing power of the endowment assets. Under this policy, as approved by the Board of Trustees, the endowment assets are invested within the risk tolerances of the University to provide an expected total return and inflation over the long term.

(d) Strategies Employed for Achieving Objectives

To satisfy its long-term return objectives, the University relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current yield (interest and dividends). The University employs a diversified asset allocation strategy across public equity, absolute return/fixed income, private equity/venture capital, and real assets to achieve its long-term return objectives within a prudent

risk framework. The Endowment's long-term target asset allocation is approved by the Investment Committee of the Board of Trustees. The portfolio is periodically rebalanced to the target weightings for each asset class.

(e) Relationship between Investment Objectives and Spending Policy

The University's Board of Trustees has established a spending policy that determines how endowment distributions are made. The University employs a total return endowment spending policy that establishes the amount of endowment investment return available to support current operating and capital needs while preserving the purchasing power of the endowment over the long term. The distribution of endowment investment return in 2024 was based on 5.0% of the average fair value of the endowment over the previous 60 months ended on August 31, 2024, and 5.0% of the average fair value of the endowment over the previous 48 months in 2023. The University considers the historical average market value in setting the annual appropriation amount. Accordingly, the University expects the current spending policy to allow its endowment to maintain its purchasing power if projected growth rates are achieved. Additional real growth will be provided through new gifts and any excess investment return. The payout rate is approved annually by the Board of Trustees as part of the budget process.

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2024 AND 2023

(8) Fair Values of Assets and Liabilities

The following table summarizes the valuation of the University's assets and liabilities according to the fair value hierarchy levels as of August 31, 2024 (in thousands):

		Fair Value Hierarchy			
	Investments Measured at NAV ⁽¹⁾	Level 1	Level 2	Level 3	Total Fair Value
FINANCIAL ASSETS:					
Short-term investments and cash equivalents	\$ —	306,155	152,258	—	458,413
Public equity	3,016,609	887,226	—	3	3,903,838
Absolute return/fixed income	881,389	1,486,413	323,683	—	2,691,485
Private equity/venture capital	3,676,543	82	—	37,519	3,714,144
Real assets	904,317	3,639	1,500	1,641	911,097
Derivative instruments	—	(898)	—	—	(898)
Total investments at fair value	8,478,858	2,682,617	477,441	39,163	11,678,079
Interests in perpetual funds held by others	—	—	—	2,013,211	2,013,211
Total assets at fair value	8,478,858	2,682,617	477,441	2,052,374	13,691,290
FINANCIAL LIABILITIES:					
Derivative instruments – interest rate swaps	—	—	(32,604)	—	(32,604)
Funds held in trust for others ⁽²⁾	(1,183,408)	—	—	—	(1,183,408)
Total liabilities at fair value	\$ (1,183,408)	—	(32,604)	—	(1,216,012)

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2024 AND 2023

The following table summarizes the valuation of the University's assets and liabilities according to the fair value hierarchy levels as of August 31, 2023 (in thousands):

		Fair Value Hierarchy			
	Investments Measured at NAV ⁽¹⁾	Level 1	Level 2	Level 3	Total Fair Value
FINANCIAL ASSETS:					
Short-term investments and cash equivalents	\$ —	630,459	161,798	—	792,257
Public equity	2,923,078	697,275	4,922	3	3,625,278
Absolute return/fixed income	909,030	451,267	686,107	—	2,046,404
Private equity/venture capital	3,642,905	—	—	24,611	3,667,516
Real assets	908,907	199	1,500	1,194	911,800
Derivative instruments	—	1,020	49,273	—	50,293
Total investments at fair value	8,383,920	1,780,220	903,600	25,808	11,093,548
Interests in perpetual funds held by others	—	—	—	1,716,576	1,716,576
Total assets at fair value	8,383,920	1,780,220	903,600	1,742,384	12,810,124
FINANCIAL LIABILITIES:					
Derivative instruments – interest rate swaps	—	—	(39,664)	—	(39,664)
Funds held in trust for others ⁽²⁾	(1,109,200)	—	—	—	(1,109,200)
Total liabilities at fair value	\$ (1,109,200)	—	(39,664)	—	(1,148,864)

⁽¹⁾ Certain investments that are measured at fair value using the net asset value (NAV) per share (or its equivalent) practical expedient have not been categorized in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the accompanying consolidated statements of financial position.

⁽²⁾ Emory uses net asset value of units held in endowment pool as an estimate for fair value.

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2024 AND 2023

The following tables present a summary of the University's activity for investments categorized as Level 3 for the years ended August 31, 2024 and 2023 (in thousands):

2024			
	Purchases	Sales	Transfers out ⁽¹⁾
Private equity/venture capital	\$ 93	(37)	–
Real assets	1	(207)	–
Total Investments	94	(244)	–
Interests in perpetual funds held by others	17,500	–	(6,000)
Total assets	\$ 17,594	(244)	(6,000)

2023			
	Purchases	Sales	Transfers out ⁽¹⁾
Private equity/venture capital	\$ 6,275	(559)	–
Real assets	8	(43)	–
Total Investments	6,283	(602)	–
Interests in perpetual funds held by others	17,500	–	(5,984)
Total assets	\$ 23,783	(602)	(5,984)

⁽¹⁾ Transfers of interests in perpetual funds held by others is due to funds released from operations.

(9) Derivative Instruments and Hedging Activities

(a) Debt

Historically, as a component of the debt portfolio, the University entered into interest rate swap agreements that effectively convert a portion of variable rate debt to fixed rates and are used to manage interest rate risk. Since the inception of the interest rate swap agreements, the debt portfolio has changed to incorporate fixed rate debt not associated with derivatives. The University's

exchange arrangements are exposed to credit loss in the event of nonperformance by the counterparty and to interest rate risk driven by any potential basis risk with variable rate debt. Certain of the University's derivative instruments contain provisions requiring long-term, unsecured debt to be maintained at specified credit ratings from Moody's Investors Service and Standard and Poor's Ratings Service. If the ratings of the University's debt were to fall below certain benchmarks, the counterparty could request immediate payment on derivative instruments in net liability positions. As of August 31, 2024, the University's long-term debt ratings exceeded these benchmarks.

At August 31, 2024, Emory had four interest rate swap agreements expiring on various dates ranging from September 1, 2035 through December 1, 2042. These agreements require Emory to pay fixed interest rates to the counterparties varying from 3.2% to 3.6% in exchange for variable rate payments from the counterparties based on a percentage of Term Secured Overnight Financing Rate (SOFR) plus a spread.

Net settlement transactions related to the agreements described above resulted in interest revenue totaling \$1.2 million and in interest expense totaling \$1.0 million and, interest expenses related to nonintegrated agreements, reflected as nonoperating gain of \$0.8 million and \$0.0 million during 2024 and 2023, respectively. During fiscal year 2024 the University terminated four interest rate swap agreements resulting in a gain of \$6.0 million recorded within non-operating activities, net on the accompanying consolidated statements of activities. The fair value of each of the remaining exchange agreement is estimated based on pricing models that utilize significant observable inputs, such as relevant current interest rates, which reflect assumptions on the amount the University would receive or pay to terminate the agreement at the reporting date. As such, the University's exchange agreements are categorized as Level 2 in the fair value hierarchy.

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2024 AND 2023

The following table summarizes the debt-related derivative instruments as of and for the years ended August 31 (in thousands):

Interest Rate Swaps		2024			2023	
Inception	Maturity	Notional Amount ⁽¹⁾	Liability Fair Value ⁽²⁾	Unrealized Loss	Liability Fair Value	Unrealized Gain
August 4, 2005	September 1, 2035	\$ —	—	—	\$ (4,981)	8,022
August 25, 2005	September 1, 2035	—	—	—	(1,788)	2,679
December 1, 2007	September 1, 2035	75,000	(6,994)	(1,553)	(5,441)	5,285
May 1, 2008	September 1, 2038	75,000	(8,712)	(1,400)	(7,312)	6,190
December 1, 2008	December 1, 2042	100,000	(9,671)	(2,408)	(7,264)	9,460
December 1, 2009	September 1, 2035	75,000	(7,227)	(1,546)	(5,681)	5,312
June 23, 2015	September 1, 2035	—	—	—	(5,409)	7,969
June 23, 2015	September 1, 2035	—	—	—	(1,788)	2,685
Total		\$ 325,000	(32,604)	(6,907)	\$ (39,664)	47,602

⁽¹⁾ The notional amount is the predetermined dollar amount on which the exchanged interest payments are based.

⁽²⁾ Swaps with zero liability fair value for 2024 were terminated during the fiscal year.

Emory is exposed to financial loss in the event of nonperformance by a counterparty to any of the financial instruments described above. General market conditions could impact the credit standing of the counterparties and therefore, potentially impact the value of the instruments. Emory management, with consultation from third-party financial advisers, controls this counterparty credit risk by considering the credit rating, business risk, and reputation of any counterparty before entering into a transaction, monitoring for any change in the credit standing of its counterparty during the life of the transaction, and requiring collateral be posted when predetermined thresholds are crossed.

(10) Property and Equipment, Net

Property and equipment, net as of August 31 is summarized as follows (in thousands):

	2024	2023
Land and improvements	\$ 253,178	\$ 252,264
Buildings and improvements	5,397,810	4,979,437
Equipment	3,678,621	3,509,917
Finance lease ROU assets (note 11)	25,248	24,926
Library and museum assets	579,064	555,924
Construction in progress	249,121	503,778
	10,183,042	9,826,246
Less: accumulated depreciation	(5,462,688)	(5,132,809)
Less: accumulated amortization of finance leases	(13,022)	(11,337)
Total property, plant, and equipment, net	\$ 4,707,332	\$ 4,682,100

The University has identified asset retirement obligations predominantly from commitments to remove asbestos and lead paint in the University's facilities at the time of major renovation or demolition. The liability was estimated using an inflation rate of 5.0% and a discount rate of 4.25%.

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2024 AND 2023

(11) Leases

The University has operating and finance leases for office buildings, research and development facilities, hospital and educational buildings, and certain equipment. Leases have remaining lease terms of 1 year to 25 years, some of which include purchase options or options to extend the leases.

Operating leases except for leases with an initial term less than 12 months for which the University made the short-term election are included in operating lease right-of-use assets and operating lease liabilities in the accompanying consolidated statements of financial position. Finance leases are included in property, plant, and equipment, net, and finance lease liabilities in the accompanying consolidated statements of financial position.

Operating lease liabilities represent the remaining fixed lease payments discounted to present value, while the right-of-use (ROU) assets include any lease payments made, lease incentives received, and are amortized over the term of the lease. Renewal options are excluded from the calculation of lease liabilities unless it is reasonably assured that the renewal option will be exercised. Lease costs associated with operating lease assets are recognized on a straight-line basis within operating expenses over the term of the lease.

Finance lease ROU assets are amortized within operating expenses on a straight-line basis over the shorter of the estimated useful lives of the assets or the lease term. The interest component of a finance lease is included in interest expense and recognized using the effective interest-method over the lease term. Variable lease costs, such as common area maintenance, property taxes, and insurance are expensed as incurred.

Emory has lease agreements with lease and nonlease components. The University elected a practical expedient, primarily for its copier leases, whereby nonlease components are not separated from the lease component. This results in all of the lease and nonlease components being combined, and accounted for, as a

single lease component and included in the measurement of the ROU assets and lease liabilities.

The components of lease expense for the year ended August 31, are as follows (in thousands):

	2024	2023
Finance lease cost	\$ 2,368	\$ 2,917
Amortization of ROU assets	1,686	2,235
Interest on lease liabilities	682	682
Operating lease cost	41,201	42,056
Short-term lease cost	25,518	20,203
Total lease expense	\$ 69,087	\$ 65,176

Aggregate future payments under noncancelable operating and finance leases as of August 31, 2024 are as follows (in thousands):

	Operating Leases	Finance Leases
2025	38,106	1,576
2026	30,910	1,507
2027	26,155	1,334
2028	21,435	1,131
2029	19,441	1,046
Thereafter	94,792	16,929
Total lease payments	230,839	23,523
Less: amounts representing interest	(23,914)	(7,025)
Total obligation	\$ 206,925	16,498

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2024 AND 2023

Supplemental cash flow information related to leases for the year ended August 31 is as follows (in thousands):

	2024	2023
Other information		
Cash paid for amounts included in the measurement of lease liabilities		
Operating cash flows from operating leases	\$ 35,376	\$ 38,357
Operating cash flows from finance leases	1,686	2,235
Financing cash flows from finance leases	1,194	1,715
Right-of-use assets obtained in exchange for new lease obligations		
Operating leases	1,407	10,284
Finance leases	407	2,736
Weighted-average remaining lease term -- finance lease	19 years	20 years
Weighted-average remaining lease term -- operating lease	10 years	10 years
Weighted-average discount rate -- finance lease	3.93%	3.90%
Weighted-average discount rate -- operating lease	2.21%	2.25%

Emory is the lessor in a long-term noncancelable operating sublease for space to serve as an expanded point of entry for imaging and surgical cases for Emory Healthcare at its Executive Park property. The lease agreement's underlying asset will continue to be classified as the original lessor's fixed asset.

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2024 AND 2023

(12) Bonds and Notes Payable

Bonds and notes payable, including unamortized premiums, discounts, and issuance costs, consisted of the following as of August 31 (dollars in thousands):

	Average Interest Rate	Final Maturity	Outstanding Principal	
			2024	2023
Tax-exempt, fixed-rate revenue bonds:				
2023 Series A	5.00%	September 1, 2033	\$ 142,500	\$ 142,500
2023 Series B	5.00	September 1, 2033	234,750	234,750
2022 Series A	5.00	September 1, 2032	212,055	212,055
2020 Series B	4.63	September 1, 2041	486,470	486,470
2019 Series A	4.96	September 1, 2039	187,085	194,625
2019 Series B	5.00	September 1, 2048	39,725	39,725
2016 Series A	4.62	October 1, 2046	130,030	130,030
2016 Series B	4.16	October 1, 2043	186,770	189,915
2013 Series A	5.01	October 1, 2043	177,850	177,850
Total tax-exempt, fixed-rate revenue bonds			1,797,235	1,807,920
Tax-exempt, variable-rate revenue bonds:				
2022 Series B	3.54	September 1, 2052	110,380	110,380
Total tax-exempt, variable-rate revenue bonds			110,380	110,380
Taxable, fixed-rate reveue bonds:				
2020 Series A	2.41	September 1, 2050	943,750	943,750
1994 Series C	8.00	October 1, 2024	825	1,590
Total taxable, fixed-rate revenue bonds			944,575	945,340
Taxable, variable-rate reveue bonds:				
2022 Series C-1 ⁽¹⁾	5.72	September 1, 2052	110,450	110,450
2022 Series C-2 ⁽¹⁾	5.67	September 1, 2052	110,445	110,445
Total taxable, variable-rate revenue bonds			220,895	220,895
Unamortized bond premiums			241,856	269,923
Bond issuance costs			(10,662)	(11,177)
Total bonds and notes payable			\$ 3,304,279	\$ 3,343,281

⁽¹⁾ Average reset rates taken from Electronic Municipal Market Access (EMMA), plus credit facility and remarketing fees.

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2024 AND 2023

The University incurred interest expenses of \$110.3 million and \$94.9 million in 2024 and 2023, respectively, net of capitalized interest of \$17.5 million and \$8.7 million in 2024 and 2023, respectively. During 2024, the average interest rate on the University's tax-exempt variable demand bonds, including fees, was 3.54% and the average interest rate on taxable variable bonds, including fees, was 5.70%. Related indices for this period were 3.50% for tax-exempt debt Securities Industry and Financial Markets Association Index (SIFMA), and 5.32% for taxable debt.

As of August 31, 2024 the aggregate annual maturities of bonds and notes payable for the next five years and thereafter are as follows (in thousands):

	2024
PAYABLE IN FISCAL YEAR:	
2025	\$ 9,990
2026	290,610
2027	11,825
2028	12,185
2029	12,845
Thereafter	2,735,630
	3,073,085
Unamortized net premium	241,856
Unamortized net bond issuance costs	(10,662)
	\$ 3,304,279

The 2008 taxable Commercial Paper program of \$350.0 million had an outstanding balance of \$0.0 million, as of August 31, 2024 and 2023 under this program. During fiscal year 2024, the University borrowed \$350.0 million under this program, which was paid back in full prior to year-end.

The University has three credit facilities to enable the University to purchase tendered variable rate debt in the event of a failed remarketing. It has a direct-pay letter of credit supporting the 2022 C-1 bonds totaling \$110.5 million, a standby bond purchase agreement supporting 2022 C-2 bonds totaling \$110.5 million, and a revolving credit agreement supporting any self-liquidity debt totaling \$175.0 million. These credit facilities are committed for the sole purpose of supporting these debt instruments and cannot be used for operating needs of the University. There were no draws against any of these facilities in 2024 or 2023.

The University has a syndicated line of credit of \$750.0 million that expires in April 2026. During fiscal year 2024, the University borrowed \$150.0 million against the line of credit, which was paid back in full prior to year-end. There is no outstanding balance as of August 31, 2024, and 2023. Through November 2024, the University has borrowed \$325.0 million against the line of credit.

The University has a letter of credit with a commercial bank totaling \$1.1 million. There were no outstanding balances as of August 31, 2024 or 2023. The letter of credit agreement expires in March 2025.

The terms of the University's long-term debt provide for certain financial and nonfinancial covenants, including provisions as to the use of the proceeds, limits as to arbitrage and bond issuance costs, and various other administrative requirements.

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2024 AND 2023

(13) Net Assets

The following is a summary of net assets as of August 31 (in thousands):

	2024			2023		
	Without Donor Restrictions	With Donor Restrictions	Total	Without Donor Restrictions	With Donor Restrictions	Total
Emory undesignated funds	\$ 2,418,671	–	2,418,671	\$ 2,392,517	–	2,392,517
Endowment funds	2,610,644	5,478,198	8,088,842	2,367,757	5,126,203	7,493,960
Investment in plant	1,261,517	–	1,261,517	1,181,279	–	1,181,279
Interest in perpetual funds held by others	–	2,013,211	2,013,211	–	1,716,576	1,716,576
Contributions receivable, net	–	150,498	150,498	–	178,474	178,474
Annuity and other split-interest agreements	–	11,292	11,292	–	10,917	10,917
Capital maintenance, infrastructure, and other donor purposes	–	58,039	58,039	–	59,858	59,858
	\$ 6,290,832	7,711,238	14,002,070	\$ 5,941,553	7,092,028	13,033,581

(14) Retirement and Deferred Compensation Plans

The University has a defined-contribution plan under the Code, Section 403(b), covering eligible employees. The University contributes an amount equal to 6% of each eligible employee's compensation to the plan as well as a supplemental contribution of 3% based on a 1.5 to 1 match of employee contributions of up to 2% of compensation. Employer contributions cliff vest after three years of service.

Emory Healthcare sponsors a retirement plan, covering most full-time employees, under which annuities are purchased with contributions made by Emory Healthcare. Benefits to eligible employees were based on a formula defined in the plan. Benefits are paid as a monthly annuity at age 65 or an eligible employee can elect a reduced benefit as early as age 55. The benefits are vested only to the extent of the annuities purchased. Benefits were frozen as of 12/31/2011. Emory Healthcare also has a defined-contribution plan under the Code, Section 403(b), covering eligible employees. Emory Healthcare contributes an amount equal to 2% of each eligible employee's compensation to the plan as well as a supplemental contribution of up to 5% based on a 1 to 1 match of employee contributions of up to 4% for eligible employees with less than 10 years of service and 5% if 10 or more years of service. Employer contributions cliff vest after three years of service.

TEC sponsors a defined-contribution plan under the Code, Section 403(b), The Emory Clinic, Inc. Retirement Savings Plan

covering eligible employees. TEC contributes an amount equal to 6% of each eligible employee's compensation to the plan as well as a supplemental contribution of 3% based on a 1.5 to 1 match of employee contributions of up to 2% of compensation. Employer contributions cliff vest after three years of service.

Retirement expenses for these plans totaled \$227.5 million and \$204.7 million during 2024 and 2023, respectively, and are included in fringe benefits expense in the accompanying consolidated statements of activities.

The University sponsors the Code Section 457(b) Deferred Compensation Plan primarily for the purpose of providing deferred compensation for a select group of management or highly compensated employees who are eligible for participation and elect to make salary deferrals under the Deferred Compensation Plan. These assets are fully vested and available to the participating employees at the time of termination of employment from the University. As of August 31, 2024 and 2023, respectively, the University held assets of \$270.7 million and \$220.1 million under the Retirement Plan. These assets are included in other assets, which are designated by the University to pay future salary deferral plan payments. The assets are held in separate investment funds for which the majority are classified as Level 1 in the fair value hierarchy. Associated liabilities for the obligations of \$270.7 million and \$220.1 million as of August 31, 2024 and 2023, respectively, are included in accrued liabilities for benefit obligations and professional liabilities and considered Level 2 in the fair value hierarchy.

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2024 AND 2023

(15) Pension Plans – Emory Healthcare

Emory Healthcare sponsors a defined-benefit pension plan (the Plan). The Plan was curtailed effective December 31, 2011. The terms of the curtailment generally provide that no further benefit accrual under the Plan is provided for service after the effective date nor will new entrants into the Plan be permitted after the effective date.

On December 31, 2022, Emory Healthcare split the Plan into two separate plans. All participants with a lump sum value of less than \$5,000 at December 31, 2022 remained in the original plan and were offered to receive the present value of their pension benefit in a lump sum. The lump sum payouts reduced both the projected benefit obligation and plan assets by \$1.5 million. All other participants and beneficiaries were transferred to the new plan (Plan 2). The total amount of projected benefit obligation and the original plan assets that were transferred to Plan 2 were \$327.3 million and \$281.7 million, respectively. Effective May 1, 2023, Emory Healthcare terminated the original plan. As a result of the termination, a one-time settlement charge of \$0.4 million is reflected in other nonoperating activities in the accompanying consolidated statements of activities as of August 31, 2023. No changes were made to the plan benefits.

The Plan's investment objectives related to its defined benefit plan are to protect long-term asset value by applying prudent, low-risk, high-quality investment disciplines and to enhance the values by maximizing investment returns through active security management within the Plan's investment policy framework. Asset allocation strategies and investment management structure are designed to meet the Plan's investment objectives.

The Plan's expected long-term rate of return on assets is determined by reviewing the historical return of each asset category comprising the Plan's target asset allocation.

The Joint Operating Company (JOC) assumed certain defined-benefit pension liabilities covering certain employees of the entities contributed to the JOC by Saint Joseph's Health System SJHS (the SJHS Pension Plan). The plan was curtailed, effective December 31, 2011, and the JOC has agreed to provide for funding of the plan, generally over 10 years, beginning in fiscal year 2015, subject to certain terms and conditions.

The SJHS Pension Plan's expected long-term rate of return on assets is determined by reviewing the historical return of each asset category comprising the plan's target asset allocation. The accumulated benefit obligations at August 31, 2024 and 2023 are the same as the projected benefit obligations.

The changes in the projected benefit obligations as of and for the years ended August 31 are as follows (in thousands):

		2024		2023	
		Emory Healthcare	SJHS	Emory Healthcare	SJHS
Projected benefit obligation, beginning of year	\$	304,320	123,478	\$ 329,276	134,574
Interest cost		16,427	6,632	15,337	6,328
Actuarial (gain) loss		12,173	4,064	(26,874)	(10,119)
Plan settlements		—	—	(1,467)	—
Benefits paid		(13,941)	(7,629)	(11,952)	(7,305)
Projected benefit obligation, end of year	\$	318,979	126,545	\$ 304,320	123,478

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2024 AND 2023

The changes in the fair value of plan assets, funded status of the plans, and the status of amounts recognized in the accompanying consolidated statements of financial position as of and for the years ended August 31 are as follows (in thousands):

	2024		2023	
	Emory Healthcare	SJHS	Emory Healthcare	SJHS
Fair Value of plan assets, beginning of year	\$ 265,138	124,932	\$ 283,952	128,194
Actual return on plan assets	28,510	10,864	(5,395)	2,232
Employer contributions	–	575	–	1,812
Plan settlements	–	–	(1,467)	–
Benefits paid	(13,941)	(7,629)	(11,952)	(7,305)
Fair value of plan assets, end of year	\$ 279,707	128,742	\$ 265,138	124,933
Funded status - accrued pension cost recognized in the consolidated statements of financial position	\$ (39,272)	2,197	\$ (39,182)	1,454

The components of net periodic pension cost for the years ended August 31 are as follows (in thousands):

	2024		2023	
	Emory Healthcare	SJHS	Emory Healthcare	SJHS
Interest cost	\$ 16,427	6,632	\$ 15,337	6,328
Expected return on assets	(13,851)	(7,213)	(15,595)	(6,514)
Amortization of prior service cost	–	(438)	–	(438)
Settlement loss recognized	–	–	449	–
Amortization of net loss	–	1,898	213	2,092
Net periodic pension cost	\$ 2,576	879	\$ 404	1,468

Net periodic pension costs are recognized as employees render the services necessary to earn the pension benefits

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2024 AND 2023

Weighted average assumptions used to determine benefit obligations in the accompanying consolidated statements of financial position as of August 31 are as follows:

	2024		2023	
	Emory Healthcare	SJHS	Emory Healthcare	SJHS
Discount rate	5.25%	5.21%	5.56%	5.55%
Expected long-term rate of return on plan assets	4.50	5.95	4.95	5.20

Weighted average assumptions used to determine net periodic pension cost for the years ended August 31 are as follows:

	2024		2023	
	Emory Healthcare	SJHS	Emory Healthcare	SJHS
Discount rate	5.56%	5.55%	4.84%	4.84%
Expected long-term rate of return on plan assets	4.50	5.95	4.95	5.20

The following tables summarize the plan assets, which are recorded at fair value as of August 31 as follows (in thousands):

2024									
	Emory			Fair Value Hierarchy			Total	Target	
	Healthcare	SJHS	Total	Level 1	Level 2	NAV	Fair Value	Allocation ⁽¹⁾	
INVESTMENTS:									
Short-term investments and cash equivalents	\$	1,794	3,235	5,029	5,006	23	—	5,029	—%
Public equity		101,614	9,367	110,981	1,427	101,353	8,201	110,981	64
Absolute return		15,668	—	15,668	—	—	15,668	15,668	4
Private equity/venture capital		15,200	7	15,207	—	—	15,207	15,207	2
Fixed income		145,431	116,133	261,564	—	230,328	31,236	261,564	30
Total investments	\$	279,707	128,742	408,449	6,433	331,704	70,312	408,449	100%

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2024 AND 2023

2023									
	Emory		Total	Fair Value Hierarchy			Total	Target	
	Healthcare	SJHS		Level 1	Level 2	NAV	Fair Value	Allocation ⁽¹⁾	
INVESTMENTS:									
Short-term investments and cash equivalents	\$	20,491	4,854	25,345	25,345	—	—	25,345	—%
Public equity		77,134	16,739	93,873	4,327	76,881	12,665	93,873	64
Absolute return		13,963	—	13,963	—	—	13,963	13,963	4
Private equity/venture capital		12,568	—	12,568	—	—	12,568	12,568	2
Fixed income		140,982	103,340	244,322	—	219,755	24,567	244,322	30
Total investments	\$	265,138	124,933	390,071	29,672	296,636	63,763	390,071	100%

⁽¹⁾ While each plan has an individual target asset allocation, the percentage represents the averages for all plans assets.

Cash Flows

Emory Healthcare expects to contribute \$3.1 million to the Emory Healthcare Pension Plan, and \$0.6 million to the SJHS Pension Plan during fiscal year 2025.

Expected Future Benefit Payments

Emory Healthcare annual future benefit payments, excluding lump-sum settlements, are expected to range from \$16.1 million to \$20.4 million for the next five years. SJHS Pension Plan annual future benefit payments, excluding lump-sum settlements, are expected to range from \$7.9 million to \$8.9 million for the next five years.

Other Items

Emory Healthcare uses the straight-line method to amortize prior service cost for both plans.

(16) Postretirement Healthcare and Life Insurance Benefits

The University sponsors a postretirement life insurance and healthcare benefits plan. Participants hired after 2002 pay the full retiree-specific premium equivalent and are therefore assumed to pay the full cost of their coverage. The University and Emory Healthcare each fund a separate trust (VEBA Trust) for retiree health and life benefits. The assets of the VEBA Trust are invested primarily in equity and fixed-income securities. The University funds these benefits only to the extent of current retiree claims. The University measures its participation in the VEBA Trust at August 31 each fiscal year.

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2024 AND 2023

The changes in the accumulated postretirement benefit obligation (APBO) as of August 31 are as follows (in thousands):

	2024			2023	
	Emory University	Emory Healthcare	Total	Total	
APBO, beginning of year	\$ 92,873	51,778	144,651	\$	151,161
Service cost	612	202	814		1,035
Interest cost	4,999	2,782	7,781		6,969
Actuarial loss (gains)	6,569	1,206	7,775		(7,569)
Benefits paid	(5,047)	(2,373)	(7,420)		(6,945)
APBO, end of year	\$ 100,006	53,595	153,601	\$	144,651

The discount rate to determine APBO as of August 31, 2024 and 2023 was 5.25% and 5.56%, respectively.

The changes in the fair value of plan assets, funded status of the plan, and the status of the accrued postretirement benefit obligation recognized in the accompanying consolidated statements of financial position as of and for the years ended August 31 are as follows (in thousands):

	2024			2023	
	Emory University	Emory Healthcare	Total	Total	
Fair value of plan assets, beginning of year	\$ 89,906	15,566	105,472	\$	101,134
Actual return on plan assets	13,489	2,354	15,843		6,507
Benefits paid from plan assets	–	(2,373)	(2,373)		(2,169)
Fair value of plan assets, end of year	\$ 103,395	15,547	118,942	\$	105,472
Funded status – accrued postretirement benefit cost recognized in the consolidated statements of financial position	\$ 3,389	(38,048)	(34,659)	\$	(39,179)

The components of net periodic postretirement benefit cost for the years ended August 31 are as follows (in thousands):

	2024			2023	
	Emory University	Emory Healthcare	Total	Total	
Service cost of benefits earned	\$ 612	202	814	\$	1,035
Interest cost on APBO	4,999	2,782	7,781		6,969
Expected return on plan assets	(5,844)	(913)	(6,757)		(6,980)
Recognized net actuarial loss	964	–	964		1,739
Net periodic postretirement benefit cost	\$ 731	2,071	2,802	\$	2,763

Discount rate and expected return on plan assets used to determine net periodic postretirement benefit cost for the years ended August 31, 2024 and 2023 was 5.56% and 4.8%, respectively, and 6.50% and 7.0%, respectively.

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2024 AND 2023

The amounts accumulated in net assets without donor restrictions follow as of August 31 (in thousands):

	2024			2023	
	Emory University	Emory Healthcare	Total	Total	
Net unrecognized actuarial loss	\$ 19,970	4,819	24,789	\$	27,064
Prior service cost	—	—	—		—
Total	\$ 19,970	4,819	24,789	\$	27,064

In fiscal year 2025, there is no gain or loss expected to be amortized for Emory University or for Emory Healthcare from net assets without donor restrictions into net periodic postretirement benefit cost.

Plan Assets

The Investment Committee of Emory University's Board of Trustees approves the investment guidelines and asset allocation targets for the pension benefits and postretirement benefits plans. The primary objective of the investments is to ensure the solvency of the plans over time to meet plan obligations.

The secondary objective is to meet or exceed the plans' actuarial assumed rate of return over time without taking excess risk. The funds are diversified by asset class in accordance with established allocation targets and rebalanced as needed. Specific investments are apportioned to a combination of institutional pooled funds and mutual funds.

The following table summarizes the VEBA Trust assets for the University and Emory Healthcare as of August 31 (in thousands):

2024						
	Total Fair Value	Fair Value Hierarchy		NAV	Target	
		Level 1	Level 2		Allocation ⁽¹⁾	
Fixed income	\$ 58,729	603	58,083	43	55%	
Public equity	41,818	—	38,362	3,456	30	
Absolute return	11,972	5,560	—	6,412	10	
Private equity/venture capital	5,661	—	—	5,661	5	
Short-term investment and cash equivalent	762	762	—	—	—	
Total investments	\$ 118,942	6,925	96,445	15,572	100%	

2023						
	Total Fair Value	Fair Value Hierarchy		NAV	Target	
		Level 1	Level 2		Allocation ⁽¹⁾	
Fixed income	\$ 27,923	10,148	16,775	1,000	29%	
Public equity	60,887	—	47,370	13,517	56	
Absolute return	10,753	5,047	—	5,706	10	
Private equity/venture capital	4,666	—	—	4,666	5	
Short-term investment and cash equivalent	1,243	1,243	—	—	—	
Total investments	\$ 105,472	16,438	64,145	24,889	100%	

⁽¹⁾ While each plan has an individual target asset allocation, the percentage represents the averages for all plans assets.

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2024 AND 2023

Cash Flows

Emory University and Emory Healthcare expect to contribute \$5.5 million and \$0.0 million, respectively, to the postretirement benefit plan during fiscal year 2025.

Expected Future Benefit Payments

Annual future benefit payments are expected to range from \$5.5 million to \$6.2 million for Emory University and from \$3.3 million to \$3.5 million for Emory Healthcare for the next five years.

(17) Functional Expenses

The accompanying consolidated statements of activities present expenses by natural classification. The University also summarizes expenses by functional classification, in accordance with its mission. The University's primary program services are instruction, research, public service, and the delivery of healthcare and medical services. Expenses for academic support, institutional support, and independent operations/auxiliary enterprises are generally incurred in support of these primary program activities, with academic support being related to student financial aid. Capital and plant expenditures, costs for operation and maintenance of plant, interest on indebtedness, and depreciation and amortization are allocated using a variety of cost allocation techniques, such as square footage and time and effort.

The accompanying consolidated statements of activities include the following functional expenses for the years ended August 31 (in thousands, net of the cost allocations and recharges referenced above):

2024						
		Instruction and Academic Support	Research and Public Service	Non-Academic Operations ⁽¹⁾	Healthcare and Medical Services ⁽²⁾	Total
Salaries	\$	493,873	453,234	333,865	3,391,158	4,672,130
Fringe benefits		126,704	119,777	92,303	741,865	1,080,649
Student financial aid		24,248	—	—	—	24,248
Other operating expenses		168,372	417,479	20,048	2,607,650	3,213,549
Interest on indebtedness		8,575	9,663	15,484	76,564	110,286
Depreciation and amortization		59,748	72,690	50,714	215,027	398,179
Total expenses	\$	881,520	1,072,843	512,414	7,032,264	9,499,041

⁽¹⁾ Non-Academic Operations includes \$301.1 million of institutional support and \$211.3 million of independent operations and auxiliary enterprises.

⁽²⁾ Healthcare and Medical Services – The portion of patient care services related to Emory Healthcare expense is \$6.7 billion. Healthcare administrative costs are \$759.6 million, included therein.

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2024 AND 2023

2023						
		Instruction and Academic Support	Research and Public Service	Non-Academic Operations ⁽¹⁾	Healthcare and Medical Services ⁽²⁾	Total
Salaries	\$	458,433	407,302	304,208	3,143,794	4,313,737
Fringe benefits		109,991	108,730	86,453	630,693	935,867
Student financial aid		22,604	—	—	—	22,604
Other operating expenses		156,650	347,188	85,948	2,256,311	2,846,097
Interest on indebtedness		12,812	14,438	23,822	41,824	92,896
Depreciation and amortization		55,535	67,501	47,503	188,881	359,420
Total expenses	\$	816,025	945,159	547,934	6,261,503	8,570,621

⁽¹⁾ Non-Academic Operations includes \$327.0 million of institutional support and \$220.9 million of independent operations and auxiliary enterprises.

⁽²⁾ Healthcare and Medical Services – The portion of patient care services related to Emory Healthcare expense is \$6.0 billion. Healthcare administrative costs are \$720.8 million, included therein.

Costs related to the University's operation and maintenance of property, including depreciation of property and equipment and interest on related debt, are allocated to program, and supporting activities based upon information reported in the space study and debt financing records. Fundraising costs were approximately \$60.0 million and \$56.2 million in 2024 and 2023, respectively.

(18) Medical Professional and General Liability Insurance Coverage

CCIC, Emory Healthcare's wholly owned offshore captive insurer, provides claims-made primary medical professional and general liability coverage for the University, the Hospitals, Emory Clinic, Emory Specialty Associates, and Wesley Woods Center.

As of August 31, 2024 and 2023, the University has recorded an accrual for estimated losses associated with all retained CCIC risks of approximately \$382.9 million (discounted at 2.5%) and \$306.0 million (discounted at 2.5%), respectively.

Emory has purchased layered excess and umbrella reinsurance coverage beyond the primary and buffer layers retained by CCIC, through various carriers, for a grand total of \$228.0 million per claim and in the aggregate for the full program.

The estimated liability for professional and general liability claims will be significantly affected if current and future claims differ from historical trends. While the University monitors reported claims closely and considers potential outcomes as estimated by its actuaries when determining its professional and general liability accruals, the complexity of the claims, the extended period of time to settle the claims, and the wide range

of potential outcomes complicate the estimation. The University's management believes adequate provision has been made for the related risk.

(19) Related-Party Transactions

The Carter Center, Inc. (CCI) is a nonprofit corporation founded by former U.S. President Jimmy Carter and Rosalynn Carter, which sponsors various domestic and international programs. The Board of Trustees of CCI is comprised of between 14 to 26 members of which half are elected by the University, including the University's president, and half, one of which shall be a lineal descendant of President and Mrs. Carter, are elected by the Carter Center class trustees. The University's Board of Trustees has the authority to approve amendments to CCI's articles of incorporation and bylaws. Funds held in trust for others include \$1.1 billion and \$1.0 billion, representing CCI's investment in the University's long-term investment portfolio as of August 31, 2024 and 2023, respectively. CCI is permitted partial withdrawals of up to 10% per year (inclusive of regular spending payouts), with 30 days' written notice prior to a calendar quarter or fiscal year end. A full withdrawal request by CCI requires at least one years' written notice and is subject to a multi-year distribution schedule in line with the duration of the long-term investment portfolio, as agreed upon by both CCI and the University.

Emory University and Children's Healthcare of Atlanta, Inc. (Children's), a Georgia nonprofit corporation, established the Emory + Children's Pediatric Institute (the Institute) effective September 1, 2018 under a Master Affiliation Agreement (the affiliation agreement). Under the terms of the affiliation agreement, approximately 350 Emory University School of

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2024 AND 2023

Medicine Department of Pediatrics faculty physicians and PhD researchers transferred to the Institute and became employees thereof. The affiliation agreement restructured previous arrangements between the parties for pediatric teaching, research, and related clinical services. The ownership of the Institute is 50% Emory University and 50% Children's, with equal representation on the governing board. The funding obligations of each party are specified by the affiliation agreement, and each party funds its mission-related expenses. The University reports research and teaching expenses provided by the faculty members in salaries, fringe benefits, professional fees and purchased services, and other operating expenses in the accompanying consolidated statements of activities.

(20) Commitments and Contingencies

Purchase Commitments

Emory University and Emory Healthcare are in the process of constructing, renovating, and equipping certain facilities for which the outstanding commitments at August 31, 2024 totaled \$45.5 million and \$138.2 million, respectively.

Federal and State Regulatory Matters

Expenditures and indirect costs related to federal and state grants and contracts are subject to adjustment based upon review by the granting agencies. The amounts, if any, of expenditures which may be disallowed by the granting agencies, are not expected to have a material effect on the University's consolidated financial statements.

The University is subject to many federal and state regulations, and as a result, there may be one or more pending government investigations ongoing at any time. While the outcome of these actions is not presently determinable, it is the opinion of management that any resulting liability from these actions will not have a material adverse effect on the accompanying consolidated statements of financial position.

Other Legal Matters

Lawsuits and claims have been filed against the University in the ordinary course of business. As one of the nation's largest research universities and academic medical centers, the University has active litigation that takes several forms. The University's policy is to accrue for litigation and claims when such amounts are probable and can be reasonably estimated based on consultation with external legal counsel and Emory General Counsel. The University also has a comprehensive program of primary and excess insurance.

Emory Healthcare and SJHS have a JOC under the name of Emory/Saint Joseph's, Inc. to further the respective missions of Emory Healthcare and CHE Trinity Health. Under the JOC Contribution Agreement, Emory Healthcare maintains a 51% controlling ownership interest in the JOC. SJHS has a noncontrolling membership interest in the JOC of 49%. Effective August 31, 2014, CHE Trinity Health has a put right, as defined in the JOC Contribution Agreement, that may be exercised at any time with written notice to Emory Healthcare. Upon the occurrence of such event, Emory Healthcare may be required to purchase from SJHS its noncontrolling interest in the JOC. On March 25, 2022, CHE Trinity Health filed a complaint against Emory Healthcare in the Superior Court of Fulton County, Georgia, alleging breach of contract relating to a potential sale of CHE Trinity Health's 49% membership interest in the JOC. In September 2023, the Superior Court of Fulton, County, Georgia granted Summary Judgment in favor of Emory Healthcare and ruled that the Memorandum of Understanding dictating the valuation process and purchase process is an unenforceable agreement. In October 2023, CHE Trinity Health filed an appeal of the ruling with the Georgia Court of Appeals. In the event Emory Healthcare closes the purchase of CHE Trinity's membership interest in the JOC, Emory Healthcare has sufficient sources of available liquidity to consummate the transaction.

In July 2024, the United States District Court for the Northern District of Illinois approved a settlement agreement in *Carbone, et al. v. Brown University, et al.* The Court granted final judgement and disposed all claims against the settling parties, Emory included. The amount of the settlement was previously recorded in fiscal year 2023 and paid out in fiscal year 2024.

(21) Subsequent Events

Emory has evaluated subsequent events after the accompanying consolidated statements of financial position date of August 31, 2024 through December 18, 2024, the date the consolidated financial statements were issued and noted that there are no other items to disclose that would have a material impact on the University's accompanying consolidated statements of financial position.

SUPPLEMENTARY INFORMATION

EMORY UNIVERSITY (EXCLUDING EMORY HEALTHCARE)
STATEMENTS OF FINANCIAL POSITION - SUPPLEMENTARY INFORMATION
SCHEDULE 1

AUGUST 31, 2024 AND 2023 (Dollars in thousands)

	August 31, 2024	August 31, 2023
ASSETS:		
Cash and cash equivalents	\$ 385,644	\$ 711,916
Student accounts receivable, net	19,886	20,466
Loans receivable, net	14,524	15,143
Contributions receivable, net	150,498	178,701
Other receivables, net	268,501	241,070
Prepaid expenses, deferred charges, and other assets	195,325	160,822
Investments	11,131,500	10,581,455
Interests in perpetual funds held by others	2,013,211	1,716,576
Operating lease right-of-use assets	72,498	78,661
Property and equipment, net	2,436,750	2,412,140
Due from affiliates	1,577,897	1,293,910
Total assets	\$ 18,266,234	\$ 17,410,860
LIABILITIES AND NET ASSETS:		
Accounts payable and accrued liabilities	\$ 275,192	\$ 279,234
Deferred revenue	322,433	359,413
Interest payable	53,624	46,338
Liability for derivative instruments	32,604	39,664
Bonds and notes payable	3,304,279	3,343,281
Accrued liabilities for benefit obligations and professional liabilities	200,149	172,313
Operating lease liabilities	79,122	85,000
Finance lease liabilities	16,498	17,378
Funds held in trust for others	1,183,408	1,109,200
Annuities payable	13,737	13,245
Government advances for federal loan programs	13,281	13,834
Asset retirement obligations	69,147	66,273
Total liabilities	5,563,474	5,545,173
Net assets without donor restrictions	5,023,115	4,803,697
Net assets with donor restrictions	7,679,645	7,061,990
Total net assets	12,702,760	11,865,687
TOTAL LIABILITIES AND NET ASSETS	\$ 18,266,234	\$ 17,410,860

See accompanying independent auditors' report.

EMORY UNIVERSITY (EXCLUDING EMORY HEALTHCARE)
STATEMENTS OF ACTIVITIES - SUPPLEMENTARY INFORMATION
SCHEDULE 2

YEAR ENDED AUGUST 31, 2024 (WITH SUMMARIZED COMPARATIVE INFORMATION FOR AUGUST 31, 2023) (Dollars in thousands)

	Net Assets without Donor Restrictions	Net Assets with Donor Restrictions	Total August 31, 2024	Total August 31, 2023
OPERATING REVENUE				
Tuition and fees, net of scholarship allowance	\$ 532,165	-	\$ 532,165	\$ 522,206
Sales and services of auxiliary enterprises, net of scholarship allowance	83,169	-	83,169	78,507
Endowment spending distribution	280,141	-	280,141	245,478
Distribution from perpetual funds	49,094	-	49,094	44,830
Other investment income designated for current operations	83,112	-	83,112	87,487
Gifts and contributions for current use	50,401	10,750	61,151	70,121
Grants and contracts	790,137	-	790,137	704,398
Indirect cost recoveries	235,529	-	235,529	213,104
Medical services	359,413	-	359,413	292,244
Independent operations	23,695	-	23,695	19,221
Other revenue	172,138	-	172,138	211,575
Net assets released from restrictions	35,644	(16,133)	19,511	7,292
Total operating revenue	2,694,638	(5,383)	2,689,255	2,496,463
Operating support from Emory Healthcare	115,421	-	115,421	83,138
Total operating revenue and other support	2,810,059	(5,383)	2,804,676	2,579,601
OPERATING EXPENSES				
Salaries	1,582,886	-	1,582,886	1,438,433
Fringe benefits	409,598	-	409,598	363,609
Student financial aid	24,248	-	24,248	22,604
Other operating expenses	603,836	-	603,836	572,672
Interest on indebtedness	33,995	-	33,995	51,481
Depreciation and amortization	189,963	-	189,963	176,871
Total operating expenses	2,844,526	-	2,844,526	2,625,670
NET OPERATING ACTIVITIES	(34,467)	(5,383)	(39,850)	(46,069)
NONOPERATING ACTIVITIES, NET				
Investment return	233,024	278,797	511,821	(36,704)
Change in undistributed income from perpetual funds held by others	-	285,135	285,135	22,918
Gifts and contributions for capital and long-term investment	6,364	104,400	110,764	136,166
Other losses	(2,020)	-	(2,020)	(698)
Gain on retirement of debt	5,982	-	5,982	-
Change in fair value of derivative instruments	(12,361)	-	(12,361)	47,602
Net periodic benefit cost other than service cost	(119)	-	(119)	115
Changes in pension and other postretirement obligations	2,040	-	2,040	5,825
Other nonoperating items, net	1,775	(6,583)	(4,808)	(4,992)
Net assets released from restrictions	19,200	(38,711)	(19,511)	(7,292)
Total nonoperating activities, net	253,885	623,038	876,923	162,940
CHANGE IN NET ASSETS	219,418	617,655	837,073	116,871
BEGINNING NET ASSETS	4,803,697	7,061,990	11,865,687	11,748,816
ENDING NET ASSETS	\$ 5,023,115	7,679,645	\$ 12,702,760	\$ 11,865,687

See accompanying independent auditors' report.

EMORY UNIVERSITY (EXCLUDING EMORY HEALTHCARE)
STATEMENT OF CASH FLOWS - SUPPLEMENTARY INFORMATION
SCHEDULE 3

YEAR ENDED AUGUST 31, 2024 (Dollars in thousands)

	August 31, 2024
CASH FLOWS FROM OPERATING ACTIVITIES:	
Change in net assets	\$ 837,073
Adjustments to reconcile change in net assets to net cash used in operating activities:	
Contributions and pledge payments restricted for long-term investment and capital projects	(82,799)
Contributions of donated securities	(37,384)
Proceeds from sale of donated securities	4,444
Net realized and unrealized gains on investments	(777,721)
Loss on disposal of property and equipment	2,020
Change in undistributed income from perpetual funds held by others	(285,135)
Depreciation and amortization	187,321
Amortization of bond premiums and issuance costs	(27,110)
Amortization of right-of-use assets	10,661
Change in pension and other postretirement	(1,309)
Change in fair value of derivative instruments	(7,060)
Change in operating assets:	
Accounts and other receivables, net	(26,851)
Contributions receivable for operations	12,133
Prepaid expenses, deferred charges, and other assets	(34,503)
Interests in perpetual funds	6,000
Due to/from affiliates	(283,987)
Change in operating liabilities:	
Accounts payable, accrued liabilities, and interest payable	(11,838)
Asset retirement obligations	2,874
Accrued liabilities for benefit obligations and professional liabilities	29,145
Lease liabilities, net	(8,698)
Deferred revenue	(36,980)
Net cash used in operating activities	(529,704)
CASH FLOWS FROM INVESTING ACTIVITIES:	
Disbursements of loans to students	(1,874)
Repayment of loans from students	2,493
Proceeds from sales and maturities of investments	11,637,123
Purchases of investments	(11,306,318)
Purchases of property, plant, and equipment	(200,233)
Decrease in funds held in trust for others	(28,921)
Net cash provided by investing activities	\$ 102,270

(Continued)

EMORY UNIVERSITY (EXCLUDING EMORY HEALTHCARE)
STATEMENT OF CASH FLOWS - SUPPLEMENTARY INFORMATION
SCHEDULE 3

YEAR ENDED AUGUST 31, 2024 (Dollars in thousands)

August 31, 2024

CASH FLOWS FROM FINANCING ACTIVITIES:

Contributions and pledge payments restricted for long-term investment and capital projects	\$	81,369
Proceeds from sale of donated securities restricted for long-term investment and capital projects		32,940
Proceeds from bonds payable, including commercial paper		350,000
Principal repayments of bonds payable, including commercial paper		(361,450)
Payments on finance lease obligations		(1,194)
Debt issuance costs		(442)
Change in annuities payable		492
Change in government advances for federal loan programs		(553)
Net cash provided by financing activities		101,162
Net change in cash, cash equivalents, and restricted cash		(326,272)
Cash, cash equivalents, and restricted cash at beginning of year		711,916
Cash, cash equivalents, and restricted cash at end of year	\$	385,644

See accompanying independent auditor's report.



KPMG LLP
Suite 2000
303 Peachtree Street, N.E.
Atlanta, GA 30308-3210

Independent Auditors' Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With Government Auditing Standards

The Board of Trustees
Emory University:

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the consolidated financial statements of Emory University and its subsidiaries (the University), which comprise the University's consolidated statement of financial position as of August 31, 2024, and the related consolidated statements of activities, and cash flows for the year then ended, and the related notes to the consolidated financial statements, and have issued our report thereon dated December 18, 2024.

Report on Internal Control Over Financial Reporting

In planning and performing our audit of the consolidated financial statements, we considered the University's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the consolidated financial statements, but not for the purpose of expressing an opinion on the effectiveness of the University's internal control. Accordingly, we do not express an opinion on the effectiveness of the University's internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A material weakness is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected, on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.

Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether the University's consolidated financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.



Purpose of This Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the University's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

KPMG LLP

Atlanta, Georgia
December 18, 2024

**SUPPLEMENTARY SCHEDULE OF EXPENDITURES OF
FEDERAL AWARDS**

EMORY UNIVERSITY AND ITS SUBSIDIARIES
Supplementary Schedule of Expenditures of Federal Awards
Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Research and Development Cluster:				
U.S. Department of Agriculture:				
Agricultural Research Basic and Applied Research	58-6040-022	10.001	\$ —	20,378
Total AL No. 10.001			—	20,378
Wholesale Farmers and Alternative Market Development	22-TMMSD-GA-0009	10.164	23,478	104,335
Pass-through Michigan State University	AM230300WAMSC013	10.164	—	32,114
Total AL No. 10.164			23,478	136,449
Sustainable Agriculture Research and Education:				
Pass-through University of Georgia	20213864034724	10.215	45,012	89,731
Total AL No. 10.215			45,012	89,731
Agriculture and Food Research Initiative (AFRI)	2019-67013-29371	10.310	—	46,341
Agriculture and Food Research Initiative (AFRI)	20196701729642	10.310	—	44,745
Agriculture and Food Research Initiative (AFRI)	20206703431728	10.310	—	13,835
Agriculture and Food Research Initiative (AFRI)	20216703435147	10.310	—	34,902
Agriculture and Food Research Initiative (AFRI)	20226701336133	10.310	—	34,894
Agriculture and Food Research Initiative (AFRI)	20236701240012	10.310	—	78,706
Agriculture and Food Research Initiative (AFRI)	20246701742441	10.310	—	3,819
Pass-through Kansas State University	20206701931157	10.310	—	(114)
Pass-through Mississippi State University	2021-67016-34571	10.310	—	31,048
Pass-through Texas Agricultural and Mechanical Univ	20226701536335	10.310	—	4,213
Pass-through University of Minnesota	20216702334488	10.310	36,845	52,637
Pass-through University of Pittsburgh	20206701733075	10.310	—	85,524
Total AL No. 10.310			36,845	430,550
Partnerships for Climate-Smart Commodities				
Pass-through Rodale Institute	RI-CS04172023-100-Emory	10.937	—	2,876,085
Total AL No. 10.937			—	2,876,085
Contract				
Pass-through Florida Organic Growers	23-NOPXX-FL-0001	10.CTR	—	2,339
Total AL No. 10.CTR			—	2,339
U.S. Department of Agriculture Total			105,335	3,555,532
U.S. Department of Defense:				
Basic and Applied Scientific Research	N00014-24-1-2221	12.300	—	33,283
Total AL No. 12.300			—	33,283
Scientific Research - Combating Weapons of Mass Destruction	HDTRA11810029	12.351	—	(71)
Total AL No. 12.351			—	(71)
Military Medical Research And Development	HT94252310006	12.420	—	107,216
Military Medical Research And Development	HT94252310007	12.420	—	87,270
Military Medical Research And Development	HT94252310134	12.420	—	152,936
Military Medical Research And Development	HT94252310192	12.420	—	187,097
Military Medical Research And Development	HT94252310193	12.420	—	176,440
Military Medical Research And Development	HT94252310318	12.420	143,971	274,601
Military Medical Research And Development	HT94252310420	12.420	—	689,888
Military Medical Research And Development	HT94252310525	12.420	29,016	470,167
Military Medical Research And Development	HT9425-23-1-0609	12.420	—	84,158
Military Medical Research And Development	HT94252310984	12.420	—	130,852
Military Medical Research And Development	S352L5PJLMP8	12.420	—	120,433
Military Medical Research And Development	W81XWH-17-1-0634	12.420	97,874	97,874
Military Medical Research And Development	W81XWH1910498	12.420	41,272	25,819
Military Medical Research And Development	W81XWH1910567	12.420	40,344	40,344
Military Medical Research And Development	W81XWH2010446	12.420	—	(2,152)

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Supplementary Schedule of Expenditures of Federal Awards

Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Military Medical Research And Development	W81XWH2010525	12.420	—	8,556
Military Medical Research And Development	W81XWH2010526	12.420	—	26,792
Military Medical Research And Development	W81XWH-20-1-0851	12.420	—	102,990
Military Medical Research And Development	W81XWH2110124	12.420	—	7,389
Military Medical Research And Development	W81XWH-21-1-0160	12.420	32,894	314,891
Military Medical Research And Development	W81XWH2110237	12.420	96,391	341,662
Military Medical Research And Development	W81XWH2210073	12.420	—	70,029
Military Medical Research And Development	W81XWH2210236	12.420	—	143,343
Military Medical Research And Development	W81XWH2210338	12.420	40,816	86,948
Military Medical Research And Development	W81XWH2210572	12.420	28,207	120,755
Military Medical Research And Development	W81XWH2211040	12.420	72,177	289,418
Pass-through Dana Farber Cancer Institute	W81HWH2110098	12.420	—	73,696
Pass-through Fdn for Atlanta Veterans Educ and Res	W81XWH-08-02-0062	12.420	—	271
Pass-through Fred Hutchinson Research Center	HT94252311028	12.420	—	9,844
Pass-through Georgia Institute of Technology	W81XWH-20-1-0649	12.420	—	49,041
Pass-through Henry M Jackson Foundation	HT9425230022	12.420	—	7,203
Pass-through Public Health Institute	S352L5PJLMP8.	12.420	—	205,792
Pass-through University of Georgia	W81XWH2210261	12.420	—	64,505
Pass-through University of Maryland, Baltimore	066469933	12.420	—	20,159
Pass-through University of Michigan	W81XWH2010336	12.420	—	41,704
Pass-through University of Washington Saint Louis	W81XWH2210665	12.420	—	13,048
Pass-through Veterans Medical Research Foundation	HT94252310669	12.420	—	25,418
Pass-through Wayne State University	W81XWH-19-1-0794	12.420	—	3,593
Total AL No. 12.420			622,962	4,669,990
Basic Scientific Research	W911NF-13-1-0182	12.431	—	(3,296)
Total AL No. 12.431			—	(3,296)
Basic, Applied, and Advanced Research in Science and Engineering:				
Pass-through University of Maryland, Baltimore	FA95502210259	12.630	—	236,249
Total AL No. 12.630			—	236,249
Uniformed Services University Medical Research Projects:				
Pass-through Henry M Jackson Foundation	HU00012120029	12.750	—	32,297
Total AL No. 12.750			—	32,297
Air Force Defense Research Sciences Program	FA95501810420	12.800	2,020,361	2,164,064
Air Force Defense Research Sciences Program	FA9550-20-1-0372	12.800	—	2,641
Air Force Defense Research Sciences Program	FA9550-20-1-0411	12.800	—	299
Air Force Defense Research Sciences Program	FA9550-23-1-0321	12.800	—	75,450
Air Force Defense Research Sciences Program	FA9550-23-1-0727	12.800	—	88,227
Pass-through Clemson University	FA9550-23-1-0153	12.800	—	215,741
Total AL No. 12.800			2,020,361	2,546,422
Research and Technology Development:				
Pass-through Georgia Institute of Technology	HR0011-19-2-0008	12.910	—	1,243,608
Pass-through Stanford University	W911NF2320019	12.910	—	1,134,143
Pass-through University of California San Francisco	HR0011-19-2-0007	12.910	—	75
Total AL No. 12.910			—	2,377,826
Contract	0011751760	12.CTR	—	247,465
Contract	DE-AC52-07NA27344	12.CTR	—	41,275
Contract	W81XWH	12.CTR	—	2,511
Contract	W81XWH1910281	12.CTR	—	609
Contract	W81XWH2110213	12.CTR	—	180,832
Contract	W81XWH2210922	12.CTR	—	649,620
Contract	W81XWH22D0013	12.CTR	—	151,201
Pass-through Adv Tech Intl Med Cbrn Defense Consort	2020-467	12.CTR	1,497,674	4,118,773
Pass-through Coalition For National Trauma Research	W81XWH-15-9-001	12.CTR	—	5,385

EMORY UNIVERSITY AND ITS SUBSIDIARIES
Supplementary Schedule of Expenditures of Federal Awards
Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through Georgia Institute of Technology	N6600122C4012	12.CTR	—	840,773
Pass-through University of Dayton	FA8651-20-F-1024	12.CTR	—	88,382
Pass-through University of North Carolina Chapel Hill	W81XWH22C0122	12.CTR	—	335,751
Total AL No. 12.CTR			1,497,674	6,662,577
U.S. Department of Defense Total			4,140,997	16,555,277
U.S. Department of the Interior: Great Lakes Restoration	F22AC02246	15.662	23,100	52,885
Total AL No. 15.662			23,100	52,885
U.S. Department of the Interior Total			23,100	52,885
U.S. Department of Justice: Community-Based Violence Intervention and Prevention Initiative	15PBJA-23-GG-05206-CVIP	16.045	122,397	169,788
Total AL No. 16.045			122,397	169,788
National Institute of Justice Research, Evaluation, and Development Project Grants: Pass-through George Mason University	2019-R2-CX-0005	16.560	—	23,812
Total AL No. 16.560			—	23,812
U.S. Department of Justice Total			122,397	193,600
U.S. Department of State: Academic Exchange Programs – Hubert H. Humphrey Fellowship Program: Pass-through Institute of International Education	S-ECAGD-23-CA-0009	19.010	—	63,883
Total AL No. 19.010			—	63,883
U.S. Department of State Total			—	63,883
U.S. Department of Transportation: National Priority Safety Programs: Pass-through Governors Office of Highway Safety	69A3752030000405BGAH	20.616	—	42,925
Pass-through Governors Office of Highway Safety	69A3752330000405BGAH	20.616	—	239,126
Total AL No. 20.616			—	282,051
Contract	693JJ922D000025	20.CTR	34,316	553,272
Contract	693JJ923F000252	20.CTR	59,281	100,149
Pass-through University of Michigan	693JJ921D000021	20.CTR	—	43,583
Pass-through University of Michigan	DTNH2215D00017/693JJ918F000234	20.CTR	—	2,806
Total AL No. 20.CTR			93,597	699,810
U.S. Department of Transportation Total			93,597	981,861
National Aeronautics and Space Administration: Science	80NSSC19K0191	43.001	45,781	85,517
Science	80NSSC20K0309	43.001	—	(1,067)
Science	80NSSC21K0507	43.001	45,981	261,997
Science	80NSSC22K0292	43.001	—	85,522
Science	80NSSC22K1659	43.001	—	849
Pass-through California Institute of Technology	1588347	43.001	—	119,973
Pass-through California Institute of Technology	80NM0018D0004	43.001	—	38,344
Pass-through National Institute of Aerospace	80NSSC21K0514	43.001	—	4,155
Pass-through Spelman College	80NSSC23K0028	43.001	—	17,305
Pass-through University of Georgia	80NSSC22K1167	43.001	—	113,835
Total AL No. 43.001			91,762	726,430
Aeronautics Pass-through California Institute of Technology	NMO710860	43.002	—	41,389
Total AL No. 43.002			—	41,389

EMORY UNIVERSITY AND ITS SUBSIDIARIES
Supplementary Schedule of Expenditures of Federal Awards
Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Exploration	80NSSC18K1116	43.003	—	21,775
Exploration	80NSSC21K0251	43.003	—	26,229
Total AL No. 43.003			—	48,004
National Aeronautics and Space Administration Total			91,762	815,823
National Endowment for the Humanities: Promotion of the Humanities Division of Preservation and Access	PW-277494-21	45.149	5,065	128,251
Total AL No. 45.149			5,065	128,251
Promotion of the Humanities Research	RZ-292797-23	45.161	—	7,683
Pass-through University of Wisconsin-Madison	RZ-292847-24	45.161	—	11,137
Total AL No. 45.161			—	18,820
Promotion of the Humanities Professional Development	AV-279598-21	45.163	—	1,375
Total AL No. 45.163			—	1,375
National Endowment for the Humanities Total			5,065	148,446
National Science Foundation:				
Engineering	1818476	47.041	—	(130)
Engineering	1926387	47.041	—	116,400
Engineering	2002815	47.041	—	4,886
Engineering	2005786	47.041	—	48,122
Engineering	2044657	47.041	—	235,969
Engineering	2231857	47.041	—	98,206
Engineering	2306371	47.041	—	148,870
Engineering	2326144	47.041	—	115,151
Engineering	2326931	47.041	71,340	108,429
Engineering	2333224	47.041	—	99
Engineering	2430423	47.041	—	28,025
Engineering	2127509	47.041	—	130,208
Pass-through Amer Society For Engineering Education	UA-2019-0921	47.041	—	178,963
Pass-through Center for the Advancement of Science In Space	1749677	47.041	3,709	8,734
Pass-through Georgia Institute of Technology	EEC-1648035	47.041	—	76,387
Pass-through Georgia Institute of Technology	1928481	47.041	—	29,000
Total AL No. 47.041			75,049	1,327,319
Mathematical And Physical Sciences	1557960	47.049	—	(1,550)
Mathematical And Physical Sciences	1611102	47.049	—	(6,150)
Mathematical And Physical Sciences	1700982	47.049	40,202	38,289
Mathematical And Physical Sciences	1751636	47.049	—	(2,669)
Mathematical And Physical Sciences	1755698	47.049	—	(9,998)
Mathematical And Physical Sciences	1764385	47.049	—	9,804
Mathematical And Physical Sciences	1900532	47.049	—	(44)
Mathematical And Physical Sciences	1905782	47.049	—	59,762
Mathematical And Physical Sciences	1951682	47.049	—	21,425
Mathematical And Physical Sciences	1956154	47.049	—	214,011
Mathematical And Physical Sciences	2003962	47.049	—	9,730
Mathematical And Physical Sciences	2004126	47.049	—	11
Mathematical And Physical Sciences	2004846	47.049	—	62,319
Mathematical And Physical Sciences	2010524	47.049	—	65,872
Mathematical And Physical Sciences	2012686	47.049	—	44,734
Mathematical And Physical Sciences	2014173	47.049	—	83,195
Mathematical And Physical Sciences	2015540	47.049	—	44,238
Mathematical And Physical Sciences	2026841	47.049	—	44,606
Mathematical And Physical Sciences	2038019	47.049	—	494
Mathematical And Physical Sciences	2038118	47.049	—	310,203
Mathematical And Physical Sciences	2051019	47.049	—	4,432

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Supplementary Schedule of Expenditures of Federal Awards

Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Mathematical And Physical Sciences	2055579	47.049	—	138,333
Mathematical And Physical Sciences	2103515	47.049	—	83,071
Mathematical And Physical Sciences	2108290	47.049	—	206,675
Mathematical And Physical Sciences	2108621	47.049	—	59,061
Mathematical And Physical Sciences	2108774	47.049	—	247,548
Mathematical And Physical Sciences	2143815	47.049	—	121,900
Mathematical And Physical Sciences	2146260	47.049	—	137,829
Mathematical And Physical Sciences	2152661	47.049	—	24,640
Mathematical And Physical Sciences	2205266	47.049	—	63,535
Mathematical And Physical Sciences	2206187	47.049	—	65,986
Mathematical And Physical Sciences	2208294	47.049	—	124,326
Mathematical And Physical Sciences	2208412	47.049	—	58,411
Mathematical And Physical Sciences	2242508	47.049	—	194,282
Mathematical And Physical Sciences	2246659	47.049	—	88,364
Mathematical And Physical Sciences	2247013	47.049	—	47,601
Mathematical And Physical Sciences	2300347	47.049	—	61,739
Mathematical And Physical Sciences	2302356	47.049	—	6,700
Mathematical And Physical Sciences	2305112	47.049	—	217,489
Mathematical And Physical Sciences	2308017	47.049	—	(1,052)
Mathematical And Physical Sciences	2309751	47.049	—	83,528
Mathematical And Physical Sciences	2311665	47.049	—	168,460
Mathematical And Physical Sciences	2312105	47.049	—	236,612
Mathematical And Physical Sciences	2326893	47.049	—	47,520
Mathematical And Physical Sciences	2329296	47.049	—	11,145
Mathematical And Physical Sciences	2337930	47.049	—	108,042
Mathematical And Physical Sciences	2340500	47.049	—	41,269
Mathematical And Physical Sciences	2340746	47.049	—	79,532
Mathematical And Physical Sciences	2349014	47.049	—	35,532
Mathematical And Physical Sciences	2349045	47.049	—	51,595
Mathematical And Physical Sciences	2349534	47.049	—	175,274
Mathematical And Physical Sciences	2350187	47.049	—	42,877
Mathematical And Physical Sciences	2400095	47.049	—	4,805
Mathematical And Physical Sciences	2404274	47.049	—	32,245
Mathematical And Physical Sciences	2411264	47.049	—	33,990
Mathematical And Physical Sciences	2411718	47.049	—	50,092
Pass-through Boston University	2327697	47.049	—	51,849
Pass-through Georgia Institute of Technology	1806833	47.049	—	100,000
Pass-through Georgia Institute of Technology	2310741	47.049	—	47,482
Pass-through Harvard University	2132338	47.049	—	64,584
Pass-through Virginia Tech	2136142	47.049	—	4,617
Total AL No. 47.049			40,202	4,410,202
Geosciences:				
Pass-through Georgia State University	2228192	47.050	—	27,263
Pass-through Rutgers University	2108984	47.050	—	(3,979)
Pass-through University Corp For Atmospheric Research	1755088	47.050	—	109,811
Total AL No. 47.050			—	133,095
Computer And Information Science And Engineering	1838200	47.070	—	(106)
Computer And Information Science And Engineering	2003720	47.070	—	11,705
Computer And Information Science And Engineering	2103592	47.070	—	334,168
Computer And Information Science And Engineering	2106359	47.070	—	11,019
Computer And Information Science And Engineering	2106446	47.070	67,535	107,715
Computer And Information Science And Engineering	2110926	47.070	4,789	4,789
Computer And Information Science And Engineering	2124104	47.070	—	196,744
Computer And Information Science And Engineering	2125530	47.070	90,857	255,524
Computer And Information Science And Engineering	2145411	47.070	—	226,205
Computer And Information Science And Engineering	2232829	47.070	—	325
Computer And Information Science And Engineering	2302968	47.070	—	87,368

EMORY UNIVERSITY AND ITS SUBSIDIARIES
Supplementary Schedule of Expenditures of Federal Awards
Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Computer And Information Science And Engineering	2303655	47.070	—	36,674
Computer And Information Science And Engineering	2303678	47.070	—	139,048
Computer And Information Science And Engineering	2310114	47.070	—	68,597
Computer And Information Science And Engineering	2311574	47.070	—	91,507
Computer And Information Science And Engineering	2312502	47.070	—	128,221
Computer And Information Science And Engineering	2319449	47.070	—	89,714
Computer And Information Science And Engineering	2324784	47.070	—	18,080
Computer And Information Science And Engineering	2340539	47.070	—	49,065
Computer And Information Science And Engineering	2411530	47.070	—	2,904
Computer And Information Science And Engineering	2420678	47.070	—	64,248
Computer And Information Science And Engineering	2426997	47.070	—	5,671
Pass-through Computing Research Association	2127309	47.070	—	92,139
Pass-through Duke University	ISS-2211526	47.070	—	35,853
Pass-through Georgia Institute of Technology	1915504	47.070	—	9,450
Pass-through Georgia Institute of Technology	2205152	47.070	—	105,418
Pass-through University of Tennessee Knoxville	2200140	47.070	—	34,562
Pass-through University of Virginia	2041952	47.070	—	40,251
Total AL No. 47.070			163,181	2,246,858
Biological Sciences	1624104	47.074	—	(50)
Biological Sciences	1655163	47.074	—	(7,059)
Biological Sciences	1750553	47.074	—	105,142
Biological Sciences	1755418	47.074	—	90,102
Biological Sciences	1922720	47.074	—	69,844
Biological Sciences	1927411	47.074	—	95,677
Biological Sciences	1931697	47.074	—	70,779
Biological Sciences	2032610	47.074	—	393
Biological Sciences	2050009	47.074	—	17,357
Biological Sciences	2106137	47.074	—	12,035
Biological Sciences	2202255	47.074	—	173,909
Biological Sciences	2208659	47.074	—	44,286
Biological Sciences	2209996	47.074	—	159,534
Biological Sciences	2239526	47.074	—	147,332
Biological Sciences	2243665	47.074	124,672	374,820
Biological Sciences	2310626	47.074	—	188,001
Biological Sciences	2318831	47.074	—	73,687
Biological Sciences	2329634	47.074	—	154,266
Biological Sciences	2330206	47.074	—	62,727
Biological Sciences	2418128	47.074	—	87,469
Pass-through Case Western Reserve University	DBI-2015317	47.074	—	221,577
Pass-through University of California Riverside	2119820	47.074	—	87,977
Pass-through University of Texas Austin	2227399	47.074	—	150,941
Total AL No. 47.074			124,672	2,380,746
Social, Behavioral, And Economic Sciences	1822677	47.075	—	(3,235)
Social, Behavioral, And Economic Sciences	1853185	47.075	—	28,071
Social, Behavioral, And Economic Sciences	1945046	47.075	—	88,779
Social, Behavioral, And Economic Sciences	1946767	47.075	—	73,915
Social, Behavioral, And Economic Sciences	1946768	47.075	—	976
Social, Behavioral, And Economic Sciences	1947845	47.075	—	(768)
Social, Behavioral, And Economic Sciences	2051553	47.075	—	186,813
Social, Behavioral, And Economic Sciences	2120917	47.075	—	9,479
Social, Behavioral, And Economic Sciences	2127373	47.075	—	71,963
Social, Behavioral, And Economic Sciences	2127913	47.075	—	96,151
Social, Behavioral, And Economic Sciences	2147325	47.075	—	11,411
Social, Behavioral, And Economic Sciences	2214387	47.075	—	33,310
Social, Behavioral, And Economic Sciences	2218064	47.075	—	48,264
Social, Behavioral, And Economic Sciences	2219815	47.075	—	57,436
Social, Behavioral, And Economic Sciences	2244460	47.075	—	102,713

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Supplementary Schedule of Expenditures of Federal Awards

Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Social, Behavioral, And Economic Sciences	2307271	47.075	68,742	141,494
Social, Behavioral, And Economic Sciences	2314791	47.075	—	11,309
Social, Behavioral, And Economic Sciences	2314858	47.075	—	28,021
Social, Behavioral, And Economic Sciences	2403479	47.075	—	189,803
Social, Behavioral, And Economic Sciences	2417535	47.075	—	41,459
Social, Behavioral, And Economic Sciences	2417905	47.075	—	67,410
Social, Behavioral, And Economic Sciences	2418389	47.075	—	59,847
Pass-through Case Western Reserve University	2129072	47.075	—	93,446
Pass-through Princeton University	2033912	47.075	—	244,056
Pass-through University of Massachusetts Boston	2321010	47.075	—	2,327
Pass-through University of Colorado	2149191	47.075	—	16,153
Total AL No. 47.075			68,742	1,700,603
Education And Human Resources	1821533	47.076	—	289,924
Education And Human Resources	1937971	47.076	—	1,658,939
Education And Human Resources	2010333	47.076	—	104,902
Education And Human Resources	2142262	47.076	—	2,167
Education And Human Resources	2422606	47.076	—	2,972
Pass-through Carnegie Mellon University	2128954	47.076	—	18,401
Total AL No. 47.076			—	2,077,305
Polar Programs	2025795	47.078	—	24,797
Total AL No. 47.078			—	24,797
Office of International Science and Engineering	1827201	47.079	—	296
Total AL No. 47.079			—	296
Integrative Activities	2331578	47.083	—	612,640
Total AL No. 47.083			—	612,640
NSF Technology, Innovation, and Partnerships	2302890	47.084	177,941	480,622
Pass-through Arizona State University	2328217	47.084	—	148,503
Pass-through University of Missouri Columbia	2303003	47.084	—	17,181
Pass-through University of Missouri Columbia	2350104	47.084	—	241,513
Pass-through Vytal Plant Science Research	2308676	47.084	—	8,999
Total AL No. 47.084			177,941	896,818
National Science Foundation Total			649,787	15,810,679
U.S. Environmental Protection Agency:				
Surveys, Studies, Research, Investigations, Demonstrations, and Special Purpose Activities Relating to the Clean Air Act				
Pass-through Environmental Community Action	02D45623	66.034	—	76,802
Total AL No. 66.034			—	76,802
Science To Achieve Results (STAR) Research Program	83479901	66.509	—	13,750
Science To Achieve Results (STAR) Research Program	84019801	66.509	—	142,750
Science To Achieve Results (STAR) Research Program	84042901	66.509	—	48,427
Science To Achieve Results (STAR) Research Program	84048501	66.509	130,840	323,745
Pass-through Carleton University	4962-RFA17-2/18-4	66.509	—	(6,564)
Pass-through Dartmouth College	83544201	66.509	—	(13,899)
Total AL No. 66.509			130,840	508,209
Office of Research and Development Consolidated Research/Training/Fellowships:				
Pass-through North Carolina State University	84008102	66.511	—	28,420
Pass-through Silent Spring Institute	84043001	66.511	—	47,598
Pass-through University of Colorado	83234701	66.511	—	51,769
Total AL No. 66.511			—	127,787

EMORY UNIVERSITY AND ITS SUBSIDIARIES
Supplementary Schedule of Expenditures of Federal Awards
Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Solid Waste Management Assistance Grants	02D01621	66.808	—	22,170
Total AL No. 66.808			—	22,170
Environmental Education Grants	01D14720	66.951	5,000	6,249
Environmental Education Grants	02D34022	66.951	—	53,891
Total AL No. 66.951			5,000	60,140
Contract:				
Pass-through Health Effects Institute	CR-83998101	66.CTR	131,158	228,913
Total AL No. 66.CTR			131,158	228,913
U.S. Environmental Protection Agency Total			266,998	1,024,021
U.S. Department of Energy:				
Office Of Science Financial Assistance Program	DE-FG02-01ER15153	81.049	—	108,501
Office Of Science Financial Assistance Program	DE-FG02-01ER15153-24	81.049	—	6,352
Office Of Science Financial Assistance Program	DEFG0207ER15906	81.049	—	418,075
Office Of Science Financial Assistance Program	DESC0019374	81.049	1,044,864	1,452,098
Office Of Science Financial Assistance Program	DE-SC0020101	81.049	—	124,870
Office Of Science Financial Assistance Program	DE-SC0020996	81.049	—	50,354
Office Of Science Financial Assistance Program	DE-SC0022314	81.049	—	24,514
Office Of Science Financial Assistance Program	DE-SC0023327	81.049	—	114,188
Office Of Science Financial Assistance Program	DE-SC0024410	81.049	18,292	38,317
Office Of Science Financial Assistance Program	DE-SC0024524	81.049	—	110,591
Office Of Science Financial Assistance Program	DE-SC0024532	81.049	—	120,918
Office Of Science Financial Assistance Program	DE-SC008798	81.049	—	346,998
Pass-through University of Arizona	0023411	81.049	—	212,895
Pass-through University of North Carolina Chapel Hill	DE-SC0021173	81.049	—	279,554
Total AL No. 81.049			1,063,156	3,408,225
Contract	89233218CNA000001	81.CTR	—	3,014
Total AL No. 81.CTR			—	3,014
U.S. Department of Energy Total			1,063,156	3,411,239
U.S. Department of Education:				
Overseas Programs – Doctoral Dissertation Research Abroad	P022A220003	84.022	—	16,997
Overseas Programs – Doctoral Dissertation Research Abroad	P022A230003	84.022	—	17,154
Total AL No. 84.022			—	34,151
Fund for the Improvement of Postsecondary Education	P116Z230070	84.116	—	91,334
Total AL No. 84.116			—	91,334
Research in Special Education:				
Pass-through Florida State University	R324A180193	84.324	182,793	238,093
Total AL No. 84.324			182,793	238,093
U.S. Department of Education Total			182,793	363,578
U.S. Department of Health and Human Services:				
Chronic Diseases: Research, Control, and Prevention	U01DP006488	93.068	76,944	1,024,296
Chronic Diseases: Research, Control, and Prevention	U18DP006747	93.068	314,950	686,879
Total AL No. 93.068			391,894	1,711,175
Birth Defects and Developmental Disabilities – Prevention and Surveillance	NU50DD000057	93.073	—	505,468
Birth Defects and Developmental Disabilities – Prevention and Surveillance	NU50DD000098	93.073	1,497	43,081
Birth Defects and Developmental Disabilities – Prevention and Surveillance	NU84DD000020	93.073	45,032	400,699

EMORY UNIVERSITY AND ITS SUBSIDIARIES
Supplementary Schedule of Expenditures of Federal Awards
Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through Johns Hopkins University	U01DD001297	93.073	—	21,762
Pass-through University of Iowa	U01DD001223	93.073	—	4,605
Total AL No. 93.073			46,529	975,615
Family Smoking Prevention and Tobacco Control Act Regulatory Research				
Pass-through Georgia State University	R01CA239308	93.077	—	9,276
Total AL No. 93.077			—	9,276
Blood Disorder Program: Prevention, Surveillance, and Research:				
Pass-through Georgia State University	NU58DD0000021	93.080	—	8,677
Pass-through Georgia State University	NU58DD000003	93.080	7,568	9,841
Pass-through Georgia State University	NU58DD000021	93.080	—	891
Pass-through Hemophilia of Georgia	NU27DD000020	93.080	—	28,325
Pass-through Hemophilia of Georgia	NU27DD000020-03-00	93.080	—	3,711
Total AL No. 93.080			7,568	51,445
Prevention of Disease, Disability, and Death through Immunization and Control of Respiratory and Related Diseases				
Pass-through Amer Geriatrics Society	NH23IP922656	93.083	—	159,670
Total AL No. 93.083			—	159,670
COVID-19 – Prevention Of Disease, Disability, And Death By Infectious Diseases	U54CK000601	93.084	427,625	998,219
Prevention Of Disease, Disability, And Death By Infectious Diseases	U01PS005244	93.084	258,991	1,007,297
Prevention Of Disease, Disability, And Death By Infectious Diseases	U01PS005260	93.084	29,788	114,461
Prevention Of Disease, Disability, And Death By Infectious Diseases	U54CK000601	93.084	124,948	727,137
Pass-through Children's Hospital of Philadelphia	U54CK000610	93.084	—	90,533
Pass-through Georgia Dept of Public Health	NU50CK000626	93.084	—	492,603
Pass-through Rush University Medical Center	U54CK000607	93.084	—	27,992
Pass-through State University of New York Albany	NU38PS004650	93.084	—	540,972
Pass-through University of Iowa	U54CK000613	93.084	—	23,964
Pass-through Yale University	U01CK000572	93.084	—	134,807
Total AL No. 93.084			841,352	4,157,985
Advancing System Improvements for Key Issues in Women's Health				
Pass-through Boston Medical Center	ASTWH220118	93.088	—	32,318
Total AL No. 93.088			—	32,318
Food and Drug Administration Research	R01FD005746	93.103	71,064	284,888
Pass-through Critical Path Institute (C-Path)	U18FD005320	93.103	—	455,672
Pass-through Yale University	U01FD005938	93.103	—	2,595
Total AL No. 93.103			71,064	743,155
Maternal And Child Health Federal Consolidated Programs	R4250214	93.110	—	60,669
Maternal And Child Health Federal Consolidated Programs	T76MC28446	93.110	16,312	311,318
Pass-through Organization of Teratology Information S	UG4MC27861	93.110	—	75,554
Total AL No. 93.110			16,312	447,541
Environmental Health	D43ES030927	93.113	197,031	261,310
Environmental Health	F30ES036439	93.113	—	8,385
Environmental Health	F31ES031845	93.113	—	15,112
Environmental Health	F31ES036103	93.113	—	4,318
Environmental Health	F32ES033908	93.113	—	6,422
Environmental Health	F32ES034241	93.113	—	66,764
Environmental Health	K00ES033033	93.113	—	75,187
Environmental Health	K12ES033593	93.113	89,103	562,143
Environmental Health	K99ES036289	93.113	—	35,727
Environmental Health	KES035082A	93.113	—	55,572
Environmental Health	P20ES036110	93.113	—	649,790
Environmental Health	P2CES033430	93.113	452,784	899,976

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Supplementary Schedule of Expenditures of Federal Awards

Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Environmental Health	P30ES019776	93.113	86,052	1,325,651
Environmental Health	P30RD019776	93.113	—	(5,304)
Environmental Health	P50ES026071	93.113	—	176
Environmental Health	R01ES025775	93.113	—	5,364
Environmental Health	R01ES026082	93.113	11,373	11,374
Environmental Health	R01ES027859	93.113	—	486,704
Environmental Health	R01ES028346	93.113	197,420	425,224
Environmental Health	R01ES029212	93.113	230,053	286,714
Environmental Health	R01ES031980	93.113	120,878	467,283
Environmental Health	R01ES032009	93.113	280,428	640,619
Environmental Health	R01ES032140	93.113	47,525	379,993
Environmental Health	R01ES032440	93.113	—	403,087
Environmental Health	R01ES032446	93.113	64,692	449,433
Environmental Health	R01ES032831	93.113	206,158	954,255
Environmental Health	R01ES033241	93.113	528,343	880,172
Environmental Health	R01ES033530	93.113	836,790	1,478,139
Environmental Health	R01ES033603	93.113	—	636,575
Environmental Health	R01ES034175	93.113	227,479	746,999
Environmental Health	R01ES034796	93.113	—	431,733
Environmental Health	R01ES035738	93.113	—	63,802
Environmental Health	R03ES035184	93.113	17,141	77,131
Environmental Health	R21ES032117	93.113	—	40,268
Environmental Health	R21ES032344	93.113	27,035	94,028
Environmental Health	R21ES034130	93.113	10,864	216,245
Environmental Health	R21ES034139	93.113	62,056	245,882
Environmental Health	R21ES034190	93.113	—	151,369
Environmental Health	R24ES028528	93.113	13,771	187,055
Environmental Health	R24ES029490	93.113	—	256,640
Environmental Health	T32ES012870	93.113	—	429,104
Environmental Health	U24ES028507	93.113	254,636	414,412
Environmental Health	U24ES028528	93.113	—	159,796
Environmental Health	U24ES029490	93.113	—	22,057
Environmental Health	R01ES019620	93.113	—	6,721
Pass-through Alaska Community Action on Toxics	R01ES032836	93.113	—	31,345
Pass-through Brown University	R01ES029995	93.113	—	18,143
Pass-through Colorado State University	R01ES030945	93.113	—	2,959
Pass-through Columbia University	R01ES035390	93.113	—	9,298
Pass-through Harvard University	R01ES025531-05	93.113	—	21,008
Pass-through Johns Hopkins University	R01ES033688	93.113	—	255,533
Pass-through Mount Sinai School of Medicine	R01ES032144	93.113	—	123,703
Pass-through Rutgers University	R01ES029528	93.113	—	31,568
Pass-through University of Nevada	R01ES032392	93.113	—	429,426
Pass-through University of Arizona	R01ES035035	93.113	—	57,468
Pass-through University of Colorado	R01ES035691	93.113	—	7,152
Pass-through University of Illinois at Chicago	R01ES032176	93.113	—	211,152
Pass-through University of Kentucky	R01ES032157	93.113	—	21,649
Pass-through University of Michigan	R01ES035087	93.113	—	111,674
Pass-through University of Michigan	R21ES033750	93.113	—	69,944
Pass-through University of Rochester	R00ES027870	93.113	—	(12,237)
Pass-through University of Southern California	R01ES029944	93.113	—	22,077
Pass-through University of Southern California	R01ES030364	93.113	—	80,332
Pass-through Wayne State University	R01ES031584	93.113	—	83,729
Total AL No. 93.113			3,961,612	16,585,330
Oral Diseases And Disorders Research	F31DE032588	93.121	—	36,617
Oral Diseases And Disorders Research	R00DE026810	93.121	—	177,807
Oral Diseases And Disorders Research	R01DE026941	93.121	—	(423)
Oral Diseases And Disorders Research	R01DE028342	93.121	27,754	450,919
Oral Diseases And Disorders Research	R01DE028351	93.121	—	369,533

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Supplementary Schedule of Expenditures of Federal Awards

Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Oral Diseases And Disorders Research	R01DE028905	93.121	117,160	486,542
Oral Diseases And Disorders Research	R01DE030342	93.121	213,035	663,638
Oral Diseases And Disorders Research	R01DE031271	93.121	169,135	580,387
Oral Diseases And Disorders Research	R01DE032243	93.121	23,782	425,892
Oral Diseases And Disorders Research	R01DE033433	93.121	—	90,387
Oral Diseases And Disorders Research	R01DE033635	93.121	—	32,904
Oral Diseases And Disorders Research	R01DE033691	93.121	—	68,829
Oral Diseases And Disorders Research	R03DE030118	93.121	—	171,082
Oral Diseases And Disorders Research	R03DE032084	93.121	21,259	92,926
Oral Diseases And Disorders Research	R21DE030632	93.121	—	73,781
Oral Diseases And Disorders Research	R56DE031771	93.121	—	166,022
Pass-through Baylor College of Medicine	R21DE032344	93.121	—	47,293
Pass-through Children's Hospital of Philadelphia	R01DE027983	93.121	—	121,139
Pass-through Children's Hospital of Philadelphia	R01DE032332	93.121	—	31,136
Pass-through Rutgers University	R01DE032216	93.121	—	169,613
Pass-through University of Colorado	R01DE032681	93.121	—	15,088
Pass-through University of Pittsburgh	R01DE032319	93.121	—	82,072
Pass-through University of Washington	R01DE027362	93.121	—	129,859
Total AL No. 93.121			<u>572,125</u>	<u>4,483,043</u>
Nurse Anesthetist Traineeship	A2231815	93.124	—	56,382
Total AL No. 93.124			<u>—</u>	<u>56,382</u>
COVID-19 – Centers For Research And Demonstration For Health Promotion And Disease Prevention	U48DP006377	93.135	499,752	2,574,248
Total AL No. 93.135			<u>499,752</u>	<u>2,574,248</u>
Injury Prevention And Control Research And State And Community Based Programs	R01CE003104	93.136	—	2,524
Injury Prevention And Control Research And State And Community Based Programs	R01CE003509	93.136	248,691	600,439
Injury Prevention And Control Research And State And Community Based Programs	R01CE003580	93.136	26,076	228,376
Injury Prevention And Control Research And State And Community Based Programs	R01CE003604	93.136	—	334,137
Injury Prevention And Control Research And State And Community Based Programs	R49CE003072	93.136	86,371	1,054,018
Injury Prevention And Control Research And State And Community Based Programs	U01CE002939	93.136	57,616	267,908
Total AL No. 93.136			<u>418,754</u>	<u>2,487,402</u>
Community Programs to Improve Minority Health Grant Program:				
Pass-through Georgia State University	CPIMP221348	93.137	—	58,119
Total AL No. 93.137			<u>—</u>	<u>58,119</u>
NIEHS Superfund Hazardous Substances Basic Research and Education:				
Pass-through Michigan State University	P42ES004911	93.143	—	98,159
Total AL No. 93.143			<u>—</u>	<u>98,159</u>
Health Program for Toxic Substances and Disease Registry:				
Pass-through American Academy of Pediatrics	5 NU61TS000296-04-00	93.161	31,317	42,175
Pass-through American Academy of Pediatrics	NU61TS000296	93.161	7,211	262,059
Pass-through American Academy of Pediatrics	NU61TS000296	93.161	14,475	126,329
Total AL No. 93.161			<u>53,003</u>	<u>430,563</u>
Human Genome Research	R01HG012941	93.172	—	376,321
Pass-through Morehouse School of Medicine	RM1HG012334	93.172	—	515,060
Pass-through University of Chicago	RM1HG008935	93.172	—	100,554
Total AL No. 93.172			<u>—</u>	<u>991,935</u>
Research Related To Deafness And Communication Disorders	R01DC008343	93.173	—	280,399
Research Related To Deafness And Communication Disorders	R01DC014021	93.173	44,990	19,635
Research Related To Deafness And Communication Disorders	R01DC020749	93.173	—	294,810
Research Related To Deafness And Communication Disorders	R01DC021478	93.173	—	201,219
Research Related To Deafness And Communication Disorders	R21DC019711	93.173	—	155,712

EMORY UNIVERSITY AND ITS SUBSIDIARIES
Supplementary Schedule of Expenditures of Federal Awards
Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Research Related To Deafness And Communication Disorders	R21DC021029	93.173	—	162,428
Research Related To Deafness And Communication Disorders	U01DC020452	93.173	22,831	295,487
Pass-through Harvard University	R21DC019567	93.173	—	93,546
Pass-through Massachusetts General Hospital	P50DC015446	93.173	—	13,837
Pass-through Massachusetts General Hospital	R01DC020247	93.173	—	14,436
Pass-through Medical University of South Carolina	U01DC017521	93.173	—	252
Pass-through University of Central Florida	R01DC009029	93.173	—	185,602
Pass-through University of Central Florida	R01DC020799	93.173	—	28,749
Pass-through University of Kansas	R01DC020418	93.173	—	32,977
Total AL No. 93.173			67,821	1,779,089
COVID-19 – Immunization Research, Demonstration, Public Information and Education Training and Clinical Skills Improvement Projects	U01IP001200	93.185	100,791	514,053
Immunization Research, Demonstration, Public Information and Education Training and Clinical Skills Improvement Projects	U01IP001117	93.185	—	35,054
Immunization Research, Demonstration, Public Information and Education Training and Clinical Skills Improvement Projects	U01IP001200	93.185	260,726	563,815
Pass-through Yale University	U01PO1110	93.185	—	(1,570)
Total AL No. 93.185			361,517	1,111,352
Telehealth Programs	H2ARH39957	93.211	—	261,894
Pass-through University of Arizona	U1U42527	93.211	—	101,187
Total AL No. 93.211			—	363,081
Research and Training in Complementary and Integrative Health	F31AT011988	93.213	—	10,799
Research and Training in Complementary and Integrative Health	F31AT012140	93.213	—	47,257
Research and Training in Complementary and Integrative Health	K01AT010488	93.213	—	100,081
Research and Training in Complementary and Integrative Health	K24AT009893	93.213	—	170,275
Research and Training in Complementary and Integrative Health	R01AT011267	93.213	259,393	753,060
Research and Training in Complementary and Integrative Health	R01AT011990	93.213	365,404	634,605
Research and Training in Complementary and Integrative Health	R33AT010457	93.213	27,677	527,877
Research and Training in Complementary and Integrative Health	R34AT012509	93.213	—	941
Research and Training in Complementary and Integrative Health	R61AT012421	93.213	290,176	765,278
Pass-through University of Illinois at Chicago	UH3AT011265	93.213	—	80,052
Pass-through Veterans Medical Research Foundation	U01AT010332	93.213	—	21,914
Total AL No. 93.213			942,650	3,112,139
National Research Service Awards Health Services Research Training	T32HS029585	93.225	—	172,550
Total AL No. 93.225			—	172,550
Research On Healthcare Costs, Quality And Outcomes	R01HS026081	93.226	63,302	63,302
Research On Healthcare Costs, Quality And Outcomes	R01HS026232	93.226	—	4,483
Research On Healthcare Costs, Quality And Outcomes	R03HS027689	93.226	—	(625)
Research On Healthcare Costs, Quality And Outcomes	R03HS029417	93.226	—	36,187
Research On Healthcare Costs, Quality And Outcomes	R36HS029137	93.226	—	14,507
Research On Healthcare Costs, Quality And Outcomes	U18HS029944	93.226	7,500	237,898
Pass-through Children's Hospital of Philadelphia	R01HS029188	93.226	5,946	16,699
Pass-through Medstar Health Research Institute	R18HS029291	93.226	—	10,276
Pass-through University of Georgia	R01HS029009	93.226	—	41,277
Pass-through University of Georgia	R21HS028485	93.226	—	36,654
Pass-through University of Pittsburgh	U18HS028380	93.226	—	1,225
Pass-through University of Wisconsin-Madison	R01HS026724	93.226	—	7,997
Total AL No. 93.226			76,748	469,880
National Center On Sleep Disorders Research	R00HL147212	93.233	—	249,000
National Center On Sleep Disorders Research	R01HL157954	93.233	—	674,497
National Center On Sleep Disorders Research	R01HL162712	93.233	—	571,622
Pass-through Beth Israel Deaconess Medical Center	R01HL161253	93.233	—	283,224
Pass-through Brigham and Womens Hospital	R01HL164462	93.233	—	42,528
Pass-through New York University	R01HL160324	93.233	—	54
Total AL No. 93.233			—	1,820,925

EMORY UNIVERSITY AND ITS SUBSIDIARIES
Supplementary Schedule of Expenditures of Federal Awards
Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Mental Health Research Grants	F31MH126623	93.242	—	32,058
Mental Health Research Grants	F31MH127911	93.242	—	31,425
Mental Health Research Grants	F31MH127915	93.242	—	47,592
Mental Health Research Grants	F31MH130274	93.242	—	15,618
Mental Health Research Grants	F31MH132407	93.242	—	67,319
Mental Health Research Grants	F31MH133373	93.242	—	54,101
Mental Health Research Grants	F31MH135662	93.242	—	7,056
Mental Health Research Grants	F32MH124273	93.242	—	(7,859)
Mental Health Research Grants	F32MH132175	93.242	—	82,705
Mental Health Research Grants	F32MH134528	93.242	—	68,516
Mental Health Research Grants	F32MH134631	93.242	—	68,877
Mental Health Research Grants	F32MH135636	93.242	—	56,209
Mental Health Research Grants	K00MH139443	93.242	—	14,028
Mental Health Research Grants	K01MH121653	93.242	—	196,821
Mental Health Research Grants	K01MH126308	93.242	—	191,526
Mental Health Research Grants	K01MH133970	93.242	—	134,921
Mental Health Research Grants	K01MH135783	93.242	—	26,389
Mental Health Research Grants	K01MH136861	93.242	—	37,322
Mental Health Research Grants	K23MH114037	93.242	—	31
Mental Health Research Grants	K23MH114771	93.242	—	109,071
Mental Health Research Grants	K23MH122626	93.242	—	46,069
Mental Health Research Grants	K23MH123816	93.242	—	172,963
Mental Health Research Grants	K23MH128128	93.242	—	21,294
Mental Health Research Grants	K23MH130651	93.242	15,826	168,762
Mental Health Research Grants	P50MH100023	93.242	22,472	1,109,909
Mental Health Research Grants	P50MH100029	93.242	303,904	278,414
Mental Health Research Grants	R00MH119319	93.242	—	342,325
Mental Health Research Grants	R01MH082833	93.242	—	12,309
Mental Health Research Grants	R01MH105561	93.242	214,327	310,563
Mental Health Research Grants	R01MH108605	93.242	—	(386)
Mental Health Research Grants	R01MH108826	93.242	226,789	852,862
Mental Health Research Grants	R01MH112788	93.242	—	500
Mental Health Research Grants	R01MH115174	93.242	74,668	511,801
Mental Health Research Grants	R01MH115831	93.242	—	155,935
Mental Health Research Grants	R01MH116695	93.242	—	8,762
Mental Health Research Grants	R01MH117009	93.242	11,692	515,444
Mental Health Research Grants	R01MH117103	93.242	—	145,543
Mental Health Research Grants	R01MH117122	93.242	11,661	138,831
Mental Health Research Grants	R01MH117315	93.242	—	577,385
Mental Health Research Grants	R01MH118285	93.242	176,329	752,394
Mental Health Research Grants	R01MH118534	93.242	147,635	432,783
Mental Health Research Grants	R01MH118771	93.242	—	559,811
Mental Health Research Grants	R01MH118982	93.242	226,884	478,091
Mental Health Research Grants	R01MH119251	93.242	108,151	485,047
Mental Health Research Grants	R01MH120262	93.242	—	479,156
Mental Health Research Grants	R01MH121363	93.242	138,186	765,877
Mental Health Research Grants	R01MH121622	93.242	53,042	240,722
Mental Health Research Grants	R01MH121962	93.242	—	663,535
Mental Health Research Grants	R01MH122341	93.242	—	720,722
Mental Health Research Grants	R01MH123352	93.242	453,926	562,186
Mental Health Research Grants	R01MH125457	93.242	119,718	756,070
Mental Health Research Grants	R01MH125956	93.242	—	594,866
Mental Health Research Grants	R01MH126083	93.242	—	797,829
Mental Health Research Grants	R01MH126195	93.242	19,240	904,916
Mental Health Research Grants	R01MH126985	93.242	—	689,704
Mental Health Research Grants	R01MH128045	93.242	20,500	626,384
Mental Health Research Grants	R01MH128130	93.242	130,535	591,397
Mental Health Research Grants	R01MH128158	93.242	—	786,731
Mental Health Research Grants	R01MH128244	93.242	—	830,430

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Supplementary Schedule of Expenditures of Federal Awards

Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Mental Health Research Grants	R01MH128705	93.242	—	476,532
Mental Health Research Grants	R01MH128872	93.242	—	546,212
Mental Health Research Grants	R01MH129855	93.242	125,920	819,805
Mental Health Research Grants	R01MH130755	93.242	—	414,457
Mental Health Research Grants	R01MH131434	93.242	—	213,588
Mental Health Research Grants	R01MH131910	93.242	—	575,106
Mental Health Research Grants	R01MH132059	93.242	—	334,247
Mental Health Research Grants	R01MH132470	93.242	133,312	596,202
Mental Health Research Grants	R01MH133259	93.242	76,484	347,288
Mental Health Research Grants	R01MH133612	93.242	—	314,565
Mental Health Research Grants	R01MH133740	93.242	—	315,894
Mental Health Research Grants	R01MH133798	93.242	—	17,886
Mental Health Research Grants	R01MH134267	93.242	—	646,453
Mental Health Research Grants	R03MH135363	93.242	—	6,511
Mental Health Research Grants	R03MH135518	93.242	—	41,902
Mental Health Research Grants	R21MH120414	93.242	—	32,700
Mental Health Research Grants	R21MH124200	93.242	6,281	3,536
Mental Health Research Grants	R21MH127404	93.242	—	215,077
Mental Health Research Grants	R21MH132012	93.242	—	216,526
Mental Health Research Grants	R21MH133823	93.242	—	167,476
Mental Health Research Grants	R25MH101079	93.242	—	218,160
Mental Health Research Grants	R33MH121625	93.242	—	552,535
Mental Health Research Grants	R33MH124200	93.242	8,510	180,646
Mental Health Research Grants	R34MH116805	93.242	57,878	139,157
Mental Health Research Grants	R34MH119007	93.242	5,000	151,863
Mental Health Research Grants	R34MH124638	93.242	—	(577)
Mental Health Research Grants	R34MH128048	93.242	11,532	200,775
Mental Health Research Grants	R34MH129187	93.242	24,979	155,320
Mental Health Research Grants	R34MH132497	93.242	—	222,502
Mental Health Research Grants	R36MH136806	93.242	—	15,136
Mental Health Research Grants	R37MH117103	93.242	—	341,996
Mental Health Research Grants	R56MH129019	93.242	33,210	392,524
Mental Health Research Grants	R61MH121625	93.242	—	1,879
Mental Health Research Grants	RF1MH119622	93.242	—	73,322
Pass-through Boston University	R01MH133670	93.242	—	39,127
Pass-through Brown University	R00MH112413	93.242	—	136,694
Pass-through Brown University	R01MH117960	93.242	—	42,112
Pass-through Carnegie Mellon University	R01MH129725	93.242	—	101,857
Pass-through Childrens Hospital of Los Angeles	R01MH120133	93.242	—	6,230
Pass-through Columbia University	R01MH104606	93.242	—	(4,214)
Pass-through Hartford Hospital	R01MH119815	93.242	—	15,396
Pass-through Johns Hopkins University	R01MH129656	93.242	—	508,122
Pass-through Johns Hopkins University	R01MH132150	93.242	—	525,111
Pass-through Massachusetts General Hospital	R21MH132947	93.242	—	33,037
Pass-through Md Anderson	R01MH120299	93.242	—	135,808
Pass-through Rhode Island Hospital	R01MH125796	93.242	—	300,112
Pass-through Rutgers University	R01MH126449	93.242	—	105,852
Pass-through Rutgers University	R01MH134265	93.242	—	23,488
Pass-through St Louis University	R01MH125820	93.242	—	(2,238)
Pass-through State University of New York Stony Brook	R01MH120293	93.242	—	28,361
Pass-through University of Alabama Birmingham	R34MH128044	93.242	—	10,511
Pass-through University of Alabama Birmingham	R34MH128072	93.242	—	43,428
Pass-through University of California Los Angeles	R01MH100027	93.242	—	63,423
Pass-through University of California Los Angeles	R01MH118514	93.242	—	95,682
Pass-through University of California Los Angeles	R01MH118973	93.242	—	36,587
Pass-through University of California San Diego	R01MH123641	93.242	—	67,726
Pass-through University of California San Diego	R01MH124590	93.242	—	133,134
Pass-through University of California San Francisco	R01MH123396	93.242	—	105,470
Pass-through University of Colorado Denver	R01MH134957	93.242	—	55,464

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Supplementary Schedule of Expenditures of Federal Awards

Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through University of Georgia	R01MH116039	93.242	—	16,523
Pass-through University of Georgia	R01MH120092	93.242	—	169,368
Pass-through University of Illinois at Chicago	R01MH116721	93.242	—	79,464
Pass-through University of Louisiana at Lafayette	R01MH125395	93.242	—	214,677
Pass-through University of Maryland, Baltimore	R01MH121102	93.242	—	245,926
Pass-through University of Michigan	R01MH115765	93.242	—	8,964
Pass-through University of Michigan	R01MH123388	93.242	—	86,378
Pass-through University of Michigan	R01MH125857	93.242	—	50,701
Pass-through University of Michigan	R01MH126693	93.242	—	26,239
Pass-through University of Michigan	R34MH135799	93.242	—	2,116
Pass-through University of Pittsburgh	R01MH115922	93.242	—	28,749
Pass-through University of Pittsburgh	R01MH116943	93.242	—	21,287
Pass-through University of Pittsburgh	R01MH118270	93.242	—	20,054
Pass-through University of Pittsburgh	R01MH121619	93.242	—	22,022
Pass-through University of Pittsburgh	R01MH125816	93.242	—	40,454
Pass-through University of Pittsburgh	R01MH130376	93.242	—	24,901
Pass-through University of Rochester	R01MH045573	93.242	—	43,375
Pass-through University of Washington Saint Louis	R01MH123723	93.242	—	142,834
Pass-through Vanderbilt University	R01MH123662	93.242	—	18,121
Pass-through Vanderbilt University Medical Center	R61MH123029	93.242	—	86,510
Pass-through Washington University	R01MH120194	93.242	—	53,304
Pass-through Washington University	R01MH125820	93.242	—	36,195
Pass-through Wayne State University	R33MH111935	93.242	—	93,015
Pass-through Yale University	R01MH125205	93.242	—	160,730
Pass-through Yale University	U01MH124639	93.242	—	148,403
Pass-through Yale University	U01MH137298	93.242	—	1,144
Total AL No. 93.242			2,958,591	32,716,597
Substance Abuse and Mental Health Services Projects of Regional and National Significance	H79SM081774	93.243	48,290	1,001,663
Pass-through American Psychiatric Association	H79SM080818	93.243	—	214,962
Total AL No. 93.243			48,290	1,216,625
Advanced Nursing Education Workforce Grant Program	T9642058	93.247	—	423,030
Total AL No. 93.247			—	423,030
Children's Hospitals Graduate Medical Education Payment Program	F32HS029592	93.255	—	49,660
Total AL No. 93.255			—	49,660
Occupational Safety And Health Program	R01OH011782	93.262	130,824	357,313
Occupational Safety And Health Program	R21OH012557	93.262	—	167,270
Pass-through State University of New York Stony Brook	U01OH012257	93.262	—	20,805
Total AL No. 93.262			130,824	545,388
COVID-19 – Alcohol Research Programs	U01AA029345	93.273	45,510	67,966
Alcohol Research Programs	F31AA029938	93.273	—	33,430
Alcohol Research Programs	K01AA028258	93.273	—	125,712
Alcohol Research Programs	K08AA024512	93.273	—	51,737
Alcohol Research Programs	K99AA031333	93.273	—	101,506
Alcohol Research Programs	R01AA022601	93.273	—	(12)
Alcohol Research Programs	R01AA026086	93.273	—	(37,405)
Alcohol Research Programs	R01AA027020	93.273	—	473,736
Alcohol Research Programs	R01AA027396	93.273	—	332,050
Alcohol Research Programs	R01AA028527	93.273	—	270,421
Alcohol Research Programs	R01AA029690	93.273	8,567	501,747
Alcohol Research Programs	R01AA030893	93.273	—	214,154
Alcohol Research Programs	R21AA028606	93.273	6,630	19,010
Alcohol Research Programs	U01AA026108	93.273	184,341	432,721
Pass-through Boston Medical Center	P01AA029541	93.273	—	19,072
Pass-through Columbia University	R01AA030529	93.273	—	144,034

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Supplementary Schedule of Expenditures of Federal Awards

Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through Duke University	R01AA029819	93.273	—	41,807
Pass-through Fdtn for Atlanta Veterans Educ and Res	M21026	93.273	—	178
Pass-through Georgia State University	R01AA030275	93.273	—	36,248
Pass-through University of California San Diego	R01AA027785	93.273	—	12,456
Pass-through University of Colorado	R24AA019661	93.273	—	5,564
Pass-through Virginia Commonwealth University	R01AA030549	93.273	—	328,609
Total AL No. 93.273			245,048	3,174,741
COVID-19 – Drug Abuse and Addiction Research Programs	U01DA056000	93.279	69,970	469,325
Drug Abuse and Addiction Research Programs	DP1DA042103	93.279	9,193	175,611
Drug Abuse and Addiction Research Programs	F31DA055447	93.279	—	17,364
Drug Abuse and Addiction Research Programs	F31DA059435	93.279	—	37,300
Drug Abuse and Addiction Research Programs	K01DA051696	93.279	—	273,083
Drug Abuse and Addiction Research Programs	K01DA053438	93.279	—	181,967
Drug Abuse and Addiction Research Programs	K01DA053985	93.279	—	172,240
Drug Abuse and Addiction Research Programs	K23DA057415	93.279	—	178,526
Drug Abuse and Addiction Research Programs	R01DA042742	93.279	244,222	94,663
Drug Abuse and Addiction Research Programs	R01DA044297	93.279	—	408,757
Drug Abuse and Addiction Research Programs	R01DA045612	93.279	127,610	619,286
Drug Abuse and Addiction Research Programs	R01DA046197	93.279	8,316	132,673
Drug Abuse and Addiction Research Programs	R01DA046619	93.279	3,022	3,022
Drug Abuse and Addiction Research Programs	R01DA049257	93.279	299,396	642,084
Drug Abuse and Addiction Research Programs	R01DA051302	93.279	168,066	705,087
Drug Abuse and Addiction Research Programs	R01DA052859	93.279	—	54,082
Drug Abuse and Addiction Research Programs	R01DA052909	93.279	95,377	828,694
Drug Abuse and Addiction Research Programs	R01DA056235	93.279	96,789	647,314
Drug Abuse and Addiction Research Programs	R01DA056436	93.279	—	12,971
Drug Abuse and Addiction Research Programs	R01DA056770	93.279	21,288	1,061,987
Drug Abuse and Addiction Research Programs	R01DA057599	93.279	70,374	492,938
Drug Abuse and Addiction Research Programs	R01DA058065	93.279	5,889	727,213
Drug Abuse and Addiction Research Programs	R01DA059182	93.279	—	12,454
Drug Abuse and Addiction Research Programs	R21DA033478	93.279	—	352
Drug Abuse and Addiction Research Programs	R34DA054483	93.279	—	5,487
Drug Abuse and Addiction Research Programs	R36DA061555	93.279	—	5,404
Drug Abuse and Addiction Research Programs	RF1DA055667	93.279	262,108	530,164
Drug Abuse and Addiction Research Programs	RF1NS135504	93.279	61,286	465,349
Drug Abuse and Addiction Research Programs	T32DA050552	93.279	—	244,944
Drug Abuse and Addiction Research Programs	U01DA055360	93.279	—	2,002,374
Drug Abuse and Addiction Research Programs	UG3DA048502	93.279	254,344	1,246,421
Drug Abuse and Addiction Research Programs	UH3DA050234	93.279	381,111	1,021,064
Pass-through Boston Medical Center	R01DA058367	93.279	—	13,301
Pass-through Friends Research Institute	R01DA056888	93.279	—	26,727
Pass-through Jackson Laboratory	R01DA037927	93.279	—	9,688
Pass-through Johns Hopkins University	R33DA047022	93.279	—	256,994
Pass-through Miriam Hospital	R01DA044504	93.279	—	5,167
Pass-through Miriam Hospital	R01DA056787	93.279	—	330,877
Pass-through Miriam Hospital	R25DA037190	93.279	—	2,041
Pass-through Northwestern University	R01DA055502	93.279	—	69,790
Pass-through Oregon Health and Science University	R01DA046229	93.279	—	87,234
Pass-through RAND	P50DA046351	93.279	—	10,574
Pass-through University of California San Diego	U24DA055325	93.279	—	134,617
Pass-through University of Colorado	R01DA049800	93.279	—	23,427
Pass-through University of Colorado Denver	P50DA056408	93.279	—	32,178
Pass-through University of Kentucky	R01DA055872	93.279	—	11,004
Pass-through University of Kentucky	UH3DA044798	93.279	—	200,215
Pass-through University of Miami	UG1DA013720	93.279	—	29,495
Pass-through Vanderbilt University	U01DA055347	93.279	—	32,014
Pass-through Wake Forest University	R01DA052214	93.279	—	41,859

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Supplementary Schedule of Expenditures of Federal Awards

Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through Yale University	UG1DA015831	93.279	—	370,726
Total AL No. 93.279			2,178,361	15,158,128
Centers for Disease Control and Prevention Investigations and Technical Assistance				
Pass-through Fdtn for Atlanta Veterans Educ and Res	NU50CK000485	93.283	—	2,994,895
Pass-through University of California Los Angeles	U01CI000353	93.283	—	6,000
Total AL No. 93.283			—	3,000,895
COVID-19 – Discovery And Applied Research For Technological Innovations To Improve Human Health	U54EB027690	93.286	1,001,367	11,638,692
Discovery And Applied Research For Technological Innovations To Improve Human Health	R01EB027147	93.286	59,960	367,314
Discovery And Applied Research For Technological Innovations To Improve Human Health	R01EB027774	93.286	117,146	290,893
Discovery And Applied Research For Technological Innovations To Improve Human Health	R01EB028350	93.286	63,593	255,216
Discovery And Applied Research For Technological Innovations To Improve Human Health	R01EB029320	93.286	149,817	510,844
Discovery And Applied Research For Technological Innovations To Improve Human Health	R01EB029857	93.286	254,857	509,984
Discovery And Applied Research For Technological Innovations To Improve Human Health	R01EB035582	93.286	—	21,190
Discovery And Applied Research For Technological Innovations To Improve Human Health	R13EB035467	93.286	—	3,200
Discovery And Applied Research For Technological Innovations To Improve Human Health	R21EB029622	93.286	2,093	103,429
Discovery And Applied Research For Technological Innovations To Improve Human Health	R21EB031545	93.286	42,214	103,417
Discovery And Applied Research For Technological Innovations To Improve Human Health	R21EB033994	93.286	—	195,241
Discovery And Applied Research For Technological Innovations To Improve Human Health	R56EB033332	93.286	—	376,121
Discovery And Applied Research For Technological Innovations To Improve Human Health	U54EB027690	93.286	331,509	793,258
Pass-through Beth Israel Deaconess Medical Center	R01EB030362	93.286	—	42,120
Pass-through Georgia Institute of Technology	R01E029331	93.286	—	5,108
Pass-through Georgia Institute of Technology	R01EB028916	93.286	—	8,021
Pass-through Georgia Institute of Technology	R01EB031101	93.286	—	167,363
Pass-through Georgia Institute of Technology	R21EB031535	93.286	—	18,683
Pass-through Georgia Institute of Technology	T32EB025816	93.286	—	109,598
Pass-through Massachusetts General Hospital	R01EB027122	93.286	—	104,924
Pass-through University of Maryland, Baltimore	R01EB032680	93.286	—	147,685
Total AL No. 93.286			2,022,556	15,772,301
Minority Health And Health Disparities Research	F31MD017935	93.307	—	39,985
Minority Health And Health Disparities Research	F31MD018957	93.307	—	44,792
Minority Health And Health Disparities Research	K01MD016170	93.307	21,548	140,387
Minority Health And Health Disparities Research	K01MD018637	93.307	10,241	134,415
Minority Health And Health Disparities Research	K23MD015088	93.307	—	116,410
Minority Health And Health Disparities Research	R01MD011682	93.307	—	12,871
Minority Health And Health Disparities Research	R01MD013320	93.307	140,630	436,503
Minority Health And Health Disparities Research	R01MD015204	93.307	351,533	944,198
Minority Health And Health Disparities Research	R01MD016031	93.307	—	854,737
Minority Health And Health Disparities Research	R21MD017943	93.307	—	114,254
Pass-through Brown University	R01MD017080	93.307	—	(1,474)
Pass-through Columbia University	R01MD016386	93.307	—	73,207
Pass-through Columbia University	R01MD016899	93.307	—	43,878
Pass-through Florida International University	U54MD012393	93.307	—	23,072
Pass-through Georgetown University	R01MD017071	93.307	—	132,616
Pass-through Medical University of South Carolina	R01MD015395	93.307	—	57,959
Pass-through Meharry Medical College	P50MD017347	93.307	—	4,898
Pass-through New York University	R01MD018528	93.307	—	305,132
Pass-through University of Puerto Rico	U54MD007600	93.307	—	20,638
Pass-through University of Cincinnati	R25MD019150	93.307	—	8,056
Pass-through University of Illinois at Chicago	R21MD015813	93.307	—	4,473
Pass-through University of Michigan	R01MD016244	93.307	—	59,135
Pass-through University of Minnesota	R01MD013801	93.307	—	52,328
Pass-through University of Pennsylvania	R01MD013558	93.307	—	79,478
Pass-through University of Southern California	R01MD011698	93.307	—	78,484
Pass-through Yale University	R01MD016386	93.307	—	19,095
Total AL No. 93.307			523,952	3,799,527

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Supplementary Schedule of Expenditures of Federal Awards

Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
COVID-19 – Trans-Nih Research Support	P30DK111024	93.310	164,120	223,904
COVID-19 – Trans-Nih Research Support	U01DK132737	93.310	158,833	791,323
COVID-19 – Trans-Nih Research Support	U01MD018313	93.310	189,044	631,029
Trans-Nih Research Support	DP2GM149749	93.310	56,129	406,096
Trans-Nih Research Support	DP2GM154151	93.310	—	422,555
Trans-Nih Research Support	DP5OD023100	93.310	—	32,441
Trans-Nih Research Support	OT2OD030535	93.310	39,350	89,084
Trans-Nih Research Support	R01CA271304	93.310	—	434,784
Trans-Nih Research Support	R03HD108261	93.310	—	119,214
Trans-Nih Research Support	U24DK112341	93.310	584,218	1,215,215
Trans-Nih Research Support	U2CES030163	93.310	—	(72,765)
Trans-Nih Research Support	UG3OD023318	93.310	—	1,045,183
Trans-Nih Research Support	UH3OD023318	93.310	—	69,637
Trans-Nih Research Support	UH3TR002855	93.310	—	939,160
Pass-through Aim-Ahead	OT2OD032581	93.310	—	165,276
Pass-through Albert Einstein College of Medicine	UH3OD023320	93.310	—	216
Pass-through Cerebral Palsy Foundation	UG3OD035546	93.310	—	27,863
Pass-through Duke University	U2COD023375	93.310	—	35
Pass-through Georgia Institute of Technology	UG3TR002855	93.310	—	123
Pass-through Massachusetts General Hospital	OT2OD032701	93.310	—	755,511
Pass-through Mount Sinai School of Medicine	DP5OD031876	93.310	—	81,491
Pass-through National Alliance for Hispanic Health	OT2OD02577	93.310	—	59,056
Pass-through New York University	UH3OD023305	93.310	—	258
Pass-through Research Triangle Institute	R03HD106123	93.310	—	45,483
Pass-through University of North Texas Health Sci Ctr	OT2OD032581	93.310	—	10,000
Pass-through University of California San Francisco	R33HD105618	93.310	—	331,761
Pass-through University of California San Francisco	R61HD105618	93.310	—	(633)
Pass-through University of Colorado	OT2OD036113	93.310	—	330,265
Pass-through University of Illinois Urbana Champaign	R21HD106125	93.310	—	2,749
Pass-through University of Miami	OT2OD026551	93.310	—	307,469
Pass-through University of Miami	OT2OD26551	93.310	—	1,396,585
Pass-through University of Michigan	U54CA280805	93.310	—	79,731
Pass-through University of North Carolina	UH3OD023348	93.310	—	10,867
Pass-through Women & Infants Hospital of Rhode Island	UH3OD023347	93.310	—	136,370
Total AL No. 93.310			1,191,694	10,087,336
Emerging Infections Programs				
Pass-through Georgia Dept of Public Health	NU50CK000645	93.317	67,133	5,421,453
Total AL No. 93.317			67,133	5,421,453
COVID-19 – Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Systems, Capacity and Security	NU14GH001238	93.318	135,029	255,609
Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Systems, Capacity and Security	NU14GH001238	93.318	68,060	191,024
Total AL No. 93.318			203,089	446,633
Strengthening Public Health through Surveillance, Epidemiologic Research, Disease Detection and Prevention				
Pass-through Baylor College of Medicine	U01GH002235	93.326	—	52,000
Total AL No. 93.326			—	52,000
The Healthy Brain Initiative: Technical Assistance to Implement Public Health Actions related to Cognitive Health, Cognitive Impairment, and Caregiving at the State and Local Levels				
Pass-through Alzheimers Association	NU58DP006912	93.334	—	41,486
Total AL No. 93.334			—	41,486
National Center For Advancing Translational Sciences	KL2TR0002381	93.350	447,215	1,381,221
National Center For Advancing Translational Sciences	R03TR003669	93.350	—	78,789
National Center For Advancing Translational Sciences	R03TR004022	93.350	—	28,064
National Center For Advancing Translational Sciences	R03TR004312	93.350	—	48,735
National Center For Advancing Translational Sciences	TL1TR002382	93.350	168,944	904,759

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Supplementary Schedule of Expenditures of Federal Awards

Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
National Center For Advancing Translational Sciences	U54TR001456	93.350	—	196
National Center For Advancing Translational Sciences	UL1TR002378	93.350	4,304,652	10,243,693
Pass-through Oregon Health and Science University	U01TR002631	93.350	—	33,603
Pass-through University of Michigan	R01TR004244	93.350	—	18,692
Pass-through University of North Carolina Chapel Hill	U01TR003629	93.350	—	28,507
Pass-through University of North Carolina Chapel Hill	U01TR003715	93.350	—	89,249
Pass-through Wake Forest University	UG3TR004803	93.350	—	45,615
Total AL No. 93.350			4,920,811	12,901,123
Research Infrastructure Programs	P51OD011132	93.351	—	12,669,261
Research Infrastructure Programs	R13OD034052	93.351	11,834	41,663
Research Infrastructure Programs	R24OD030035	93.351	99,940	626,494
Research Infrastructure Programs	R24OD035466	93.351	—	337,048
Research Infrastructure Programs	S10OD034303	93.351	—	1,330,503
Research Infrastructure Programs	U42OD011023	93.351	—	1,720,490
Pass-through Henry M Jackson Foundation	K01OD031900	93.351	—	2,752
Pass-through Oregon Health and Science University	R24OD021324	93.351	—	52,977
Total AL No. 93.351			111,774	16,781,188
Construction Support	C06OD036046	93.352	—	151,682
Total AL No. 93.352			—	151,682
21st Century Cures Act – Beau Biden Cancer Moonshot:				
Pass-through Dana Farber Cancer Institute	U01CA243688	93.353	27,831	119,663
Pass-through University of Alabama Birmingham	U01CA246567	93.353	9,456	143,563
Pass-through University of Michigan	U01CA254822	93.353	—	74,059
Pass-through Vanderbilt University Medical Center	U2CCA233291	93.353	—	44,495
Total AL No. 93.353			37,287	381,780
Public Health Emergency Response: Cooperative Agreement for Emergency Response: Public Health Crisis Response				
Pass-through State of Hawaii Department of Health	NU90TP922177	93.354	—	127,406
Total AL No. 93.354			—	127,406
Nurse Education, Practice Quality and Retention Grants	T1Q47312	93.359	—	837,667
Nurse Education, Practice Quality and Retention Grants	UK147321	93.359	14,376	736,795
Nurse Education, Practice Quality and Retention Grants	UK1HP31697	93.359	—	5,107
Nurse Education, Practice Quality and Retention Grants	US647225	93.359	—	324,669
Total AL No. 93.359			14,376	1,904,238
Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development	IDSEP190055	93.360	61,554	98,395
Total AL No. 93.360			61,554	98,395
Nursing Research	F31NR014611	93.361	—	1,245
Nursing Research	F31NR020575	93.361	—	44,744
Nursing Research	F31NR020847	93.361	—	44,127
Nursing Research	F31NR020988	93.361	—	47,006
Nursing Research	F31NR021000	93.361	—	46,809
Nursing Research	K01NR019651	93.361	—	159,677
Nursing Research	K23NR020037	93.361	9,980	163,311
Nursing Research	K23NR020208	93.361	—	118,127
Nursing Research	K23NR020356	93.361	—	149,137
Nursing Research	K23NR020631	93.361	—	127,084
Nursing Research	K24NR018866	93.361	—	92,182
Nursing Research	P30NR018090	93.361	—	80,172
Nursing Research	R00NR017897	93.361	29,099	120,300
Nursing Research	R01NR017018	93.361	15,637	157,265
Nursing Research	R01NR017939	93.361	48,178	196,012
Nursing Research	R01NR018666	93.361	189,415	509,249

EMORY UNIVERSITY AND ITS SUBSIDIARIES
Supplementary Schedule of Expenditures of Federal Awards
Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Nursing Research	R01NR019083	93.361	40,883	840,018
Nursing Research	R01NR019254	93.361	5,343	327,897
Nursing Research	R01NR020154	93.361	—	481,334
Nursing Research	R01NR020188	93.361	215,378	564,436
Nursing Research	R01NR020756	93.361	190,837	491,269
Nursing Research	R21NR019872	93.361	—	65,574
Nursing Research	R25NR021324	93.361	—	6,529
Nursing Research	T32NR012715	93.361	—	(2,412)
Nursing Research	T32NR020778	93.361	—	97,288
Pass-through Johns Hopkins University	R01NR020437	93.361	—	119,240
Pass-through RAND	R01NR020788	93.361	—	32,907
Pass-through State University of New York	R01NR018979	93.361	—	124,146
Total AL No. 93.361			<u>744,750</u>	<u>5,204,673</u>
21st Century Cures Act - Precision Medicine Initiative				
Pass-through University of North Carolina Chapel Hill	OT2 OD036113	93.368	—	154,100
Total AL No. 93.368			<u>—</u>	<u>154,100</u>
Advanced Research Projects Agency For Health (ARPA-H)				
	AY1AX000001	93.384	1,597,402	6,532,948
Total AL No. 93.384			<u>1,597,402</u>	<u>6,532,948</u>
National and State Tobacco Control Program				
	R01HL155711	93.387	148,681	716,263
Total AL No. 93.387			<u>148,681</u>	<u>716,263</u>
National Center for Research Resources				
Pass-through Yale University	U01HL128566	93.389	7,576	81,027
Total AL No. 93.389			<u>7,576</u>	<u>81,027</u>
Cancer Cause And Prevention Research	F99CA264407	93.393	—	(6,588)
Cancer Cause And Prevention Research	R00CA204601	93.393	—	289
Cancer Cause And Prevention Research	R01CA178999	93.393	—	325,040
Cancer Cause And Prevention Research	R01CA211574	93.393	197,611	333,773
Cancer Cause And Prevention Research	R01CA216579	93.393	100,462	337,238
Cancer Cause And Prevention Research	R01CA218155	93.393	4,843	158,078
Cancer Cause And Prevention Research	R01CA218389	93.393	21,220	207,791
Cancer Cause And Prevention Research	R01CA227918	93.393	—	276,706
Cancer Cause And Prevention Research	R01CA230268	93.393	—	220,996
Cancer Cause And Prevention Research	R01CA234538	93.393	13,656	496,863
Cancer Cause And Prevention Research	R01CA235721	93.393	49,025	612,112
Cancer Cause And Prevention Research	R01CA236871	93.393	—	123,362
Cancer Cause And Prevention Research	R01CA237318	93.393	961,499	1,526,972
Cancer Cause And Prevention Research	R01CA245063	93.393	176,734	747,336
Cancer Cause And Prevention Research	R01CA250110	93.393	86,866	357,822
Cancer Cause And Prevention Research	R01CA254403	93.393	—	814,274
Cancer Cause And Prevention Research	R01CA259192	93.393	—	655,779
Cancer Cause And Prevention Research	R01CA266574	93.393	—	306,113
Cancer Cause And Prevention Research	R01CA268024	93.393	213,728	545,675
Cancer Cause And Prevention Research	R01CA285198	93.393	18,412	308,410
Cancer Cause And Prevention Research	R03CA259665	93.393	7,122	13,360
Cancer Cause And Prevention Research	R03CA267456	93.393	17,994	29,637
Cancer Cause And Prevention Research	R21CA273773	93.393	—	116,492
Cancer Cause And Prevention Research	R37CA234119	93.393	338,679	577,813
Cancer Cause And Prevention Research	R37CA276317	93.393	—	303,925
Cancer Cause And Prevention Research	U01CA217875	93.393	—	19,787
Cancer Cause And Prevention Research	U01CA240581	93.393	55,989	454,755
Cancer Cause And Prevention Research	U01CA269181	93.393	—	712,840
Cancer Cause And Prevention Research	U01CA275113	93.393	498,641	774,005
Pass-through Baylor College of Medicine	R01CA263000	93.393	—	93,938
Pass-through Cancer Research UK	CGCSDF-2023/100009	93.393	—	35,390

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Supplementary Schedule of Expenditures of Federal Awards

Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through Case Western Reserve University	R01CA220581	93.393	—	55,764
Pass-through Dana Farber Cancer Institute	R01CA269574	93.393	—	29,268
Pass-through Dana Farber Cancer Institute	R01CA274484	93.393	—	17,116
Pass-through Duke University	R21CA274665	93.393	—	7,778
Pass-through Duke University	R21CA284299	93.393	—	26,244
Pass-through George Washington University	R01CA278229	93.393	—	125,499
Pass-through Georgia State University	R01CA248551	93.393	—	201,587
Pass-through Georgia State University	R01CA261887	93.393	9,489	13,814
Pass-through M D Anderson Cancer Center	R01CA261750	93.393	—	50,268
Pass-through Mayo Clinic	R01CA248288	93.393	—	50,611
Pass-through Mayo Clinic	U01CA195568	93.393	—	79,745
Pass-through Mayo Clinic Arizona	U01CA269264	93.393	—	31,646
Pass-through Md Anderson	R01CA207467	93.393	—	63,826
Pass-through Md Anderson	R01CA255322	93.393	—	225,490
Pass-through Moffitt Cancer Center	R01CA275974	93.393	—	47,510
Pass-through North Carolina State University	UG3CA265842	93.393	—	(535)
Pass-through North Carolina State University	UH3CA265842	93.393	—	558,717
Pass-through Ohio State University	R01CA266402	93.393	—	24,419
Pass-through Public Health Institute	R01CA264519	93.393	—	89,224
Pass-through Roswell Park Cancer Institute	R01CA258337	93.393	11,769	47,698
Pass-through State University of New York Stony Brook	R01CA235720	93.393	—	37,531
Pass-through State University of New York Stony Brook	UG3CA225021	93.393	—	67,316
Pass-through Texas Agricultural and Mechanical Univ	R01CA257559	93.393	—	14,942
Pass-through University of Alabama Birmingham	R01CA248439	93.393	9,448	34,960
Pass-through University of Alabama Birmingham	R01CA262039	93.393	—	146,657
Pass-through University of Arizona	R01CA264047	93.393	—	55,692
Pass-through University of California Irvine	R01CA262312	93.393	—	157,745
Pass-through University of California Irvine	R01CA272680	93.393	—	22,095
Pass-through University of Florida	R01CA268014	93.393	—	14,742
Pass-through University of Iowa	R01CA259048	93.393	—	65,508
Pass-through University of Kansas Medical Center	R01CA181047	93.393	—	87,998
Pass-through University of Michigan	R01CA237046	93.393	—	37,301
Pass-through University of Michigan	R37CA251464	93.393	—	264,783
Pass-through University of Michigan	R37CA275907	93.393	—	174,658
Pass-through University of Southern California	R01CA279668	93.393	—	95,402
Pass-through University of Southern California	U19CA214253	93.393	—	230,395
Pass-through University of Utah	R01CA200854	93.393	—	6,381
Pass-through University of Utah	R01CA237404	93.393	—	38,341
Pass-through University of Washington Saint Louis	R01CA235773	93.393	—	62,583
Pass-through Vanderbilt University Medical Center	R01CA230352	93.393	—	28,430
Pass-through Vanderbilt University Medical Center	UG3CA265846	93.393	—	34,019
Total AL No. 93.393			2,793,187	14,903,151
COVID-19 – Cancer Detection And Diagnosis Research	U54CA260563	93.394	28,175	1,984,024
Cancer Detection And Diagnosis Research	R01CA169188	93.394	—	9,628
Cancer Detection And Diagnosis Research	R01CA249992	93.394	100,433	677,784
Cancer Detection And Diagnosis Research	R01CA257612	93.394	32,732	461,009
Cancer Detection And Diagnosis Research	R01CA261251	93.394	—	427,736
Cancer Detection And Diagnosis Research	R01CA268287	93.394	67,047	395,259
Cancer Detection And Diagnosis Research	R01CA272991	93.394	205,569	558,579
Cancer Detection And Diagnosis Research	R01CA281932	93.394	—	88,174
Cancer Detection And Diagnosis Research	R21CA256280	93.394	—	(6,597)
Cancer Detection And Diagnosis Research	R21CA256375	93.394	—	4,844
Cancer Detection And Diagnosis Research	R21CA256605	93.394	32,960	42,703
Cancer Detection And Diagnosis Research	R21CA259935	93.394	—	16,233
Cancer Detection And Diagnosis Research	R21CA286283	93.394	—	13,410
Cancer Detection And Diagnosis Research	U01CA113913	93.394	3,687	661,368
Cancer Detection And Diagnosis Research	U01CA264039	93.394	298,879	617,249
Pass-through Case Western Reserve University	U01CA260513	93.394	—	77,373

EMORY UNIVERSITY AND ITS SUBSIDIARIES
Supplementary Schedule of Expenditures of Federal Awards
Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through Children's Hospital of Philadelphia	R01CA248501	93.394	—	57,172
Pass-through Fred Hutchinson Research Center	U01CA224255	93.394	—	45,141
Pass-through Georgia Institute of Technology	R01CA273878	93.394	—	15,463
Pass-through Georgia Institute of Technology	R37CA239039	93.394	—	3,906
Pass-through Georgia Institute of Technology	R61CA281667	93.394	—	28,234
Pass-through Memorial Sloan Kettering Cancer Center	U24CA264369	93.394	—	60,616
Pass-through Northwestern University	R01CA240639	93.394	—	50,368
Pass-through Ohio State University	R01CA237133	93.394	—	32,097
Pass-through Rhode Island Hospital	U24CA265879	93.394	—	27,254
Pass-through Rice University	R21CA255894	93.394	—	18,028
Pass-through State Univ of New York Downstate Med Ctr	R01CA24966701A	93.394	—	20,519
Pass-through Thomas Jefferson University	R01CA236857	93.394	—	30,506
Pass-through Univ of Arkansas for Medical Services	U24CA215109	93.394	—	(136)
Pass-through University of South Florida	R01CA240319	93.394	13,733	57,920
Pass-through University of Washington Seattle	R01CA268207	93.394	—	342,402
Pass-through University of Wisconsin-Madison	R01CA264017	93.394	—	4,352
Total AL No. 93.394			783,215	6,822,618
Cancer Treatment Research	P01CA257906	93.395	—	1,881,310
Cancer Treatment Research	R00CA222493	93.395	—	3,582
Cancer Treatment Research	R01CA215718	93.395	—	33,670
Cancer Treatment Research	R01CA223220	93.395	—	378,297
Cancer Treatment Research	R01CA226992	93.395	—	346,372
Cancer Treatment Research	R01CA228406	93.395	65,461	281,025
Cancer Treatment Research	R01CA228414	93.395	9,775	9,759
Cancer Treatment Research	R01CA238471	93.395	—	282,621
Cancer Treatment Research	R01CA245386	93.395	—	290,780
Cancer Treatment Research	R01CA255257	93.395	—	407,584
Cancer Treatment Research	R01CA257861	93.395	—	488,790
Cancer Treatment Research	R01CA262123	93.395	—	513,883
Cancer Treatment Research	R01CA267694	93.395	—	722,804
Cancer Treatment Research	R01CA276135	93.395	—	222,433
Cancer Treatment Research	R01CA277686	93.395	58,570	414,374
Cancer Treatment Research	R01CA281148	93.395	—	199,530
Cancer Treatment Research	R01CA284386	93.395	—	56,707
Cancer Treatment Research	R01CA285566	93.395	—	5,127
Cancer Treatment Research	R01CA287083	93.395	—	2,751
Cancer Treatment Research	R01CA287782	93.395	—	29,913
Cancer Treatment Research	R01CA287866	93.395	—	171,209
Cancer Treatment Research	R21CA256456	93.395	—	66,185
Cancer Treatment Research	R21CA266088	93.395	24,102	157,781
Cancer Treatment Research	R21CA267365	93.395	—	24,953
Cancer Treatment Research	R21CA267612	93.395	—	113,498
Cancer Treatment Research	R21CA267914	93.395	90,870	233,053
Cancer Treatment Research	R21CA270903	93.395	—	110,901
Cancer Treatment Research	R21CA277103	93.395	—	193,813
Cancer Treatment Research	R21CA282579	93.395	—	147,139
Cancer Treatment Research	R21CA285254	93.395	—	7,757
Cancer Treatment Research	R37CA255459	93.395	—	367,626
Cancer Treatment Research	R50CA233168	93.395	—	267
Cancer Treatment Research	R50CA276010	93.395	—	154,815
Cancer Treatment Research	UG1CA233247	93.395	—	430,614
Cancer Treatment Research	UG1CA233259	93.395	480,497	574,163
Pass-through Baylor College of Medicine	R21CA260331	93.395	—	12,231
Pass-through Childrens Healthcare of Atlanta	U10CA180886	93.395	—	60,209
Pass-through Childrens Healthcare of Atlanta	UM1CA228823	93.395	—	112,333
Pass-through City of Hope	R01CA194742	93.395	—	10,374
Pass-through Clark Atlanta University	R01CA256058	93.395	—	20,169
Pass-through Ecog-Acrin Medical Research Foundation	U10CA180820	93.395	—	64,179

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Supplementary Schedule of Expenditures of Federal Awards

Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through Indiana University	R01CA235632	93.395	35,264	129,297
Pass-through Johns Hopkins University	UM1CA186691	93.395	—	5,593
Pass-through Medical University of South Carolina	P01CA203628	93.395	—	(7,154)
Pass-through St Jude Childrens Research Hospital	UM1CA081457	93.395	22,687	116,897
Pass-through University of Arizona	UG1CA242596	93.395	—	23,307
Pass-through University of California San Francisco	R01CA266596	93.395	—	3,907
Pass-through University of Chicago	R37CA272755	93.395	—	71,492
Pass-through University of North Carolina Chapel Hill	R01CA249190	93.395	—	257,938
Pass-through University of North Carolina Chapel Hill	R01CA259077	93.395	—	125,649
Pass-through University of Pittsburgh	R21CA263394	93.395	—	54,947
Pass-through University of Tennessee Health Sciences nce Ctr	R01CA240447	93.395	—	239,914
Pass-through Washington University	R01CA258681	93.395	—	8,198
Total AL No. 93.395			787,226	10,634,566
Cancer Biology Research	P30CA138292	93.396	—	471
Cancer Biology Research	R01CA175316	93.396	—	239,615
Cancer Biology Research	R01CA236369	93.396	—	202,867
Cancer Biology Research	R01CA247367	93.396	47,923	401,137
Cancer Biology Research	R01CA250422	93.396	—	287,343
Cancer Biology Research	R01CA251393	93.396	70,301	559,006
Cancer Biology Research	R01CA257446	93.396	—	692,142
Cancer Biology Research	R01CA258765	93.396	28,022	471,315
Cancer Biology Research	R01CA258857	93.396	114,357	739,859
Cancer Biology Research	R01CA266613	93.396	—	429,980
Cancer Biology Research	R01CA275193	93.396	7,924	456,471
Cancer Biology Research	R01CA275199	93.396	22,462	629,561
Cancer Biology Research	R01CA275964	93.396	—	306,823
Cancer Biology Research	R01CA280069	93.396	—	70,214
Cancer Biology Research	R01CA284648	93.396	—	360,469
Cancer Biology Research	R21CA274620	93.396	—	239,318
Cancer Biology Research	R21CA280584	93.396	—	112,080
Cancer Biology Research	R35CA197603	93.396	—	229,720
Cancer Biology Research	R50CA265345	93.396	—	140,731
Cancer Biology Research	UG3CA290302	93.396	—	11,792
Pass-through Baylor College of Medicine	R01CA271588	93.396	—	46,341
Pass-through Georgia Institute of Technology	R01CA266052	93.396	—	141,194
Pass-through Georgia Institute of Technology	U01CA250040	93.396	—	213,671
Pass-through Georgia State University	R33CA235319	93.396	—	32,132
Pass-through Indiana University	R01CA121044	93.396	—	26,384
Pass-through Moffitt Cancer Center	R01CA279065	93.396	—	17,425
Pass-through Sage Bionetworks	U24CA274494	93.396	—	125,000
Pass-through University of Alabama Birmingham	U01CA223976	93.396	—	95,652
Pass-through University of Kentucky	R01CA278989	93.396	—	35,133
Pass-through University of North Carolina Chapel Hill	R01CA244361	93.396	—	8,092
Pass-through University of North Carolina Chapel Hill	R01CA248359	93.396	—	10,020
Pass-through University of Rochester	R01CA250531	93.396	—	22,992
Total AL No. 93.396			290,989	7,354,950
Cancer Centers Support Grants	P30CA138292	93.397	124,097	3,279,975
Cancer Centers Support Grants	P50CA217691	93.397	(456)	1,331,964
Cancer Centers Support Grants	U54CA284036	93.397	135,000	309,440
Pass-through Case Western Reserve University	RES600415	93.397	—	128,371
Pass-through Cleveland Clinic Foundation	U54CA274513	93.397	—	528,742
Pass-through Mayo Clinic	P50CA116201	93.397	—	51,389
Total AL No. 93.397			258,641	5,629,881
Cancer Research Manpower	F30CA243250	93.398	—	47,529
Cancer Research Manpower	F31CA243502	93.398	—	(819)
Cancer Research Manpower	F31CA246889	93.398	—	(1,043)

EMORY UNIVERSITY AND ITS SUBSIDIARIES
Supplementary Schedule of Expenditures of Federal Awards
Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Cancer Research Manpower	F31CA247564	93.398	—	34,574
Cancer Research Manpower	F31CA254207	93.398	—	31,270
Cancer Research Manpower	F31CA265249	93.398	—	15,180
Cancer Research Manpower	F31CA268737	93.398	—	24,390
Cancer Research Manpower	F31CA271764	93.398	—	(2,985)
Cancer Research Manpower	F31CA278008	93.398	—	38,986
Cancer Research Manpower	F31CA281258	93.398	—	21,168
Cancer Research Manpower	F32CA257436	93.398	—	(3,493)
Cancer Research Manpower	F99CA274690	93.398	—	12,304
Cancer Research Manpower	F99CA284255	93.398	—	34,968
Cancer Research Manpower	K07CA211956	93.398	—	4,443
Cancer Research Manpower	K08CA248962	93.398	—	256,132
Cancer Research Manpower	K08CA267055	93.398	—	248,927
Cancer Research Manpower	K08CA270401	93.398	—	232,367
Cancer Research Manpower	K12CA237806	93.398	—	577,431
Cancer Research Manpower	K22CA266739	93.398	—	174,321
Cancer Research Manpower	K99CA267674	93.398	—	50,421
Cancer Research Manpower	R00CA252616	93.398	—	302,393
Cancer Research Manpower	R25CA265864	93.398	—	124,539
Cancer Research Manpower	T32CA272392	93.398	—	160,240
Cancer Research Manpower	T32CA275777	93.398	—	185,868
Total AL No. 93.398			—	2,569,111
Cancer Control	UG1CA275400	93.399	111,519	186,963
Cancer Control	UG1CA284884	93.399	12,063	360,569
Pass-through Nrg Oncology Foundation, Inc.	UG1CA189867	93.399	—	150,874
Total AL No. 93.399			123,582	698,406
COVID-19 - Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health	NU50CK000617	93.421	—	288,107
Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health				
Pass-through CDC Foundation	5005	93.421	—	30,041
Pass-through Natl Assoc of Chronic Disease Directors	NU38OT000286	93.421	—	82,388
Pass-through Yale New Haven Health System	NU50CK000621	93.421	—	11,232
Total AL No. 93.421			—	411,768
CDC Undergraduate Public Health Scholars Program (CUPS): A Public Health Experience to Expose Undergraduates Interested in Minority Health to Public Health and the Public Health Professions				
Pass-through Kennedy Krieger Institute	NU50CD300866	93.456	—	33,729
Total AL No. 93.456			—	33,729
Congressional Directives	H79FG001059	93.493	—	168,221
Total AL No. 93.493			—	168,221
COVID-19 – Affordable Care Act (ACA) Public Health Training Centers Program	T2946687	93.516	32,400	1,029,213
COVID-19 – Affordable Care Act (ACA) Public Health Training Centers Program	T5246760	93.516	—	68,988
Affordable Care Act (ACA) Public Health Training Centers Program	UB631680	93.516	283,174	1,247,183
Total AL No. 93.516			315,574	2,345,384
University Centers for Excellence in Developmental Disabilities Education, Research, and Service:				
Pass-through University of Georgia	90DDC10002	93.632	—	166,748
Total AL No. 93.632			—	166,748
Child Abuse and Neglect Discretionary Activities				
Pass-through Research Institute at Nationwide Children's Hospital	UH3HL161338	93.670	—	217,225
Total AL No. 93.670			—	217,225
COVID-19 – Mental and Behavioral Health Education and Training Grants	U3N45397	93.732	—	559,308

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Supplementary Schedule of Expenditures of Federal Awards

Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Mental and Behavioral Health Education and Training Grants	T6249312	93.732	—	174,656
Total AL No. 93.732			—	733,964
Medical Assistance Program				
Pass-through Georgia Department of Behavioral Health	2305GA5MAP	93.778	—	351,250
Total AL No. 93.778			—	351,250
Hospital Preparedness Program (HPP) Ebola Preparedness and Response Activities:	HITEP210054	93.817	852,551	1,800,476
Hospital Preparedness Program (HPP) Ebola Preparedness and Response Activities:	U3REP220673	93.817	63,627	985,623
Pass-through Georgia Dept of Public Health	U3REP150546	93.817	—	426,629
Total AL No. 93.817			916,178	3,212,728
Health Careers Opportunity Program	D18HP32120	93.822	21,304	624,640
Total AL No. 93.822			21,304	624,640
COVID-19 - Public Health Response, Forecasting, and Analytic Capacities Related to Disease Outbreaks, Epidemics, and Pandemics	NU38FT000001	93.823	99,961	1,816,348
Total AL No. 93.823			99,961	1,816,348
COVID-19 – National Ebola Training and Education Center (NETEC)	U3REP150549	93.825	1,285,984	1,304,151
National Ebola Training and Education Center (NETEC)	U3REP150549	93.825	4,097,765	8,061,234
National Ebola Training and Education Center (NETEC)	U3REP170552	93.825	157,241	169,093
Total AL No. 93.825			5,540,990	9,534,478
Planning Grant for Healthcare and Public Health Sector Cybersecurity Information Sharing:				
Pass-through University of Florida	R01NS112291	93.835	—	316,937
Total AL No. 93.835			—	316,937
Cardiovascular Diseases Research	F31HL156426	93.837	—	(72)
Cardiovascular Diseases Research	F31HL156495	93.837	—	16,225
Cardiovascular Diseases Research	F31HL158155	93.837	—	23,707
Cardiovascular Diseases Research	F31HL170697	93.837	—	44,744
Cardiovascular Diseases Research	F31HL172677	93.837	—	7,784
Cardiovascular Diseases Research	F32HL167625	93.837	—	24,356
Cardiovascular Diseases Research	K01HL155235	93.837	—	116,600
Cardiovascular Diseases Research	K23HL143164	93.837	6,835	126,034
Cardiovascular Diseases Research	K23HL152903	93.837	—	167,040
Cardiovascular Diseases Research	K24HL148521	93.837	—	91,740
Cardiovascular Diseases Research	K24HL163696	93.837	—	108,360
Cardiovascular Diseases Research	K99HL161355	93.837	—	32,580
Cardiovascular Diseases Research	OT2HL 155038-02	93.837	—	(30,274)
Cardiovascular Diseases Research	P01HL154996	93.837	928,133	1,907,533
Cardiovascular Diseases Research	R00HL143211	93.837	—	210,002
Cardiovascular Diseases Research	R00HL144824	93.837	19,853	246,061
Cardiovascular Diseases Research	R00HL161355	93.837	—	121,352
Cardiovascular Diseases Research	R01HL109413	93.837	—	865,559
Cardiovascular Diseases Research	R01HL119798	93.837	—	(12,257)
Cardiovascular Diseases Research	R01HL122392	93.837	41,757	316,349
Cardiovascular Diseases Research	R01HL125246	93.837	—	94
Cardiovascular Diseases Research	R01HL133667	93.837	—	168,697
Cardiovascular Diseases Research	R01HL135183	93.837	148,653	794,760
Cardiovascular Diseases Research	R01HL137338	93.837	—	145,160
Cardiovascular Diseases Research	R01HL139867	93.837	—	323,913
Cardiovascular Diseases Research	R01HL140223	93.837	—	169,828
Cardiovascular Diseases Research	R01HL141406	93.837	—	239,596
Cardiovascular Diseases Research	R01HL142762	93.837	—	189,819
Cardiovascular Diseases Research	R01HL143348	93.837	290	2,172
Cardiovascular Diseases Research	R01HL144741	93.837	—	48,933
Cardiovascular Diseases Research	R01HL145644	93.837	123,726	361,195

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Supplementary Schedule of Expenditures of Federal Awards

Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Cardiovascular Diseases Research	R01HL150005	93.837	—	484,679
Cardiovascular Diseases Research	R01HL150887	93.837	3,694	298,459
Cardiovascular Diseases Research	R01HL155537	93.837	411,672	718,206
Cardiovascular Diseases Research	R01HL155549	93.837	60,572	549,129
Cardiovascular Diseases Research	R01HL156008	93.837	—	340,927
Cardiovascular Diseases Research	R01HL157242	93.837	—	564,793
Cardiovascular Diseases Research	R01HL157311	93.837	—	843,958
Cardiovascular Diseases Research	R01HL157323	93.837	530,750	774,482
Cardiovascular Diseases Research	R01HL158141	93.837	106,515	1,087,612
Cardiovascular Diseases Research	R01HL158571	93.837	17,001	453,006
Cardiovascular Diseases Research	R01HL160589	93.837	—	487,340
Cardiovascular Diseases Research	R01HL160693	93.837	161,129	618,222
Cardiovascular Diseases Research	R01HL161366	93.837	140,135	578,278
Cardiovascular Diseases Research	R01HL163998	93.837	201,212	689,993
Cardiovascular Diseases Research	R01HL164806	93.837	—	543,368
Cardiovascular Diseases Research	R01HL165252	93.837	—	531,096
Cardiovascular Diseases Research	R01HL165940	93.837	46,255	304,031
Cardiovascular Diseases Research	R01HL166004	93.837	—	683,659
Cardiovascular Diseases Research	R01HL166233	93.837	24,691	686,321
Cardiovascular Diseases Research	R01HL166817	93.837	—	629,468
Cardiovascular Diseases Research	R01HL168383	93.837	—	987,481
Cardiovascular Diseases Research	R01HL168894	93.837	59,705	319,221
Cardiovascular Diseases Research	R01HL169955	93.837	—	341,246
Cardiovascular Diseases Research	R01HL175069	93.837	—	3,557
Cardiovascular Diseases Research	R03HL155253	93.837	—	854
Cardiovascular Diseases Research	R21HL156184	93.837	—	(7,982)
Cardiovascular Diseases Research	R33HL154116	93.837	—	175,723
Cardiovascular Diseases Research	R38HL167243	93.837	—	58,860
Cardiovascular Diseases Research	R56HL164737	93.837	60,370	617,964
Cardiovascular Diseases Research	R61HL154116A	93.837	—	(3,180)
Cardiovascular Diseases Research	T32HL007745	93.837	—	583,532
Cardiovascular Diseases Research	T32HL130025	93.837	—	649,131
Cardiovascular Diseases Research	T32HL166146	93.837	90,571	277,132
Cardiovascular Diseases Research	U01HL146241	93.837	110,030	3,745,002
Cardiovascular Diseases Research	U54HL141981	93.837	67,832	302,965
Cardiovascular Diseases Research	UG1HL135682	93.837	164,171	194,854
Cardiovascular Diseases Research	UM1HL172715	93.837	—	116,083
Pass-through Albert Einstein College of Medicine	R01HL159062	93.837	—	37,588
Pass-through Ann & Robert H. Lurie Children's Hospital	R01HL118491	93.837	—	185,360
Pass-through Ann & Robert H. Lurie Children's Hospital	R01HL164773	93.837	—	1,644
Pass-through Ann & Robert H. Lurie Children's Hospital	UH3HL148318	93.837	10,680	26,495
Pass-through Beth Israel Deaconess Medical Center	R01HL086741	93.837	—	82,420
Pass-through Beth Israel Deaconess Medical Center	R01HL161697	93.837	—	18,845
Pass-through Case Western Reserve University	R01HL158071	93.837	—	175,201
Pass-through Cincinnati Childrens Hospital	U01HL131003	93.837	—	8,086
Pass-through Georgia Institute of Technology	R01HL135505	93.837	—	(1,291)
Pass-through Georgia Institute of Technology	R01HL144714	93.837	—	(12,626)
Pass-through Georgia State University	R01HL168465	93.837	—	49,083
Pass-through Indiana University	R01HL171631	93.837	10,758	18,304
Pass-through Mayo Clinic Arizona	R01HL167811	93.837	—	89,959
Pass-through Montana State University	R01HL163237	93.837	—	20,454
Pass-through Ohio State University	R01HL148581	93.837	—	(14,795)
Pass-through Research Institute at Nationwide Children's Hospital	R01HL145032	93.837	—	19,190
Pass-through Research Institute at Nationwide Children's Hospital	UG3HL161338	93.837	—	(5,039)
Pass-through Research Institute at Nationwide Children's Hospital	UG3HL166794	93.837	—	120,558
Pass-through State University of New York	R25HL105446	93.837	—	6,741
Pass-through University of Alabama Birmingham	R01HL131017	93.837	—	393,100
Pass-through University of California Berkeley	R01HL157820	93.837	—	53,136
Pass-through University of California Los Angeles	R01HL160850	93.837	—	25,887

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Supplementary Schedule of Expenditures of Federal Awards

Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through University of California San Francisco	R01HL155226	93.837	—	24,554
Pass-through University of Cincinnati	U01HL131755	93.837	—	42,623
Pass-through University of Miami	R01HL164405	93.837	—	141,138
Pass-through University of Pennsylvania	R01HL151277	93.837	—	194,295
Pass-through University of Texas Houston	K01HL149982	93.837	—	25,798
Pass-through University of Texas San Antonio	U01HL146382	93.837	—	34,637
Pass-through University of Virginia	R01HL137112	93.837	—	341,593
Pass-through University of Washington	R01HL153136	93.837	—	19,235
Pass-through Washington University	R01HL156991	93.837	—	61,718
Total AL No. 93.837			3,546,990	29,240,951
Lung Diseases Research	F31HL164049	93.838	—	53,970
Lung Diseases Research	F31HL168914	93.838	—	47,671
Lung Diseases Research	F31HL168949	93.838	—	31,258
Lung Diseases Research	K23HL151897	93.838	—	159,272
Lung Diseases Research	K23HL166775	93.838	—	153,062
Lung Diseases Research	R00HL151965	93.838	—	248,601
Lung Diseases Research	R01HL094622	93.838	—	528,982
Lung Diseases Research	R01HL113548	93.838	—	61,818
Lung Diseases Research	R01HL136414	93.838	372,796	599,751
Lung Diseases Research	R01HL139876	93.838	62,635	93,695
Lung Diseases Research	R01HL144478	93.838	37,811	152,955
Lung Diseases Research	R01HL148171	93.838	70,896	454,386
Lung Diseases Research	R01HL150658	93.838	—	387,900
Lung Diseases Research	R01HL158747	93.838	476,560	716,864
Lung Diseases Research	R01HL158979	93.838	315,003	492,464
Lung Diseases Research	R01HL159058	93.838	26,495	882,106
Lung Diseases Research	R01HL162171	93.838	6,027	602,905
Lung Diseases Research	R01HL166455	93.838	—	439,850
Lung Diseases Research	R01HL169373	93.838	—	167,442
Lung Diseases Research	R01HL171627	93.838	64,169	146,076
Lung Diseases Research	R01HL171735	93.838	—	201,272
Lung Diseases Research	R01HL173340	93.838	—	53,953
Lung Diseases Research	R35HL150803	93.838	—	973,382
Lung Diseases Research	T32HL116271	93.838	—	193,917
Lung Diseases Research	U24HL171672	93.838	14,874	137,561
Pass-through Cincinnati Childrens Hospital	R34HL158586	93.838	—	28,582
Pass-through Georgia Institute of Technology	R01HL173002	93.838	—	1,334
Pass-through Morehouse School of Medicine	OT2HL158287	93.838	—	30,751
Pass-through Mount Sinai Medical Center	R01HL164775	93.838	—	22,361
Pass-through NYU Grossman School of Medicine	OT2HL161847	93.838	—	371,941
Pass-through Purdue University	R01HL167046	93.838	—	213,049
Pass-through Society of Critical Care Medicine	R01HL162954	93.838	—	3,227
Pass-through University of Arizona	U01HL130045	93.838	—	21,884
Pass-through University of Arizona	UG3HL147016	93.838	—	44,024
Pass-through University of Colorado	OT2HL161847-01	93.838	—	246,730
Pass-through University of Florida	OT2HL161847	93.838	—	86,035
Pass-through University of Georgia	R01HL163256	93.838	—	16,992
Pass-through University of Michigan	R01HL162661	93.838	—	37,278
Total AL No. 93.838			1,447,266	9,105,301
Blood Diseases And Resources Research	1UG1HL174446-01	93.839	—	523
Blood Diseases And Resources Research	F31HL158223	93.839	—	38,440
Blood Diseases And Resources Research	F31HL160210	93.839	—	42,461
Blood Diseases And Resources Research	K08HL141635	93.839	—	164,278
Blood Diseases And Resources Research	K08HL151965	93.839	—	141,672
Blood Diseases And Resources Research	K23HL140142	93.839	57,631	57,498
Blood Diseases And Resources Research	K23HL146904	93.839	462	152,866
Blood Diseases And Resources Research	K25HL141636	93.839	—	69,322

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Supplementary Schedule of Expenditures of Federal Awards

Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Blood Diseases And Resources Research	K99HL150626	93.839	—	200,582
Blood Diseases And Resources Research	P01HL086773	93.839	—	1,206
Blood Diseases And Resources Research	R01HL082808	93.839	—	(5,217)
Blood Diseases And Resources Research	R01HL129141	93.839	—	503
Blood Diseases And Resources Research	R01HL130995	93.839	—	288,713
Blood Diseases And Resources Research	R01HL138714	93.839	—	(1,474)
Blood Diseases And Resources Research	R01HL140589	93.839	84,277	172,768
Blood Diseases And Resources Research	R01HL141335	93.839	—	9,648
Blood Diseases And Resources Research	R01HL146668	93.839	342,931	464,146
Blood Diseases And Resources Research	R01HL152074	93.839	—	516,354
Blood Diseases And Resources Research	R01HL152131	93.839	—	125,395
Blood Diseases And Resources Research	R01HL152322	93.839	1,210	343,581
Blood Diseases And Resources Research	R01HL155330	93.839	19,807	350,352
Blood Diseases And Resources Research	R01HL159213	93.839	58,276	486,435
Blood Diseases And Resources Research	R01HL162725	93.839	—	350,853
Blood Diseases And Resources Research	R01HL163637	93.839	—	7,504
Blood Diseases And Resources Research	R01HL164583	93.839	138,533	394,301
Blood Diseases And Resources Research	R03HL164333	93.839	6,942	72,409
Blood Diseases And Resources Research	R21HL173513	93.839	—	25,794
Blood Diseases And Resources Research	R33HL163743	93.839	—	230,243
Blood Diseases And Resources Research	R35HL145000	93.839	40,006	731,067
Blood Diseases And Resources Research	R35HL166654	93.839	—	668,400
Blood Diseases And Resources Research	R61HL163743	93.839	—	385,594
Blood Diseases And Resources Research	T32HL069769	93.839	73,020	160,999
Blood Diseases And Resources Research	T32HL139443	93.839	—	267,239
Blood Diseases And Resources Research	U01HL139483	93.839	—	21,296
Blood Diseases And Resources Research	UH3HL148560	93.839	609,395	1,573,850
Pass-through Ann & Robert H. Lurie Children's Hospital	R01HL136480	93.839	8,683	244
Pass-through Boston Children's Hospital	P01HL046925	93.839	—	68,373
Pass-through Boston Children's Hospital	UH3HL157564	93.839	—	22,621
Pass-through Case Western Reserve University	R56HL165946	93.839	—	236,098
Pass-through Research Triangle Institute	R01HL166254	93.839	—	35,331
Pass-through Rice University	R01HL152314	93.839	—	108,043
Pass-through Rice University	R01HL169761	93.839	—	130,266
Pass-through University of Florida	UG1HL069301	93.839	—	61,870
Pass-through University of Maryland	UH3HL143192	93.839	—	22,710
Pass-through University of Pittsburgh	UG3HL165839	93.839	—	15,016
Pass-through University of Virginia	P01HL169552	93.839	6,338	566,227
Pass-through University of Washington	UG3HL165064	93.839	—	84,909
Pass-through Vanderbilt University	U01HL156620	93.839	—	21
Pass-through Wake Forest University	R01HL161290	93.839	—	103,952
Pass-through Wake Forest University	R01HL165247	93.839	—	53,008
Pass-through Wake Forest University	R01HL166462	93.839	—	44,369
Pass-through Yale University	R21HL165306	93.839	—	17,486
Total AL No. 93.839			1,447,511	10,080,145
Transplantation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders	K23HL152368	93.840	—	215,331
Transplantation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders	K23HL173694	93.840	—	27,541
Transplantation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders	R33HL138657	93.840	—	43,258
Pass-through All India Institute of Medical Sciences	U01HL138635	93.840	—	5,493
Pass-through University of Maryland, Baltimore	HL163514-01	93.840	—	39,170
Pass-through University of Washington	R01HL137808	93.840	—	98,856
Pass-through University of Witwatersrand	UG3HL156388	93.840	—	336,162
Pass-through Yale University	R56HL166523	93.840	—	8,114
Total AL No. 93.840			—	773,925
Arthritis, Musculoskeletal And Skin Diseases Research	F31AR081697	93.846	—	48,501
Arthritis, Musculoskeletal And Skin Diseases Research	F31AR084335	93.846	—	8,553
Arthritis, Musculoskeletal And Skin Diseases Research	K01AR061453	93.846	—	(13)

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Supplementary Schedule of Expenditures of Federal Awards

Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Arthritis, Musculoskeletal And Skin Diseases Research	K23AR075888	93.846	—	162,431
Arthritis, Musculoskeletal And Skin Diseases Research	K23AR080245	93.846	—	162,890
Arthritis, Musculoskeletal And Skin Diseases Research	R01AR048615	93.846	—	17
Arthritis, Musculoskeletal And Skin Diseases Research	R01AR059364	93.846	—	(2,062)
Arthritis, Musculoskeletal And Skin Diseases Research	R01AR061987	93.846	—	(1,250)
Arthritis, Musculoskeletal And Skin Diseases Research	R01AR070736	93.846	—	30,508
Arthritis, Musculoskeletal And Skin Diseases Research	R01AR071397	93.846	—	(17,417)
Arthritis, Musculoskeletal And Skin Diseases Research	R01AR073874	93.846	42,253	104,091
Arthritis, Musculoskeletal And Skin Diseases Research	R01AR076089	93.846	—	29,559
Arthritis, Musculoskeletal And Skin Diseases Research	R01AR076153	93.846	75,205	223,894
Arthritis, Musculoskeletal And Skin Diseases Research	R01AR076427	93.846	19,273	343,752
Arthritis, Musculoskeletal And Skin Diseases Research	R01AR077926	93.846	—	230,070
Arthritis, Musculoskeletal And Skin Diseases Research	R01AR078892	93.846	230,592	348,905
Arthritis, Musculoskeletal And Skin Diseases Research	R01AR078908	93.846	73,602	317,370
Arthritis, Musculoskeletal And Skin Diseases Research	R01AR079298	93.846	68,834	538,697
Arthritis, Musculoskeletal And Skin Diseases Research	R01AR080169	93.846	—	621,406
Arthritis, Musculoskeletal And Skin Diseases Research	R01AR080750	93.846	322,000	722,371
Arthritis, Musculoskeletal And Skin Diseases Research	R21AR078463	93.846	—	142,634
Arthritis, Musculoskeletal And Skin Diseases Research	R21AR080869	93.846	15,456	179,411
Arthritis, Musculoskeletal And Skin Diseases Research	R56AR080718	93.846	—	229,377
Pass-through Cincinnati Childrens Hospital	R01AR070474	93.846	—	33,991
Pass-through Georgia Institute of Technology	R01AR077357	93.846	—	9,485
Pass-through Georgia State University	R01AR080154	93.846	—	59,095
Pass-through Louisiana State University	R01AR073277	93.846	—	65,487
Pass-through Mayo Clinic Rochester	R01AR055563	93.846	—	322,263
Pass-through Ohio University	R01AR077248	93.846	—	114,186
Pass-through State University of New York Buffalo	R01AR078785	93.846	44,107	133,087
Pass-through University of California Los Angeles	R01AR081794	93.846	—	52,671
Pass-through University of Florida	UC2AR082196	93.846	—	26,727
Pass-through University of Michigan	U01AR073485	93.846	—	23,911
Pass-through University of Washington	R34AR080279	93.846	—	13,234
Total AL No. 93.846			891,322	5,277,832
Diabetes, Digestive, and Kidney Diseases Extramural Research	DP1DK139804	93.847	—	4,249
Diabetes, Digestive, and Kidney Diseases Extramural Research	F30DK134204	93.847	—	57,275
Diabetes, Digestive, and Kidney Diseases Extramural Research	F30DK139762	93.847	—	23,464
Diabetes, Digestive, and Kidney Diseases Extramural Research	F31DK126467	93.847	—	34,651
Diabetes, Digestive, and Kidney Diseases Extramural Research	F31DK134199	93.847	—	46,905
Diabetes, Digestive, and Kidney Diseases Extramural Research	F31DK135379	93.847	—	32,804
Diabetes, Digestive, and Kidney Diseases Extramural Research	F31DK136254	93.847	—	49,816
Diabetes, Digestive, and Kidney Diseases Extramural Research	F31DK137565	93.847	—	35,342
Diabetes, Digestive, and Kidney Diseases Extramural Research	F31DK137590	93.847	—	47,668
Diabetes, Digestive, and Kidney Diseases Extramural Research	F32DK127848	93.847	—	72,271
Diabetes, Digestive, and Kidney Diseases Extramural Research	F32DK137409	93.847	—	25,509
Diabetes, Digestive, and Kidney Diseases Extramural Research	K01DK128384	93.847	—	136,801
Diabetes, Digestive, and Kidney Diseases Extramural Research	K01DK133669	93.847	1,648	171,332
Diabetes, Digestive, and Kidney Diseases Extramural Research	K23DK118189	93.847	5,918	206,375
Diabetes, Digestive, and Kidney Diseases Extramural Research	K23DK122115	93.847	—	119,040
Diabetes, Digestive, and Kidney Diseases Extramural Research	K23DK122199	93.847	—	175,159
Diabetes, Digestive, and Kidney Diseases Extramural Research	K23DK124647	93.847	—	183,034
Diabetes, Digestive, and Kidney Diseases Extramural Research	K23DK131317	93.847	—	164,567
Diabetes, Digestive, and Kidney Diseases Extramural Research	K23MH129684	93.847	—	173,546
Diabetes, Digestive, and Kidney Diseases Extramural Research	K25DK135913	93.847	—	168,001
Diabetes, Digestive, and Kidney Diseases Extramural Research	P30DK111024	93.847	462,374	1,257,613
Diabetes, Digestive, and Kidney Diseases Extramural Research	P30DK125013	93.847	256,131	1,027,659
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK044234	93.847	—	231,859
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK080684	93.847	238,317	441,049
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK087694	93.847	292,657	638,109
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK110409	93.847	—	1,764

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Supplementary Schedule of Expenditures of Federal Awards

Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK114891	93.847	77,577	134,391
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK115213	93.847	—	489,453
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK115937	93.847	—	1,544
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK116799	93.847	—	232,051
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK119229	93.847	—	189,833
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK119793	93.847	—	(7,757)
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK120814	93.847	271,709	500,273
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK124821	93.847	204,907	913,347
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK125187	93.847	163,057	776,287
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK125246	93.847	—	1,208,763
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK125647	93.847	20,259	347,998
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK125701	93.847	—	329,835
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK125936	93.847	61,601	133,932
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK127083	93.847	354,824	373,291
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK128061	93.847	—	549,778
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK128902	93.847	—	198,447
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK129950	93.847	—	654,559
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK132653	93.847	—	460,866
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK133523	93.847	23,774	704,431
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK133650	93.847	62,431	412,379
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK134509	93.847	38,507	432,118
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK135815	93.847	—	307,736
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK136023	93.847	—	125,151
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK136983	93.847	—	348,589
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK138366	93.847	1,872	34,262
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK139653	93.847	—	11,882
Diabetes, Digestive, and Kidney Diseases Extramural Research	R03DK129627	93.847	—	90,647
Diabetes, Digestive, and Kidney Diseases Extramural Research	R03DK136975	93.847	—	76,981
Diabetes, Digestive, and Kidney Diseases Extramural Research	R03DK137007	93.847	—	86,826
Diabetes, Digestive, and Kidney Diseases Extramural Research	R21DK128731	93.847	—	135,290
Diabetes, Digestive, and Kidney Diseases Extramural Research	R25DK101390	93.847	—	99,140
Diabetes, Digestive, and Kidney Diseases Extramural Research	R56DK115213	93.847	—	(1,071)
Diabetes, Digestive, and Kidney Diseases Extramural Research	T32DK108735	93.847	—	245,687
Diabetes, Digestive, and Kidney Diseases Extramural Research	TL1DK136047	93.847	63,026	539,328
Diabetes, Digestive, and Kidney Diseases Extramural Research	U01DK062470	93.847	160,122	499,158
Diabetes, Digestive, and Kidney Diseases Extramural Research	U01DK116099	93.847	11,250	290,866
Diabetes, Digestive, and Kidney Diseases Extramural Research	U01DK134191	93.847	112,308	559,041
Diabetes, Digestive, and Kidney Diseases Extramural Research	U01DK137269	93.847	—	352,389
Diabetes, Digestive, and Kidney Diseases Extramural Research	U2CDK129501	93.847	4,393	409,217
Pass-through Adventhealth Research Institute	R01DK112700	93.847	—	50,856
Pass-through Albert Einstein College of Medicine	P30DK111102	93.847	—	32,743
Pass-through Ann & Robert H. Lurie Children's Hospital	U01DK127995	93.847	—	7,479
Pass-through Baylor College of Medicine	R01DK124395	93.847	—	162,386
Pass-through Brigham and Womens Hospital	R01DK048873	93.847	—	10,672
Pass-through Brigham and Womens Hospital	R01DK056626	93.847	—	52,446
Pass-through Brigham and Womens Hospital	R01DK103046	93.847	—	113,283
Pass-through Brigham and Womens Hospital	R01DK133988	93.847	—	87,106
Pass-through Columbia University	R01DK123285	93.847	—	15,726
Pass-through Connecticut Childrens Medical Center	U01DK134356	93.847	—	483,635
Pass-through Cornell University	R01DK103046	93.847	—	(53,703)
Pass-through Drexel University	R01DK124388	93.847	—	21,044
Pass-through Duke University	R01DK118431	93.847	—	24,480
Pass-through Georgia State University	R01DK099071	93.847	—	23,356
Pass-through Georgia State University	R01DK126080	93.847	—	4,867
Pass-through Georgia State University	R01DK136624	93.847	—	73,372
Pass-through Indiana University	R01DK122701	93.847	—	23,756
Pass-through Indiana University	R01DK136283	93.847	—	81,546
Pass-through Mayo Clinic	RC2DK118619	93.847	—	(40,764)
Pass-through Michigan State University	R01DK136733	93.847	—	68,947

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Supplementary Schedule of Expenditures of Federal Awards

Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through Mount Sinai School of Medicine	U01DK119200	93.847	—	28,464
Pass-through Research Institute at Nationwide Children's Hospital	U01DK100866	93.847	—	55,512
Pass-through Sanford Health	R01DK131020	93.847	—	4,392
Pass-through The Nemours Foundation	R01DK134499	93.847	—	75,125
Pass-through University of Alabama Birmingham	R01DK128457	93.847	—	17,637
Pass-through University of Alabama Birmingham	U01DK106858	93.847	—	130,619
Pass-through University of California San Francisco	R01DK132271	93.847	—	28,331
Pass-through University of Florida	R01DK133465	93.847	—	166,289
Pass-through University of Kansas Medical Center	R01DK099611	93.847	—	12,254
Pass-through University of Michigan	U01DK133090	93.847	—	56,352
Pass-through University of Virginia	R01DK131491	93.847	—	141,935
Pass-through University of Virginia	R01DK132369	93.847	—	380,951
Pass-through Vanderbilt University	R01DK110375	93.847	—	207,269
Pass-through Vanderbilt University Medical Center	R01DK135938	93.847	—	15,240
Pass-through Virginia Commonwealth University	U01DK061731	93.847	—	39,184
Pass-through Washington University	R21DK134104	93.847	—	17,293
Total AL No. 93.847			2,888,662	21,392,880
Extramural Research Programs In The Neurosciences And Neurological Disorders	DP2NS127291	93.853	174,437	625,012
Extramural Research Programs In The Neurosciences And Neurological Disorders	DP2NS127704	93.853	16,138	337,204
Extramural Research Programs In The Neurosciences And Neurological Disorders	F31NS113530	93.853	—	(587)
Extramural Research Programs In The Neurosciences And Neurological Disorders	F31NS115479	93.853	—	5,586
Extramural Research Programs In The Neurosciences And Neurological Disorders	F31NS117086	93.853	—	(387)
Extramural Research Programs In The Neurosciences And Neurological Disorders	F31NS117129	93.853	—	1,562
Extramural Research Programs In The Neurosciences And Neurological Disorders	F31NS124269	93.853	—	36,753
Extramural Research Programs In The Neurosciences And Neurological Disorders	F31NS125984	93.853	—	48,042
Extramural Research Programs In The Neurosciences And Neurological Disorders	F31NS127419	93.853	—	48,524
Extramural Research Programs In The Neurosciences And Neurological Disorders	F31NS127530	93.853	—	15,642
Extramural Research Programs In The Neurosciences And Neurological Disorders	F31NS127537	93.853	—	52,921
Extramural Research Programs In The Neurosciences And Neurological Disorders	F31NS127545	93.853	—	45,614
Extramural Research Programs In The Neurosciences And Neurological Disorders	F31NS127574	93.853	—	49,878
Extramural Research Programs In The Neurosciences And Neurological Disorders	F31NS130993	93.853	—	49,583
Extramural Research Programs In The Neurosciences And Neurological Disorders	F31NS131020	93.853	—	49,679
Extramural Research Programs In The Neurosciences And Neurological Disorders	F31NS134314	93.853	—	46,232
Extramural Research Programs In The Neurosciences And Neurological Disorders	F31NS134380	93.853	—	47,125
Extramural Research Programs In The Neurosciences And Neurological Disorders	F31NS135955	93.853	—	16,644
Extramural Research Programs In The Neurosciences And Neurological Disorders	F32HD105458	93.853	—	999
Extramural Research Programs In The Neurosciences And Neurological Disorders	K00NS108539	93.853	—	4,785
Extramural Research Programs In The Neurosciences And Neurological Disorders	K00NS118713	93.853	—	30,549
Extramural Research Programs In The Neurosciences And Neurological Disorders	K01NS124912	93.853	—	208,446
Extramural Research Programs In The Neurosciences And Neurological Disorders	K23NS105944	93.853	—	150,505
Extramural Research Programs In The Neurosciences And Neurological Disorders	K23NS119964	93.853	—	151,416
Extramural Research Programs In The Neurosciences And Neurological Disorders	P50NS123103	93.853	113,050	2,237,452
Extramural Research Programs In The Neurosciences And Neurological Disorders	R00NS119739	93.853	—	285,901
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS037112	93.853	—	231,259
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS045962	93.853	15,227	314,285
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS047357	93.853	—	495,599
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS065992	93.853	—	392,048
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS078095	93.853	—	48,359
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS083654	93.853	—	194,462
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS084844	93.853	126,504	477,505
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS088748	93.853	128,131	637,436
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS092343	93.853	—	985
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS095269	93.853	—	(4,891)
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS097549	93.853	2,638	98,084
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS098441	93.853	—	1,220
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS099375	93.853	—	(986)
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS100908	93.853	—	103,271
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS100967	93.853	—	10,617

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Supplementary Schedule of Expenditures of Federal Awards

Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS102627	93.853	58,244	284,492
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS102850	93.853	—	(2,326)
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS102871	93.853	—	(270)
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS105971	93.853	—	85,110
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS105982	93.853	—	47,801
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS106227	93.853	—	342,344
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS106905	93.853	78,930	360,887
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS109237	93.853	150,315	405,376
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS109242	93.853	—	420,581
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS110110	93.853	75,509	376,592
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS110347	93.853	228,518	609,814
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS111280	93.853	—	506,321
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS111470	93.853	17,577	349,206
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS111969	93.853	—	60,229
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS112308	93.853	—	707,468
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS112350	93.853	—	377,249
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS113541	93.853	222,500	519,529
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS113746	93.853	451,634	662,247
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS114130	93.853	15,003	70,217
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS114221	93.853	—	468,367
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS114253	93.853	131,319	386,647
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS118819	93.853	—	745,303
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS119683	93.853	93,218	171,609
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS119758	93.853	101,129	324,684
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS119831	93.853	116,253	190,702
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS120182	93.853	1,232	980,342
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS120676	93.853	180,041	492,019
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS123447	93.853	92,425	348,008
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS123562	93.853	—	423,957
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS124764	93.853	—	621,539
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS125143	93.853	109,199	500,352
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS125317	93.853	—	416,249
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS125768	93.853	—	371,570
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS126348	93.853	—	407,138
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS126392	93.853	234,534	623,636
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS126924	93.853	—	479,514
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS127964	93.853	—	460,045
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS129984	93.853	—	28,678
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS130036	93.853	—	312,304
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS130551	93.853	—	356,763
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS132725	93.853	—	325,563
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS133344	93.853	—	40,021
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS133809	93.853	—	333,917
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS134941	93.853	—	275,141
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS137434	93.853	—	125,948
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS138733	93.853	—	50,747
Extramural Research Programs In The Neurosciences And Neurological Disorders	R03NS114791	93.853	—	1,474
Extramural Research Programs In The Neurosciences And Neurological Disorders	R03NS127079	93.853	375	60,126
Extramural Research Programs In The Neurosciences And Neurological Disorders	R21NS112740	93.853	—	292
Extramural Research Programs In The Neurosciences And Neurological Disorders	R21NS112948	93.853	—	(5,896)
Extramural Research Programs In The Neurosciences And Neurological Disorders	R21NS114603	93.853	—	53,859
Extramural Research Programs In The Neurosciences And Neurological Disorders	R21NS114882	93.853	—	5,249
Extramural Research Programs In The Neurosciences And Neurological Disorders	R21NS116639	93.853	—	241,634
Extramural Research Programs In The Neurosciences And Neurological Disorders	R21NS119985	93.853	—	25,931
Extramural Research Programs In The Neurosciences And Neurological Disorders	R21NS121850	93.853	—	3,069
Extramural Research Programs In The Neurosciences And Neurological Disorders	R21NS122013	93.853	—	241,396
Extramural Research Programs In The Neurosciences And Neurological Disorders	R21NS123487	93.853	—	126,221
Extramural Research Programs In The Neurosciences And Neurological Disorders	R21NS123882	93.853	—	319,550
Extramural Research Programs In The Neurosciences And Neurological Disorders	R21NS125287	93.853	—	253,878

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Supplementary Schedule of Expenditures of Federal Awards

Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Extramural Research Programs In The Neurosciences And Neurological Disorders	R21NS125496	93.853	68,995	169,458
Extramural Research Programs In The Neurosciences And Neurological Disorders	R21NS125502	93.853	—	238,285
Extramural Research Programs In The Neurosciences And Neurological Disorders	R21NS130378	93.853	—	249,280
Extramural Research Programs In The Neurosciences And Neurological Disorders	R21NS132010	93.853	—	129,743
Extramural Research Programs In The Neurosciences And Neurological Disorders	R21NS132071	93.853	—	195,336
Extramural Research Programs In The Neurosciences And Neurological Disorders	R21NS132393	93.853	—	216,322
Extramural Research Programs In The Neurosciences And Neurological Disorders	R21NS133633	93.853	—	147,012
Extramural Research Programs In The Neurosciences And Neurological Disorders	R21NS133638	93.853	—	191,362
Extramural Research Programs In The Neurosciences And Neurological Disorders	R21NS133933	93.853	—	141,567
Extramural Research Programs In The Neurosciences And Neurological Disorders	R21NS133960	93.853	—	252,393
Extramural Research Programs In The Neurosciences And Neurological Disorders	R21NS134172	93.853	—	349,531
Extramural Research Programs In The Neurosciences And Neurological Disorders	R21NS136877	93.853	—	25,009
Extramural Research Programs In The Neurosciences And Neurological Disorders	R33NS106120	93.853	—	141,753
Extramural Research Programs In The Neurosciences And Neurological Disorders	R34NS137017	93.853	—	918
Extramural Research Programs In The Neurosciences And Neurological Disorders	R35NS111602	93.853	—	945,976
Extramural Research Programs In The Neurosciences And Neurological Disorders	R35NS111619	93.853	—	946,400
Extramural Research Programs In The Neurosciences And Neurological Disorders	R61CA280979	93.853	—	807
Extramural Research Programs In The Neurosciences And Neurological Disorders	R61NS130128	93.853	52,029	469,912
Extramural Research Programs In The Neurosciences And Neurological Disorders	T32NS096050	93.853	—	361,342
Extramural Research Programs In The Neurosciences And Neurological Disorders	U01NS128433	93.853	—	1,407,148
Extramural Research Programs In The Neurosciences And Neurological Disorders	U24NS107234	93.853	—	407,903
Extramural Research Programs In The Neurosciences And Neurological Disorders	U24NS126936	93.853	291,282	863,712
Extramural Research Programs In The Neurosciences And Neurological Disorders	U24NS133949	93.853	202,018	584,495
Extramural Research Programs In The Neurosciences And Neurological Disorders	U54NS116025	93.853	660,856	999,756
Extramural Research Programs In The Neurosciences And Neurological Disorders	UG3NS127386	93.853	—	(33)
Extramural Research Programs In The Neurosciences And Neurological Disorders	UH3NS127386	93.853	—	666,039
Pass-through Albert Einstein College of Medicine	K12NS080223	93.853	—	26,915
Pass-through Albert Einstein College of Medicine	R01NS083085	93.853	—	151,120
Pass-through Baylor College of Medicine	U01NS114042	93.853	—	(3,410)
Pass-through Brigham and Womens Hospital	R01HL165975	93.853	—	83,831
Pass-through Cedars Sinai Medical Center	R01NS121544	93.853	—	1,255
Pass-through Children's Hospital of Philadelphia	U01NS106845	93.853	—	15,909
Pass-through Children's Hospital of Philadelphia	U54NS115052	93.853	—	15,038
Pass-through Columbia University	R01NS110826	93.853	—	95,262
Pass-through Columbia University	R01NS131606	93.853	—	19,123
Pass-through Cornell University	R01NS121544	93.853	—	32,087
Pass-through Creighton University	R01NS118731	93.853	—	59,280
Pass-through Duke University	R01NS130832	93.853	—	84,957
Pass-through George Washington University	R01NS124477	93.853	—	190,960
Pass-through George Washington University	R01NS126090	93.853	—	660,785
Pass-through Georgia Institute of Technology	R01NS115994	93.853	—	257,465
Pass-through Georgia Institute of Technology	R01NS117613	93.853	—	(2,749)
Pass-through Georgia Tech Foundation	R01NS126183	93.853	—	116,267
Pass-through Johns Hopkins University	R01NS111283	93.853	—	38,797
Pass-through Mayo Clinic	P01NS084974	93.853	—	787,665
Pass-through Mayo Clinic	R01NS132330	93.853	—	223,367
Pass-through Morehouse School of Medicine	R01NS112422	93.853	—	142,806
Pass-through Mount Sinai School of Medicine	UH3NS103550	93.853	—	56,155
Pass-through Pennsylvania State University	R01NS113912	93.853	—	28,137
Pass-through Public Health Institute	RF1NS130713	93.853	—	409,399
Pass-through Research Institute at Nationwide Children's Hospital	R01NS133037	93.853	—	24,202
Pass-through Rush University Medical Center	R01NS125294	93.853	—	48,273
Pass-through St Jude Childrens Research Hospital	R61CA280978	93.853	29,732	50,484
Pass-through Stanford University	U01NS038455	93.853	—	192,641
Pass-through Stanford University	U01NS114042	93.853	—	26,974
Pass-through Texas Agricultural and Mechanical Univ	R01NS118731	93.853	—	48,326
Pass-through University of Oregon	R01NS134772	93.853	—	12,221
Pass-through University of California Los Angeles	R01NS112799	93.853	—	8,375
Pass-through University of California Los Angeles	RF1NS130691	93.853	—	68,855

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Supplementary Schedule of Expenditures of Federal Awards

Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through University of California San Diego	R01NS124585	93.853	—	273,484
Pass-through University of Chicago	U01NS131797	93.853	—	12,088
Pass-through University of Cincinnati	U01NS086872	93.853	—	3,528
Pass-through University of Cincinnati	U01NS120910	93.853	—	7,141
Pass-through University of Florida	U01NS124613	93.853	—	35,118
Pass-through University of Georgia	R01NS130210	93.853	—	25,422
Pass-through University of Georgia	R01NS131273	93.853	—	18,926
Pass-through University of North Carolina Chapel Hill	R01NS125073	93.853	—	7,189
Pass-through University of Pennsylvania	U01NS113198	93.853	—	63,010
Pass-through University of South Carolina	R01NS117821	93.853	—	110,070
Pass-through University of Southern California	R01NS115845	93.853	—	11,048
Pass-through University of Wisconsin-Madison	R01NS108756	93.853	—	123,048
Pass-through Virginia Commonwealth University	U24NS100673	93.853	—	24,912
Pass-through Weill Cornell Medical College	R01NS093002	93.853	—	22,413
Pass-through Weill Cornell Medical College	R01NS115963	93.853	—	16,432
Total AL No. 93.853			4,238,992	40,140,773
COVID-19 – Allergy, Immunology And Transplantation Research	R01AI143875	93.855	—	171,752
COVID-19 – Allergy, Immunology And Transplantation Research	R01AI148378	93.855	—	323,500
COVID-19 – Allergy, Immunology And Transplantation Research	R01AI161570	93.855	151,299	151,339
COVID-19 – Allergy, Immunology And Transplantation Research	U01AI141993	93.855	—	2,390
COVID-19 – Allergy, Immunology And Transplantation Research	U19AI090023	93.855	—	217,583
COVID-19 – Allergy, Immunology And Transplantation Research	U19AI110483	93.855	8,015,215	9,066,133
COVID-19 – Allergy, Immunology And Transplantation Research	U19AI171403	93.855	9,158,888	14,888,539
COVID-19 – Allergy, Immunology And Transplantation Research	UM1AI148576	93.855	—	2,629,173
COVID-19 – Allergy, Immunology And Transplantation Research	UM1AI148684	93.855	11,211,128	14,348,507
Allergy, Immunology And Transplantation Research	F30AI152342	93.855	—	53,355
Allergy, Immunology And Transplantation Research	F31AI167527	93.855	—	49,431
Allergy, Immunology And Transplantation Research	F31AI172335	93.855	—	47,964
Allergy, Immunology And Transplantation Research	F31AI172377	93.855	—	54,191
Allergy, Immunology And Transplantation Research	F31AI172618	93.855	—	35,574
Allergy, Immunology And Transplantation Research	F31AI174951	93.855	—	52,429
Allergy, Immunology And Transplantation Research	F31AI176717	93.855	—	13,856
Allergy, Immunology And Transplantation Research	F31AI179103	93.855	—	44,806
Allergy, Immunology And Transplantation Research	F31AI179158	93.855	—	49,268
Allergy, Immunology And Transplantation Research	F31AI179207	93.855	—	15,721
Allergy, Immunology And Transplantation Research	F31AI179421	93.855	—	34,365
Allergy, Immunology And Transplantation Research	F31AI179424	93.855	—	51,945
Allergy, Immunology And Transplantation Research	F31AI179463	93.855	—	18,906
Allergy, Immunology And Transplantation Research	F31AI184167	93.855	—	16,533
Allergy, Immunology And Transplantation Research	F31AI186518	93.855	—	3,886
Allergy, Immunology And Transplantation Research	F31AI186550	93.855	—	2,352
Allergy, Immunology And Transplantation Research	F32AI161857	93.855	—	25,885
Allergy, Immunology And Transplantation Research	HHSN2722013000231	93.855	—	17,438
Allergy, Immunology And Transplantation Research	K01AI130326	93.855	—	527
Allergy, Immunology And Transplantation Research	K01AI166093	93.855	10,011	197,050
Allergy, Immunology And Transplantation Research	K08AI166837	93.855	—	131,843
Allergy, Immunology And Transplantation Research	K08AI180431	93.855	—	22,581
Allergy, Immunology And Transplantation Research	K23AI134182	93.855	—	62,501
Allergy, Immunology And Transplantation Research	K23AI143479	93.855	—	225,374
Allergy, Immunology And Transplantation Research	K23AI144036	93.855	—	86,332
Allergy, Immunology And Transplantation Research	K23AI144040	93.855	—	159,919
Allergy, Immunology And Transplantation Research	K23AI177081	93.855	—	187,693
Allergy, Immunology And Transplantation Research	K23AI177087	93.855	—	10,647
Allergy, Immunology And Transplantation Research	K24AI114444	93.855	—	173,445
Allergy, Immunology And Transplantation Research	K24AI165099	93.855	—	214,210
Allergy, Immunology And Transplantation Research	P01AI125180	93.855	470,338	2,430,932
Allergy, Immunology And Transplantation Research	P01AI178376	93.855	111,338	694,867
Allergy, Immunology And Transplantation Research	P30AI050409	93.855	1,303,090	5,941,999

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Supplementary Schedule of Expenditures of Federal Awards

Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Allergy, Immunology And Transplantation Research	P30AI168386	93.855	106,857	1,081,457
Allergy, Immunology And Transplantation Research	R00AI151891	93.855	—	253,646
Allergy, Immunology And Transplantation Research	R00AI169473	93.855	—	237,590
Allergy, Immunology And Transplantation Research	R01AI021150	93.855	243,749	535,335
Allergy, Immunology And Transplantation Research	R01AI030048	93.855	—	432,989
Allergy, Immunology And Transplantation Research	R01AI047498	93.855	—	2,722
Allergy, Immunology And Transplantation Research	R01AI051231	93.855	71,919	390,803
Allergy, Immunology And Transplantation Research	R01AI053668	93.855	147,585	202,675
Allergy, Immunology And Transplantation Research	R01AI064060	93.855	—	(242)
Allergy, Immunology And Transplantation Research	R01AI064462	93.855	—	174,928
Allergy, Immunology And Transplantation Research	R01AI072435	93.855	—	268,111
Allergy, Immunology And Transplantation Research	R01AI088025	93.855	49,610	727,627
Allergy, Immunology And Transplantation Research	R01AI1072435	93.855	—	3,605
Allergy, Immunology And Transplantation Research	R01AI107960	93.855	374,141	822,431
Allergy, Immunology And Transplantation Research	R01AI110482	93.855	—	(9,385)
Allergy, Immunology And Transplantation Research	R01AI110680	93.855	(1,971)	(3,949)
Allergy, Immunology And Transplantation Research	R01AI112787	93.855	—	749,133
Allergy, Immunology And Transplantation Research	R01AI113021	93.855	—	723,977
Allergy, Immunology And Transplantation Research	R01AI116933	93.855	—	496,168
Allergy, Immunology And Transplantation Research	R01AI120860	93.855	201,240	454,671
Allergy, Immunology And Transplantation Research	R01AI123383	93.855	—	573,741
Allergy, Immunology And Transplantation Research	R01AI125064	93.855	—	1,279,198
Allergy, Immunology And Transplantation Research	R01AI125202	93.855	—	(128)
Allergy, Immunology And Transplantation Research	R01AI128837	93.855	3,973	(242)
Allergy, Immunology And Transplantation Research	R01AI129862	93.855	199,474	773,029
Allergy, Immunology And Transplantation Research	R01AI130163	93.855	138,035	210,844
Allergy, Immunology And Transplantation Research	R01AI132766	93.855	—	(82,060)
Allergy, Immunology And Transplantation Research	R01AI132833	93.855	—	543,673
Allergy, Immunology And Transplantation Research	R01AI133706	93.855	—	16,467
Allergy, Immunology And Transplantation Research	R01AI135806	93.855	—	(109)
Allergy, Immunology And Transplantation Research	R01AI136533	93.855	—	437,203
Allergy, Immunology And Transplantation Research	R01AI136581	93.855	—	448,720
Allergy, Immunology And Transplantation Research	R01AI137127	93.855	—	284,028
Allergy, Immunology And Transplantation Research	R01AI138646	93.855	276,769	376,951
Allergy, Immunology And Transplantation Research	R01AI138783	93.855	48,832	61,631
Allergy, Immunology And Transplantation Research	R01AI139063	93.855	—	342,298
Allergy, Immunology And Transplantation Research	R01AI139406	93.855	27,968	410,566
Allergy, Immunology And Transplantation Research	R01AI139761	93.855	59,758	251,294
Allergy, Immunology And Transplantation Research	R01AI141327	93.855	31,147	108,545
Allergy, Immunology And Transplantation Research	R01AI143414	93.855	—	208
Allergy, Immunology And Transplantation Research	R01AI143875	93.855	349,229	545,090
Allergy, Immunology And Transplantation Research	R01AI144067	93.855	—	381,463
Allergy, Immunology And Transplantation Research	R01AI145231	93.855	—	769,543
Allergy, Immunology And Transplantation Research	R01AI145640	93.855	62,804	916,163
Allergy, Immunology And Transplantation Research	R01AI146017	93.855	206,717	363,241
Allergy, Immunology And Transplantation Research	R01AI146260	93.855	—	402,986
Allergy, Immunology And Transplantation Research	R01AI147609	93.855	139,802	383,719
Allergy, Immunology And Transplantation Research	R01AI147890	93.855	—	122,821
Allergy, Immunology And Transplantation Research	R01AI148377	93.855	—	1,059,894
Allergy, Immunology And Transplantation Research	R01AI148378	93.855	—	336,236
Allergy, Immunology And Transplantation Research	R01AI148382	93.855	804,863	1,106,875
Allergy, Immunology And Transplantation Research	R01AI148471	93.855	59,632	412,739
Allergy, Immunology And Transplantation Research	R01AI148661	93.855	9,203	1,019,546
Allergy, Immunology And Transplantation Research	R01AI149297	93.855	10,766	290,218
Allergy, Immunology And Transplantation Research	R01AI149486	93.855	—	1,101,238
Allergy, Immunology And Transplantation Research	R01AI149527	93.855	—	121,025
Allergy, Immunology And Transplantation Research	R01AI149724	93.855	—	449,268
Allergy, Immunology And Transplantation Research	R01AI150453	93.855	—	573,751
Allergy, Immunology And Transplantation Research	R01AI150774	93.855	162,500	272,200

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Supplementary Schedule of Expenditures of Federal Awards

Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Allergy, Immunology And Transplantation Research	R01AI152516	93.855	—	418,713
Allergy, Immunology And Transplantation Research	R01AI152766	93.855	—	559,192
Allergy, Immunology And Transplantation Research	R01AI153071	93.855	—	510,099
Allergy, Immunology And Transplantation Research	R01AI153102	93.855	—	514,194
Allergy, Immunology And Transplantation Research	R01AI153152	93.855	209,063	706,675
Allergy, Immunology And Transplantation Research	R01AI154894	93.855	86,099	555,322
Allergy, Immunology And Transplantation Research	R01AI155007	93.855	144,423	448,946
Allergy, Immunology And Transplantation Research	R01AI155023	93.855	67,695	1,010,089
Allergy, Immunology And Transplantation Research	R01AI156052	93.855	—	504,352
Allergy, Immunology And Transplantation Research	R01AI158484	93.855	402,879	622,520
Allergy, Immunology And Transplantation Research	R01AI161570	93.855	170,565	534,789
Allergy, Immunology And Transplantation Research	R01AI162267	93.855	6,294	892,274
Allergy, Immunology And Transplantation Research	R01AI162633	93.855	—	706,517
Allergy, Immunology And Transplantation Research	R01AI164716	93.855	—	601,026
Allergy, Immunology And Transplantation Research	R01AI165368	93.855	—	184,992
Allergy, Immunology And Transplantation Research	R01AI165644	93.855	—	528,430
Allergy, Immunology And Transplantation Research	R01AI166305	93.855	53,257	548,311
Allergy, Immunology And Transplantation Research	R01AI166988	93.855	783,502	1,337,129
Allergy, Immunology And Transplantation Research	R01AI167356	93.855	170,951	580,793
Allergy, Immunology And Transplantation Research	R01AI167724	93.855	—	1,580,757
Allergy, Immunology And Transplantation Research	R01AI172254	93.855	—	793,050
Allergy, Immunology And Transplantation Research	R01AI172452	93.855	—	514,005
Allergy, Immunology And Transplantation Research	R01AI172740	93.855	74,942	690,597
Allergy, Immunology And Transplantation Research	R01AI173229	93.855	85,346	407,216
Allergy, Immunology And Transplantation Research	R01AI173252	93.855	—	19,179
Allergy, Immunology And Transplantation Research	R01AI173946	93.855	457,417	704,597
Allergy, Immunology And Transplantation Research	R01AI174933	93.855	—	631,951
Allergy, Immunology And Transplantation Research	R01AI175428	93.855	200,562	680,439
Allergy, Immunology And Transplantation Research	R01AI176545	93.855	724,197	938,395
Allergy, Immunology And Transplantation Research	R01AI176952	93.855	—	392,233
Allergy, Immunology And Transplantation Research	R01AI177696	93.855	—	117,438
Allergy, Immunology And Transplantation Research	R01AI179476	93.855	112,461	605,147
Allergy, Immunology And Transplantation Research	R01AI179686	93.855	—	14,551
Allergy, Immunology And Transplantation Research	R01AI179782	93.855	—	46,516
Allergy, Immunology And Transplantation Research	R01AI180089	93.855	—	41,769
Allergy, Immunology And Transplantation Research	R01AI181682	93.855	—	34,155
Allergy, Immunology And Transplantation Research	R01AI182244	93.855	—	94,623
Allergy, Immunology And Transplantation Research	R01AI183455	93.855	—	3,612
Allergy, Immunology And Transplantation Research	R01AI185192	93.855	—	9,876
Allergy, Immunology And Transplantation Research	R01AI185849	93.855	—	93,230
Allergy, Immunology And Transplantation Research	R01AI186330	93.855	—	4,660
Allergy, Immunology And Transplantation Research	R01AI147839	93.855	183,148	698,951
Allergy, Immunology And Transplantation Research	R13AI143393	93.855	—	20,000
Allergy, Immunology And Transplantation Research	R13AI174629	93.855	—	6,500
Allergy, Immunology And Transplantation Research	R21AI152031	93.855	—	64,080
Allergy, Immunology And Transplantation Research	R21AI155221	93.855	—	129,182
Allergy, Immunology And Transplantation Research	R21AI156161	93.855	91,668	103,910
Allergy, Immunology And Transplantation Research	R21AI161521	93.855	—	243,453
Allergy, Immunology And Transplantation Research	R21AI163427	93.855	5,130	(12,385)
Allergy, Immunology And Transplantation Research	R21AI164733	93.855	6,265	41,843
Allergy, Immunology And Transplantation Research	R21AI167032	93.855	—	93,350
Allergy, Immunology And Transplantation Research	R21AI167418	93.855	31,321	120,390
Allergy, Immunology And Transplantation Research	R21AI171501	93.855	—	210,284
Allergy, Immunology And Transplantation Research	R21AI173471	93.855	20,705	214,110
Allergy, Immunology And Transplantation Research	R21AI174000	93.855	87,595	178,355
Allergy, Immunology And Transplantation Research	R21AI175846	93.855	—	15,285
Allergy, Immunology And Transplantation Research	R21AI175869	93.855	—	235,921
Allergy, Immunology And Transplantation Research	R21AI176458	93.855	45,091	192,382
Allergy, Immunology And Transplantation Research	R21AI176683	93.855	31,513	205,749

EMORY UNIVERSITY AND ITS SUBSIDIARIES
Supplementary Schedule of Expenditures of Federal Awards
Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Allergy, Immunology And Transplantation Research	R21AI176944	93.855	—	314,576
Allergy, Immunology And Transplantation Research	R21AI176946	93.855	—	248,639
Allergy, Immunology And Transplantation Research	R21AI178324	93.855	—	48,478
Allergy, Immunology And Transplantation Research	R21AI178702	93.855	28,932	194,810
Allergy, Immunology And Transplantation Research	R21AI180610	93.855	—	127,820
Allergy, Immunology And Transplantation Research	R21AI180913	93.855	—	12,607
Allergy, Immunology And Transplantation Research	R21AI180928	93.855	—	6,367
Allergy, Immunology And Transplantation Research	R21AI186218	93.855	—	629
Allergy, Immunology And Transplantation Research	R24AI162317	93.855	397,678	823,608
Allergy, Immunology And Transplantation Research	R25AI147391	93.855	—	6,548
Allergy, Immunology And Transplantation Research	R25AI175048	93.855	—	119,756
Allergy, Immunology And Transplantation Research	R37AI066998	93.855	—	(264)
Allergy, Immunology And Transplantation Research	R37AI076119	93.855	51,493	567,732
Allergy, Immunology And Transplantation Research	R37AI11278	93.855	89,000	264,569
Allergy, Immunology And Transplantation Research	R37AI141258	93.855	104,001	861,486
Allergy, Immunology And Transplantation Research	R37AI150556	93.855	—	223,637
Allergy, Immunology And Transplantation Research	R37AI157862	93.855	—	909,248
Allergy, Immunology And Transplantation Research	R38AI140299	93.855	—	405,532
Allergy, Immunology And Transplantation Research	R56AI150401	93.855	—	11,389
Allergy, Immunology And Transplantation Research	R56AI165149	93.855	—	(83)
Allergy, Immunology And Transplantation Research	R56AI167702	93.855	—	429,423
Allergy, Immunology And Transplantation Research	R56AI182395	93.855	—	2,191
Allergy, Immunology And Transplantation Research	T32AI070081	93.855	—	141,994
Allergy, Immunology And Transplantation Research	T32AI074492	93.855	—	412,695
Allergy, Immunology And Transplantation Research	T32AI106699	93.855	—	272,155
Allergy, Immunology And Transplantation Research	T32AI138952	93.855	—	191,830
Allergy, Immunology And Transplantation Research	T32AI157855	93.855	—	438,049
Allergy, Immunology And Transplantation Research	U01AI077821	93.855	—	446
Allergy, Immunology And Transplantation Research	U01AI103408	93.855	—	442
Allergy, Immunology And Transplantation Research	U01AI131295	93.855	543,540	867,638
Allergy, Immunology And Transplantation Research	U01AI138909	93.855	—	717,491
Allergy, Immunology And Transplantation Research	U01AI141993	93.855	18,792	542,466
Allergy, Immunology And Transplantation Research	U01AI148069	93.855	434,713	1,020,339
Allergy, Immunology And Transplantation Research	U01AI150747	93.855	568,772	981,429
Allergy, Immunology And Transplantation Research	U19 AI051731	93.855	—	15,616
Allergy, Immunology And Transplantation Research	U19AI057266	93.855	1,697,091	3,255,430
Allergy, Immunology And Transplantation Research	U19AI090023	93.855	—	40,075
Allergy, Immunology And Transplantation Research	U19AI110483	93.855	6,951,853	9,311,992
Allergy, Immunology And Transplantation Research	U19AI111121	93.855	—	(9,706)
Allergy, Immunology And Transplantation Research	U19AI158080	93.855	—	1,741,834
Allergy, Immunology And Transplantation Research	U19AI159819	93.855	392,464	2,007,892
Allergy, Immunology And Transplantation Research	U24AI120134	93.855	58,901	866,130
Allergy, Immunology And Transplantation Research	UG3AI176853	93.855	—	2,110,060
Allergy, Immunology And Transplantation Research	UM1AI069418	93.855	811,534	3,365,918
Allergy, Immunology And Transplantation Research	UM1AI124436	93.855	—	(25,307)
Allergy, Immunology And Transplantation Research	UM1AI148576	93.855	—	1,280,913
Allergy, Immunology And Transplantation Research	UM1AI164562	93.855	1,412,971	5,853,609
Allergy, Immunology And Transplantation Research	UM1AI169662	93.855	1,743,410	6,360,133
Pass-through Albert Einstein College of Medicine	R01HL149921	93.855	—	129,959
Pass-through Benaroya Research Institute	UM1AI109565	93.855	—	247,562
Pass-through Beth Israel Deaconess Medical Center	UM1AI124377	93.855	—	(5,875)
Pass-through Boston Children's Hospital	R24AI162637	93.855	—	29,414
Pass-through Boston Children's Hospital	U24AI152179	93.855	—	131,221
Pass-through Case Western Reserve University	AI072219-11	93.855	—	12,246
Pass-through Cincinnati Childrens Hospital	R01AI148276	93.855	—	16,941
Pass-through Cincinnati Childrens Hospital	R01AI176519	93.855	—	274,876
Pass-through Cincinnati Childrens Hospital	U01AI144673	93.855	—	1,148,395
Pass-through Columbia University	R01AI169938	93.855	—	327,221
Pass-through Dana Farber Cancer Institute	R33AI129017	93.855	—	13,614

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Supplementary Schedule of Expenditures of Federal Awards

Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through Duke Clinical Research Institute	UM1AI104681	93.855	—	189,752
Pass-through Duke University	5UM1AI104681-12	93.855	—	10,702
Pass-through Duke University	R01AI143457	93.855	—	149,419
Pass-through Duke University	R01AI175411	93.855	—	17,793
Pass-through Duke University	UM1AI104681	93.855	—	55,562
Pass-through FHI 360 Llc	P018001927	93.855	358,390	358,390
Pass-through FHI 360 Llc	UM1AI068619	93.855	28,585	1,294,827
Pass-through Florida State University	R01AI173084	93.855	—	13,458
Pass-through Fred Hutchinson Research Center	UM1AI068614	93.855	—	513,790
Pass-through Fred Hutchinson Research Center	UM1AI068635	93.855	—	61,085
Pass-through Fred Hutchinson Research Center	UM1AI1068635	93.855	—	53,460
Pass-through Georgia Institute of Technology	R01AI153116	93.855	—	158,172
Pass-through Georgia Institute of Technology	R01AI68408	93.855	—	172,450
Pass-through Georgia Institute of Technology	R21AI166639	93.855	—	31
Pass-through Georgia State University	R01AI141222	93.855	—	237,321
Pass-through Georgia State University	R01AI153400	93.855	—	199,878
Pass-through Georgia State University	R01AI154656	93.855	—	46,175
Pass-through Georgia State University	R33AI100246	93.855	—	(9,706)
Pass-through Georgia State University	R33AI140475	93.855	—	109,550
Pass-through Harvard Pilgrim Health Care Institute	R01A174862	93.855	—	34,503
Pass-through Harvard University	P01AI056299	93.855	—	468,820
Pass-through Henry M Jackson Foundation	U19AI144180	93.855	—	27,332
Pass-through Immune Tolerance Network	UM1AI109565	93.855	—	363,512
Pass-through Indiana University	R01AI137116	93.855	—	17,749
Pass-through J. Craig Venter Institute	R01AI170111	93.855	—	249,949
Pass-through Johns Hopkins University	R01AI172092	93.855	—	43,044
Pass-through Johns Hopkins University	U01AI069918	93.855	—	159,272
Pass-through Johns Hopkins University	U01AI138897	93.855	—	34,478
Pass-through Johns Hopkins University	UM1 AI068632	93.855	—	28,528
Pass-through Johns Hopkins University	UM1AI068632	93.855	—	31,262
Pass-through Johns Hopkins University	UM1AI164566	93.855	—	1,548,232
Pass-through Johns Hopkins University	UM2AI130836	93.855	160,014	184,031
Pass-through La Jolla Institute For Allergy	R37AI125068	93.855	—	100,972
Pass-through La Jolla Institute For Allergy	U01AI167892	93.855	—	29,598
Pass-through La Jolla Institute For Allergy	U19AI142742	93.855	—	26,775
Pass-through La Jolla Institute For Immunology	U01AI167892	93.855	—	77,540
Pass-through La Jolla Institute For Immunology	U19AI142790	93.855	—	143,263
Pass-through Massachusetts General Hospital	R01AI176533	93.855	—	526,827
Pass-through Massachusetts General Hospital	R21AI171732	93.855	—	11,741
Pass-through Massachusetts General Hospital	R37AI106878	93.855	—	121,300
Pass-through Massachusetts Institute of Technology	R61AI161297	93.855	—	(61)
Pass-through Medical University of South Carolina	U01AI125159	93.855	—	153,566
Pass-through Memorial Sloan Kettering Cancer Center	R01AI087644	93.855	—	4,699
Pass-through Mount Sinai School of Medicine	P01AI097092	93.855	—	202,023
Pass-through Mount Sinai School of Medicine	U19AI135972	93.855	—	254,327
Pass-through New York University	U01AI174997	93.855	—	9,938
Pass-through Pennsylvania State University	R01AI158706	93.855	—	92,968
Pass-through Regents of the University of California	UM1AI068636	93.855	—	12,728
Pass-through Research Institute at Nationwide Children's Hospital	R01AI096882	93.855	—	223,959
Pass-through Research Institute at Nationwide Children's Hospital	R01AI151175	93.855	—	103,513
Pass-through Research Institute at Nationwide Children's Hospital	R01AI175800	93.855	—	246,563
Pass-through Rutgers The State University	R01AI175555	93.855	—	12,520
Pass-through Rutgers University	R21AI171755	93.855	—	24,737
Pass-through Scripps Research Institute	P01AI157299	93.855	—	836,799
Pass-through Scripps Research Institute	R01AI145629	93.855	—	483,821
Pass-through Scripps Research Institute	R01AI177265	93.855	—	40,838
Pass-through Scripps Research Institute	UM1 AI144462	93.855	—	214,763
Pass-through Scripps Research Institute	UM1AI144462	93.855	—	1,716,159
Pass-through Scripps Research Institute	UM1AI164561	93.855	—	2,652,612

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Supplementary Schedule of Expenditures of Federal Awards

Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through Seattle Childrens Hospital	R01AI165351	93.855	—	9,713
Pass-through Seattle Childrens Hospital	U54AI170855	93.855	—	199,045
Pass-through Seattle Children's Research Institute	U54AI170855	93.855	—	812,322
Pass-through Seattle Children's Research Institute	U54AI70855	93.855	—	149,932
Pass-through St Jude Childrens Research Hospital	U01AI144616	93.855	—	337,490
Pass-through Stanford University	U19AI159840	93.855	—	17,789
Pass-through Stanford University	U19AI167903	93.855	—	127,197
Pass-through Stanford University	U19AI171421	93.855	—	426,550
Pass-through Temple University	R01AI178849	93.855	—	72,474
Pass-through Tufts University	R01AI137424	93.855	—	13,651
Pass-through University of Massachusetts Lowell	R33AI140472	93.855	—	82,294
Pass-through University of Alabama Birmingham	P30AI027767	93.855	—	19,746
Pass-through University of Alabama Birmingham	R01AI153365	93.855	—	105,134
Pass-through University of Alabama Birmingham	U19AI142737	93.855	—	(23,589)
Pass-through University of Alabama Birmingham	U19AI142759	93.855	—	233,229
Pass-through University of Calgary	R01AI165327	93.855	121	40,208
Pass-through University of California Berkeley	R01AI148127	93.855	—	67,223
Pass-through University of California Berkeley	U01AI151788	93.855	—	70,294
Pass-through University of California Irvine	R01AI152161	93.855	—	167,952
Pass-through University of California Irvine	R01AI175312	93.855	—	46,907
Pass-through University of California Los Angeles	UM1AI068636	93.855	—	5,120
Pass-through University of California Los Angeles	UM1AI106701	93.855	—	379,997
Pass-through University of California San Diego	P30AI036214	93.855	—	33,720
Pass-through University of California San Diego	R01AI173689	93.855	—	(3,858)
Pass-through University of California San Diego	R21AI171385	93.855	—	157,665
Pass-through University of California San Francisco	R01AI143464	93.855	—	13,498
Pass-through University of California San Francisco	R01AI151075	93.855	—	442,397
Pass-through University of California San Francisco	R01AI152161	93.855	—	(87,073)
Pass-through University of California San Francisco	R01AI158527	93.855	—	132,506
Pass-through University of California San Francisco	R01AI165706	93.855	—	103,571
Pass-through University of California San Francisco	R01AI175614	93.855	—	92,828
Pass-through University of California San Francisco	U01AI131296	93.855	—	155,837
Pass-through University of Colorado Denver	R01AI162665	93.855	—	187,048
Pass-through University of Georgia	R01AI125738	93.855	—	(1,809)
Pass-through University of Georgia	R01AI148667	93.855	—	17,199
Pass-through University of Georgia	R01AI173084	93.855	—	57,852
Pass-through University of Kentucky	R01AI141889	93.855	—	88,346
Pass-through University of Louisiana at Lafayette	R01AI139288	93.855	—	24,825
Pass-through University of Maryland, Baltimore	R01AI138797	93.855	—	(299,195)
Pass-through University of Michigan	U54AI170660	93.855	—	115,442
Pass-through University of Minnesota	U19AI174966	93.855	—	660,174
Pass-through University of Missouri Columbia	R21AI167742	93.855	—	85,470
Pass-through University of North Carolina	K23AI159073	93.855	—	4,232
Pass-through University of North Carolina	UM1AI126619	93.855	—	17,170
Pass-through University of North Carolina Chapel Hill	R01AI153007	93.855	—	53,313
Pass-through University of North Carolina Chapel Hill	UM1AI164567	93.855	—	1,168,407
Pass-through University of Pennsylvania	P01AI131338	93.855	—	(167)
Pass-through University of Pennsylvania	R01AI139188	93.855	—	186,861
Pass-through University of Pennsylvania	R01AI158452-01A1	93.855	—	34,021
Pass-through University of Pennsylvania	R01AI179666	93.855	—	340,080
Pass-through University of South Florida	R01AI153830	93.855	—	9,144
Pass-through University of Texas Medical Branch	R01AI143653	93.855	—	64,871
Pass-through University of Texas Medical Branch	U19AI171413	93.855	—	391,248
Pass-through University of Texas Southwestern	R01AI141101	93.855	—	157
Pass-through University of Texas Southwestern	R01AI161399	93.855	—	143,088
Pass-through University of Utah	R01AI147641	93.855	—	72,738
Pass-through University of Utah	R01AI169835	93.855	—	28,359
Pass-through University of Utah	R37AI150479	93.855	—	155,530
Pass-through University of Virginia	R01AI170093	93.855	—	5,126

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Supplementary Schedule of Expenditures of Federal Awards

Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through University of Washington	R01AI137679	93.855	—	37,367
Pass-through University of Washington	R01AI142647	93.855	—	242,497
Pass-through University of Washington	R01AI174979	93.855	—	11,066
Pass-through University of Washington	R01AI181634	93.855	—	31,267
Pass-through University of Wisconsin-Madison	R01AI148707	93.855	—	81,737
Pass-through Vanderbilt University Medical Center	R01AI170172	93.855	—	31,431
Pass-through Vanderbilt University Medical Center	U01AI167799	93.855	—	35,301
Pass-through Vanderbilt University Medical Center	U19AI095227	93.855	—	20,738
Pass-through Washington State University	U01AI151799	93.855	—	135,957
Pass-through Washington University	U19AI157797	93.855	—	50,394
Pass-through Weill Cornell Medical College	P01AI131276	93.855	—	(65,079)
Pass-through Yale University	R01AI112970	93.855	—	17,891
Pass-through Yale University	R01AI161399	93.855	—	(1,474)
Total AL No. 93.855			54,320,253	173,532,161
Microbiology And Infectious Diseases Research	R01GM099142	93.856	—	255,950
Total AL No. 93.856			—	255,950
Biomedical Research and Research Training	F31GM143891	93.859	—	45,717
Biomedical Research and Research Training	F31GM153153	93.859	—	21,168
Biomedical Research and Research Training	F32GM140778	93.859	—	(1,666)
Biomedical Research and Research Training	F32GM153152	93.859	—	15,357
Biomedical Research and Research Training	K12GM000680	93.859	62,338	959,873
Biomedical Research and Research Training	K23GM128221	93.859	—	28,175
Biomedical Research and Research Training	K23GM137182	93.859	32,677	256,477
Biomedical Research and Research Training	K23GM144867	93.859	—	154,374
Biomedical Research and Research Training	K09GM143517	93.859	—	106,914
Biomedical Research and Research Training	R00GM129460	93.859	—	(608)
Biomedical Research and Research Training	R01GM053640	93.859	—	60,604
Biomedical Research and Research Training	R01GM072808	93.859	—	(51)
Biomedical Research and Research Training	R01GM093278	93.859	—	353,571
Biomedical Research and Research Training	R01GM100151	93.859	—	(264)
Biomedical Research and Research Training	R01GM113243	93.859	1,668	337
Biomedical Research and Research Training	R01GM116991	93.859	—	(808)
Biomedical Research and Research Training	R01GM124280	93.859	75,281	196,733
Biomedical Research and Research Training	R01GM124472	93.859	—	(1,150)
Biomedical Research and Research Training	R01GM129495	93.859	—	(2,151)
Biomedical Research and Research Training	R01GM130950	93.859	—	345,547
Biomedical Research and Research Training	R01GM132598	93.859	—	16,152
Biomedical Research and Research Training	R01GM132985	93.859	—	506,811
Biomedical Research and Research Training	R01GM136880	93.859	—	348,927
Biomedical Research and Research Training	R01GM137011	93.859	—	385,184
Biomedical Research and Research Training	R01GM138544	93.859	—	223,417
Biomedical Research and Research Training	R01GM139842	93.859	151,836	300,740
Biomedical Research and Research Training	R01GM139967	93.859	144,923	268,235
Biomedical Research and Research Training	R01GM140632	93.859	282,365	546,615
Biomedical Research and Research Training	R01GM141074	93.859	—	345,728
Biomedical Research and Research Training	R01GM141392	93.859	—	(7,905)
Biomedical Research and Research Training	R01GM142113	93.859	—	202,377
Biomedical Research and Research Training	R01GM144563	93.859	—	69,486
Biomedical Research and Research Training	R01GM144729	93.859	—	300,178
Biomedical Research and Research Training	R01GM148075	93.859	—	392,378
Biomedical Research and Research Training	R01GM152543	93.859	16,580	133,319
Biomedical Research and Research Training	R21GM127971	93.859	—	(79)
Biomedical Research and Research Training	R21GM148931	93.859	20,905	168,901
Biomedical Research and Research Training	R25GM125598	93.859	—	193,174
Biomedical Research and Research Training	R25GM146271	93.859	—	178,333
Biomedical Research and Research Training	R35GM119426	93.859	—	506,913
Biomedical Research and Research Training	R35GM122568	93.859	—	610,098

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Supplementary Schedule of Expenditures of Federal Awards

Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Biomedical Research and Research Training	R35GM122591	93.859	—	440,281
Biomedical Research and Research Training	R35GM128570	93.859	—	559,443
Biomedical Research and Research Training	R35GM133509	93.859	—	285,689
Biomedical Research and Research Training	R35GM133719	93.859	—	344,570
Biomedical Research and Research Training	R35GM136407	93.859	—	440,038
Biomedical Research and Research Training	R35GM138123	93.859	—	454,456
Biomedical Research and Research Training	R35GM138313	93.859	22,851	408,775
Biomedical Research and Research Training	R35GM139408	93.859	—	362,603
Biomedical Research and Research Training	R35GM142503	93.859	—	441,545
Biomedical Research and Research Training	R35GM142724	93.859	—	554,116
Biomedical Research and Research Training	R35GM143050	93.859	—	548,620
Biomedical Research and Research Training	R35GM147557	93.859	—	418,166
Biomedical Research and Research Training	R35GM147558	93.859	—	501,208
Biomedical Research and Research Training	R35GM148217	93.859	—	721,509
Biomedical Research and Research Training	R35GM148416	93.859	—	499,086
Biomedical Research and Research Training	R35GM149296	93.859	20,900	274,797
Biomedical Research and Research Training	R35GM150587	93.859	—	317,294
Biomedical Research and Research Training	R35GM150760	93.859	—	436,743
Biomedical Research and Research Training	R35GM150920	93.859	—	403,631
Biomedical Research and Research Training	R35GM151220	93.859	—	414,557
Biomedical Research and Research Training	R35GM153472	93.859	—	50,639
Biomedical Research and Research Training	RM1GM145394	93.859	96,290	1,174,609
Biomedical Research and Research Training	T32GM008490	93.859	—	14,488
Biomedical Research and Research Training	T32GM095442	93.859	—	333,874
Biomedical Research and Research Training	T32GM135060	93.859	—	440,389
Biomedical Research and Research Training	T32GM142617	93.859	—	1,431,418
Biomedical Research and Research Training	T32GM145445	93.859	—	363,073
Biomedical Research and Research Training	T32GM148391	93.859	—	326,896
Biomedical Research and Research Training	T32GM149422	93.859	—	495,707
Biomedical Research and Research Training	T34GM149511	93.859	—	292,294
Pass-through Brown University	R01GM141392	93.859	—	69,475
Pass-through Cincinnati Childrens Hospital	R21GM151703	93.859	—	24,701
Pass-through Georgia Institute of Technology	R01AI148740	93.859	—	136,734
Pass-through Georgia Institute of Technology	R01GM144560	93.859	—	44,855
Pass-through Georgia Institute of Technology	R35GM147437	93.859	—	55,220
Pass-through Johns Hopkins University	R01GM147162	93.859	—	82,083
Pass-through North Carolina State University	R25GM130528	93.859	—	54,190
Pass-through Northwestern University	R01GM121359	93.859	—	33,990
Pass-through Ohio State University	R01GM130135	93.859	—	146,382
Pass-through Pennsylvania State University	R01GM121650	93.859	—	67,286
Pass-through Seattle Children's Research Institute	U54AI150472	93.859	—	9,959
Pass-through Texas Agricultural and Mechanical Univ	R01AI145640	93.859	—	123,832
Total AL No. 93.859			928,614	22,826,352
Emerging Infectious Sentinel Networks:				
Pass-through International Society of Travel Medicine	1U01CK000632-01-00	93.860	—	5,826
Total AL No. 93.860			—	5,826
Child Health And Human Development Extramural Research	75N94022P00789	93.865	—	56,228
Child Health And Human Development Extramural Research	F31HD096815	93.865	—	(210)
Child Health And Human Development Extramural Research	F31HD105452	93.865	—	35,843
Child Health And Human Development Extramural Research	F31HD106748	93.865	—	6,133
Child Health And Human Development Extramural Research	F31HD107968	93.865	—	43,907
Child Health And Human Development Extramural Research	F31HD108974	93.865	—	44,744
Child Health And Human Development Extramural Research	F31HD108988	93.865	—	40,958
Child Health And Human Development Extramural Research	F31HD111310	93.865	—	46,564
Child Health And Human Development Extramural Research	F31HD112113	93.865	—	9,306
Child Health And Human Development Extramural Research	F31HD116541	93.865	—	2,833
Child Health And Human Development Extramural Research	F32HD100176	93.865	—	79

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Supplementary Schedule of Expenditures of Federal Awards

Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Child Health And Human Development Extramural Research	F32HD108927	93.865	—	66,215
Child Health And Human Development Extramural Research	F32HD112173	93.865	—	60,448
Child Health And Human Development Extramural Research	HHSN2752008000024C	93.865	—	(2,745)
Child Health And Human Development Extramural Research	K01HD100588	93.865	—	109,825
Child Health And Human Development Extramural Research	K01HD107294	93.865	—	123,383
Child Health And Human Development Extramural Research	K12HD072245	93.865	—	440,283
Child Health And Human Development Extramural Research	K12HD085850	93.865	—	744,905
Child Health And Human Development Extramural Research	K99HD104991	93.865	—	4,959
Child Health And Human Development Extramural Research	P01HD112217	93.865	—	2,109,419
Child Health And Human Development Extramural Research	P50HD104458	93.865	826,558	1,820,439
Child Health And Human Development Extramural Research	R00HD096322	93.865	—	241,312
Child Health And Human Development Extramural Research	R00HD097290	93.865	—	174,197
Child Health And Human Development Extramural Research	R00HD103912	93.865	—	93,482
Child Health And Human Development Extramural Research	R00HD104896	93.865	—	104,258
Child Health And Human Development Extramural Research	R00HD104991	93.865	—	57,720
Child Health And Human Development Extramural Research	R00HD105984	93.865	—	228,331
Child Health And Human Development Extramural Research	R01HD081120	93.865	176,938	668,512
Child Health And Human Development Extramural Research	R01HD082373	93.865	—	349,850
Child Health And Human Development Extramural Research	R01HD090642	93.865	503,853	804,426
Child Health And Human Development Extramural Research	R01HD090925	93.865	—	41,992
Child Health And Human Development Extramural Research	R01HD092580	93.865	27,298	26,621
Child Health And Human Development Extramural Research	R01HD092595	93.865	46,296	137,819
Child Health And Human Development Extramural Research	R01HD093706	93.865	18,291	60,320
Child Health And Human Development Extramural Research	R01HD094716	93.865	—	286,316
Child Health And Human Development Extramural Research	R01HD095741	93.865	49,591	593,523
Child Health And Human Development Extramural Research	R01HD095975	93.865	—	664,749
Child Health And Human Development Extramural Research	R01HD097175	93.865	355,540	487,963
Child Health And Human Development Extramural Research	R01HD099224	93.865	—	1,516
Child Health And Human Development Extramural Research	R01HD099480	93.865	401,732	411,549
Child Health And Human Development Extramural Research	R01HD101600	93.865	308,238	512,857
Child Health And Human Development Extramural Research	R01HD102534	93.865	555,554	856,817
Child Health And Human Development Extramural Research	R01HD108310	93.865	268,313	467,259
Child Health And Human Development Extramural Research	R01HD109005	93.865	58,344	441,796
Child Health And Human Development Extramural Research	R01HD109126	93.865	17,194	739,440
Child Health And Human Development Extramural Research	R01HD110480	93.865	179,776	642,810
Child Health And Human Development Extramural Research	R01HD115644	93.865	—	11,443
Child Health And Human Development Extramural Research	R01HD115881	93.865	—	7,264
Child Health And Human Development Extramural Research	R03HD102513	93.865	—	16,471
Child Health And Human Development Extramural Research	R21HD097491	93.865	18,339	18,339
Child Health And Human Development Extramural Research	R21HD103030	93.865	—	822
Child Health And Human Development Extramural Research	R21HD107409	93.865	14,944	128,293
Child Health And Human Development Extramural Research	R21HD109652	93.865	12,333	140,224
Child Health And Human Development Extramural Research	R21HD109723	93.865	175,559	225,634
Child Health And Human Development Extramural Research	R21HD110847	93.865	—	132,398
Child Health And Human Development Extramural Research	R33HD099745	93.865	423,731	810,847
Child Health And Human Development Extramural Research	T32HD071845	93.865	—	33,724
Child Health And Human Development Extramural Research	UG1HD027851	93.865	—	343,328
Pass-through Baylor College of Medicine	P5DH104463	93.865	—	541,393
Pass-through Bradley Hospital	R01HD095837	93.865	—	99,207
Pass-through Brown University	R01HD108048	93.865	—	65,145
Pass-through Case Western Reserve University	R01HD092351	93.865	—	29,159
Pass-through Childrens Hospital of Los Angeles	R01HD101641	93.865	—	28,414
Pass-through Childrens Hospital of Los Angeles	R21HD107983	93.865	—	20,465
Pass-through Children's Hospital of Philadelphia	R01HD101528	93.865	—	1,893
Pass-through Cincinnati Childrens Hospital	PL1HD101059	93.865	—	5,255
Pass-through City University of New York	R01HD102429	93.865	—	179,194
Pass-through Drexel University	R01HD110140	93.865	—	25,260
Pass-through Florida State University	UM2HD111102	93.865	—	36,012
Pass-through Georgia State University	R01HD107016	93.865	—	64,501

EMORY UNIVERSITY AND ITS SUBSIDIARIES
Supplementary Schedule of Expenditures of Federal Awards
Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through Global Health Uganda Ltd	R01HD096559	93.865	—	15,060
Pass-through Harvard University	R01HD102342	93.865	—	59,115
Pass-through Michigan State University	R01HD096033	93.865	—	9,180
Pass-through Morehouse School of Medicine	U54HD113292-01	93.865	—	487,096
Pass-through Northwestern University	R01HD099344	93.865	—	15,719
Pass-through Population Council	P50HD106793	93.865	—	75,962
Pass-through Rush University Medical Center	R01HD107522	93.865	—	112,380
Pass-through Univ of Massachusetts Medical School	R01HD109293	93.865	—	30,740
Pass-through University of California Davis	R01HD102571	93.865	—	102,257
Pass-through University of California San Francisco	P01HD106414	93.865	—	108,839
Pass-through University of Colorado	R01HD105939	93.865	—	2,896
Pass-through University of Connecticut	R01HD106617	93.865	—	18,785
Pass-through University of Miami	R01HD101352	93.865	—	682,196
Pass-through University of Michigan	R01HD097107	93.865	—	135,588
Pass-through University of Minnesota	R01HD103634	93.865	—	13,593
Pass-through University of Pennsylvania	R01HD111643	93.865	—	230,381
Pass-through University of Pittsburgh	R01HD102313	93.865	—	79,904
Pass-through University of South Carolina	R01HD110844	93.865	—	91,648
Pass-through University of Washington	P01 HD107669	93.865	—	38,535
Pass-through Vanderbilt University Medical Center	R01HD107695	93.865	—	19,565
Pass-through Wake Forest University	R01HD099231	93.865	—	374,396
Pass-through Wayne State University	R01HD099178	93.865	—	78,017
Pass-through Weill Cornell Medical College	K12HD000850	93.865	—	113,674
Pass-through Women & Infants Hospital of Rhode Island	R01HD084515	93.865	—	233,206
Total AL No. 93.865			4,438,422	20,952,368
Aging Research	F31AG067623	93.866	—	12,120
Aging Research	F31AG071319	93.866	—	26,648
Aging Research	F31AG074665	93.866	—	47,147
Aging Research	F31AG076289	93.866	—	47,641
Aging Research	F31AG076332	93.866	—	49,754
Aging Research	F31AG079597	93.866	—	50,754
Aging Research	F31AG079670	93.866	—	45,990
Aging Research	F31AG081046	93.866	—	51,876
Aging Research	F31AG081129	93.866	—	52,226
Aging Research	F31AG086006	93.866	—	31,486
Aging Research	F32AG081135	93.866	—	74,270
Aging Research	K01AG078497	93.866	—	107,275
Aging Research	K08AG068604	93.866	—	167,156
Aging Research	K23AG065452	93.866	—	31,742
Aging Research	K23AG065505	93.866	—	132,794
Aging Research	K23AG066931	93.866	—	292,637
Aging Research	K23AG070378	93.866	—	253,172
Aging Research	K23AG073516	93.866	—	146,696
Aging Research	K23AG076977	93.866	—	207,115
Aging Research	K23AG084415	93.866	—	138,768
Aging Research	K23AG084851	93.866	—	117,088
Aging Research	P30AG064200	93.866	172,956	565,713
Aging Research	P30AG066511	93.866	253,307	3,358,993
Aging Research	R01AG055634	93.866	—	1,714
Aging Research	R01AG057714	93.866	13,699	204,470
Aging Research	R01AG058704	93.866	94,357	454,440
Aging Research	R01AG061175	93.866	—	268,603
Aging Research	R01AG061179	93.866	—	(8,474)
Aging Research	R01AG061971	93.866	—	18,529
Aging Research	R01AG062515	93.866	—	54,591
Aging Research	R01AG062577	93.866	14,197	258,475
Aging Research	R01AG062581	93.866	—	262,238
Aging Research	R01AG062691	93.866	—	986,935

EMORY UNIVERSITY AND ITS SUBSIDIARIES
Supplementary Schedule of Expenditures of Federal Awards
Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Aging Research	R01AG064464	93.866	—	121,557
Aging Research	R01AG065177	93.866	—	311,971
Aging Research	R01AG065611	93.866	393,580	927,001
Aging Research	R01AG066203	93.866	197,629	597,357
Aging Research	R01AG066956	93.866	434,137	564,625
Aging Research	R01AG067736	93.866	—	500,683
Aging Research	R01AG068247	93.866	—	464,997
Aging Research	R01AG069114	93.866	—	174,125
Aging Research	R01AG070060	93.866	—	475,647
Aging Research	R01AG070704	93.866	49,066	1,199,257
Aging Research	R01AG070937	93.866	6,342	6,926,792
Aging Research	R01AG071174	93.866	—	(23)
Aging Research	R01AG072120	93.866	157,654	598,513
Aging Research	R01AG072603	93.866	83,453	1,218,203
Aging Research	R01AG072756	93.866	—	820,687
Aging Research	R01AG074019	93.866	127,521	344,015
Aging Research	R01AG074357	93.866	107,890	573,494
Aging Research	R01AG075444	93.866	16,250	465,944
Aging Research	R01AG075820	93.866	93,108	125,808
Aging Research	R01AG075827	93.866	—	500,926
Aging Research	R01AG075963	93.866	—	76,515
Aging Research	R01AG076373	93.866	—	986,493
Aging Research	R01AG078248	93.866	—	833,207
Aging Research	R01AG078937	93.866	—	1,348,344
Aging Research	R01AG079170	93.866	212,000	669,098
Aging Research	R01AG079836	93.866	102,377	509,179
Aging Research	R01AG079956	93.866	—	442,723
Aging Research	R01AG079990	93.866	305,765	380,358
Aging Research	R01AG082833	93.866	—	598,211
Aging Research	R01AG083084	93.866	—	267,373
Aging Research	R01AG083154	93.866	—	445,549
Aging Research	R01AG083477	93.866	16,294	181,491
Aging Research	R01AG085587	93.866	—	309,805
Aging Research	R01AG089806	93.866	—	3,318
Aging Research	R01AS072309	93.866	228,950	610,288
Aging Research	R03AG067207	93.866	—	(74)
Aging Research	R03AG087436	93.866	—	38,873
Aging Research	R03AG087482	93.866	—	14,952
Aging Research	R21AG067473	93.866	—	(4,057)
Aging Research	R21AG072142	93.866	—	104,381
Aging Research	R21AG072767	93.866	—	146,151
Aging Research	R21AG074218	93.866	—	183,928
Aging Research	R21AG075247	93.866	—	946
Aging Research	R21AG078058	93.866	—	136,908
Aging Research	R21AG080247	93.866	—	118,158
Aging Research	R21AG080262	93.866	—	153,687
Aging Research	R21AG082333	93.866	—	97,662
Aging Research	R21AG083366	93.866	—	193,881
Aging Research	R21AG084231	93.866	—	97,816
Aging Research	R24AG066599	93.866	421,207	632,785
Aging Research	R34AG058835	93.866	6,513	4,554
Aging Research	R36AG075455	93.866	—	18,331
Aging Research	R56AG074886	93.866	15,953	178,114
Aging Research	R56AG083167	93.866	220,716	360,903
Aging Research	R61AG080606	93.866	—	334,294
Aging Research	RF1AG064942	93.866	632,047	1,193,423
Aging Research	RF1AG065282	93.866	133,830	785,345
Aging Research	RF1AG069114	93.866	70,136	638,801
Aging Research	RF1AG069253	93.866	—	723,371

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Supplementary Schedule of Expenditures of Federal Awards

Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Aging Research	RF1AG071170	93.866	—	730,593
Aging Research	RF1AG071587	93.866	—	30,402
Aging Research	RF1AG073428	93.866	22,364	1,544,910
Aging Research	RF1AG079199	93.866	92,828	513,023
Aging Research	RF1AG079256	93.866	195,781	618,154
Aging Research	RF1AG079269	93.866	352,075	720,491
Aging Research	RF1AG079318	93.866	—	829,800
Aging Research	RF1AG081401	93.866	—	457,518
Aging Research	U01AG052460	93.866	—	277
Aging Research	U01AG061357	93.866	40,325	625,797
Aging Research	U24AG077110	93.866	103,324	277,251
Aging Research	U54AG062334	93.866	—	122,039
Aging Research	U54AG065187	93.866	4,173,430	6,208,968
Pass-through Beth Israel Deaconess Medical Center	R01AG068141	93.866	—	7,814
Pass-through Beth Israel Deaconess Medical Center	RF2AG062181	93.866	—	386
Pass-through Brown University	U54AG063546	93.866	—	46,815
Pass-through Case Western Reserve University	R01AG067607	93.866	—	31,338
Pass-through Case Western Reserve University	R01AG077554	93.866	—	35,138
Pass-through Columbia University	R01AG062624	93.866	—	2,230
Pass-through Florida International University	R13AG069380	93.866	—	82
Pass-through Georgia Institute of Technology	R01AG082039	93.866	—	186,915
Pass-through Georgia Institute of Technology	R21AG061687	93.866	—	(8,522)
Pass-through Georgia State University	R01AG080093	93.866	—	20,111
Pass-through Georgia State University	R21AG077307	93.866	—	5,912
Pass-through Harvard University	R21AG073744	93.866	—	10,323
Pass-through Indiana University	U54AG054345	93.866	—	380,806
Pass-through M D Anderson Cancer Center	R01AG067419	93.866	—	104,752
Pass-through M D Anderson Cancer Center	R01AG071174	93.866	—	104,338
Pass-through Mayo Clinic	U01AG046139	93.866	—	(1,977)
Pass-through Mclean Hospital	R01AG061100	93.866	—	208,866
Pass-through Northwestern University	U19AG073153	93.866	—	8,958
Pass-through Northwestern University	U2CA060426	93.866	—	132,293
Pass-through Ohio State University	R21AG068831	93.866	—	369
Pass-through Oregon Health and Science University	R01AG067546	93.866	—	26,782
Pass-through Rush University Medical Center	R01AG015819	93.866	—	319,338
Pass-through State University of New York Stony Brook	R01AG067590	93.866	—	70,470
Pass-through Tulane University	R01AG077497	93.866	—	40,214
Pass-through Univ of Texas Health Sciences Ctr	R61AG078523	93.866	—	28,188
Pass-through University of Nevada	R01AG083177	93.866	—	64,396
Pass-through University of Oregon	R01AR078375	93.866	—	37,611
Pass-through University of Alabama Birmingham	R01AG061800	93.866	—	209,468
Pass-through University of Arizona	U19AG065169	93.866	—	811,848
Pass-through University of California Berkeley	R01AG077001	93.866	—	45,598
Pass-through University of California San Diego	R01AG062387	93.866	—	108,825
Pass-through University of Chicago	U19AG073153	93.866	—	137,500
Pass-through University of Florida	R01AG064786	93.866	—	286,802
Pass-through University of Florida	RF1AG064914	93.866	—	311,289
Pass-through University of Florida	RF1AG074569	93.866	—	625,884
Pass-through University of Georgia	R21AG070765	93.866	—	40,212
Pass-through University of Georgia	U01AG074960	93.866	—	10,266
Pass-through University of Illinois at Chicago	R21HD112862	93.866	—	16,228
Pass-through University of Nebraska Medical Center	R01AG069609	93.866	—	333,487
Pass-through University of New Mexico	R01AG049395	93.866	—	106,448
Pass-through University of North Carolina Chapel Hill	R01AG065394	93.866	—	57,046
Pass-through University of North Carolina Greensboro	R01AG058919	93.866	—	45,726
Pass-through University of Pittsburgh	R01AG074971	93.866	—	489,939
Pass-through University of Pittsburgh	R21AG074094	93.866	—	17,203
Pass-through University of Pittsburgh	U19AG074866-01A1	93.866	—	206,181
Pass-through University of Southern California	R01AG065482	93.866	—	5,489

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Supplementary Schedule of Expenditures of Federal Awards

Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through University of Southern California	U24AG057437	93.866	—	283,557
Pass-through University of Texas Austin	R21AG064309	93.866	—	9,980
Pass-through University of Washington	U24AG072122	93.866	—	25,025
Pass-through University of Wisconsin-Madison	R01AG070883	93.866	—	148,743
Pass-through Vanderbilt University	R01AG068606	93.866	—	17,108
Pass-through Vanderbilt University	R01AG069900	93.866	—	288,061
Pass-through Wake Forest University	R01AG075959	93.866	—	98,534
Pass-through Washington University	R01AG067505	93.866	—	578,093
Pass-through Washington University	U19AG032438	93.866	—	72,272
Pass-through Washington University	U19AG071754	93.866	—	330,248
Pass-through Yale University	R01AG075820-04	93.866	—	89,950
Pass-through Yale University	R33AG058926	93.866	—	278
Total AL No. 93.866			9,561,061	59,587,703
Vision Research	7R01EY016435-15 (REV)	93.867	—	122,400
Vision Research	F30EY035173	93.867	—	47,815
Vision Research	F31EY033691	93.867	—	44,295
Vision Research	F32EY035573	93.867	—	7,761
Vision Research	P30EY006360	93.867	—	583,332
Vision Research	R00EY029010	93.867	—	241,706
Vision Research	R01EY021592	93.867	—	4,091
Vision Research	R01EY028450	93.867	75,000	72,010
Vision Research	R01EY028859	93.867	—	156,933
Vision Research	R01EY029724	93.867	—	100,538
Vision Research	R01EY030871	93.867	121,079	277,932
Vision Research	R01EY031042	93.867	—	548,176
Vision Research	R01EY033361	93.867	176,422	613,527
Vision Research	R21EY035136	93.867	—	234,170
Vision Research	R21EY035468	93.867	510	77,161
Vision Research	T32EY007092	93.867	59,862	164,029
Vision Research	U10EY013287	93.867	—	(23,008)
Pass-through George Mason University	R21EY032152	93.867	—	29,481
Pass-through Jaeb Center For Health Research	PROTOCOL W	93.867	—	(2,434)
Pass-through Jaeb Center For Health Research	UG1EY011751	93.867	—	13,502
Pass-through Johns Hopkins University	UG1EY028091	93.867	—	31,446
Pass-through New England College of Optometry	R01EY025307	93.867	—	6,145
Pass-through Oakland University	R01EY033808	93.867	—	41,957
Pass-through University of California San Francisco	UG1EY023939	93.867	—	15,731
Pass-through University of Houston	R01EY032508	93.867	—	39,718
Pass-through University of Nebraska Medical Center	R01EY029594	93.867	—	235,770
Pass-through University of North Texas	R01EY030967	93.867	—	31,382
Total AL No. 93.867			432,873	3,715,566
Medical Library Assistance	R01LM013049	93.879	125,267	172,949
Medical Library Assistance	R01LM013323	93.879	—	8,143
Medical Library Assistance	R01LM013864	93.879	41,132	428,841
Pass-through University of California San Diego	R21LM013818	93.879	—	391
Pass-through Yale University	R01LM013712	93.879	—	102,956
Total AL No. 93.879			166,399	713,280
National Bioterrorism Hospital Preparedness Program:				
Pass-through Baylor College of Medicine	U3REP220671	93.889	—	184,113
Total AL No. 93.889			—	184,113
Cancer Prevention and Control Programs for State, Territorial, and Tribal Organizations:				
Pass-through Georgia Dept of Public Health	40500-036-22223686	93.898	—	791,256
Pass-through Georgia Dept of Public Health	NU58DP006352	93.898	—	(302)
Total AL No. 93.898			—	790,954

EMORY UNIVERSITY AND ITS SUBSIDIARIES
Supplementary Schedule of Expenditures of Federal Awards
Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Rural Health Care Services Outreach, Rural Health Network Development and Small Health Care Provider Quality Improvement	G2846273	93.912	441,612	596,836
Total AL No. 93.912			441,612	596,836
HIV Prevention Activities Non-Governmental Organization Based	NU62PS924790	93.939	12,502,958	16,610,698
Total AL No. 93.939			12,502,958	16,610,698
HIV Demonstration, Research, Public And Professional Education Projects Pass-through Ann & Robert H. Lurie Children's Hospital	U01PS005270	93.941	—	6,025
Total AL No. 93.941			—	6,025
Epidemiologic Research Studies of Acquired Immunodeficiency Syndrome (AIDS) and Human Immunodeficiency Virus (HIV) Infection in Selected Popula	U01PS005279	93.943	—	57,094
Epidemiologic Research Studies of Acquired Immunodeficiency Syndrome (AIDS) and Human Immunodeficiency Virus (HIV) Infection in Selected Popula	U01PS005282	93.943	—	62,674
Total AL No. 93.943			—	119,768
Assistance Programs For Chronic Disease Prevention And Control: Pass-through Tulane University	U18DP006523	93.945	—	22,227
Pass-through University of Florida	U18DP006512	93.945	—	29,553
Total AL No. 93.945			—	51,780
Block Grants for Prevention and Treatment of Substance Abuse: Pass-through Georgia Department of Behavioral Health	B08T1084637	93.959	—	67,838
Total AL No. 93.959			—	67,838
PPHF Geriatric Education Centers	U1Q33070	93.969	301,403	845,592
PPHF Geriatric Education Centers	U1QHP53036	93.969	—	130
Total AL No. 93.969			301,403	845,722
Cooperative Agreements for Diabetes Control Programs Pass-through Amer Assoc of Diabetes Educators	NU58DP007422	93.988	2,505,403	5,979,795
	NU58DP007378	93.988	—	157,730
Total AL No. 93.988			2,505,403	6,137,525
International Research and Research Training	D43TW007124	93.989	33,895	312,898
International Research and Research Training	D43TW009127	93.989	50,436	312,648
International Research and Research Training	D43TW010934	93.989	30,454	348,731
International Research and Research Training	D43TW011404	93.989	93,946	338,045
International Research and Research Training	D43TW012188	93.989	157,380	280,998
International Research and Research Training	D43TW012459	93.989	16,740	153,081
International Research and Research Training	R21TW012010	93.989	58,288	138,414
International Research and Research Training	U2RTW010114	93.989	345,553	448,684
Pass-through Aga Khan University	D43TW010905	93.989	—	22,099
Pass-through Universidad Peruana Cayetano Heredia	U01TW010107	93.989	—	53,174
Pass-through University of Virginia	R01TW012183	93.989	—	(1,159)
Pass-through Vanderbilt University Medical Center	D43TW009337	93.989	—	10,171
Total AL No. 93.989			786,692	2,417,784
Maternal and Child Health Services Block Grant to the States: Pass-through University of South Florida	B04MC40124	93.994	—	59,998
Total AL No. 93.994			—	59,998
Contract	00HCVGDB-2023-77665	93.CTR	—	389,831
Contract	75D30118C02645	93.CTR	5,794	1,182
Contract	75D30121C12018	93.CTR	—	2,018
Contract	75D30121D10817	93.CTR	—	85,259
Contract	75D30122C14198	93.CTR	—	162,363
Contract	75D30122C14484	93.CTR	—	284,641
Contract	75D30122C14631	93.CTR	—	405,703
Contract	75D30122P15586	93.CTR	—	(311)

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Supplementary Schedule of Expenditures of Federal Awards

Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Contract	75D30123C16053	93.CTR	—	191,409
Contract	75D301-23-C-17180	93.CTR	—	135,993
Contract	75D30123C18295	93.CTR	—	88,735
Contract	75D30123P17058	93.CTR	—	228,090
Contract	75D30123P17062	93.CTR	—	13,707
Contract	75D30123P17233	93.CTR	—	248,786
Contract	75D30123P17392	93.CTR	—	246,786
Contract	75N92022D00015	93.CTR	919,986	4,461,188
Contract	75N92022F00003	93.CTR	25,000	6,425,384
Contract	75N92022F00004	93.CTR	34,737	519,720
Contract	75N92023P00135	93.CTR	—	77,659
Contract	75N93020D00005	93.CTR	—	3,791,999
Contract	75N93021C00017	93.CTR	210,101	3,860,058
Contract	75N94020D00009	93.CTR	—	46,924
Contract	75N94021D00017	93.CTR	—	181
Contract	75R60123C00010	93.CTR	—	42,377
Contract	HSHS258201800013C	93.CTR	—	2,826
Contract	HHSN261201800003I	93.CTR	—	3,051,384
Contract	HHSN268201700205A	93.CTR	—	39,234
Contract	HHSN2722013000181	93.CTR	—	1,147
Contract	HHSN272201300018I	93.CTR	1,071,398	3,063,729
Contract	HHSN275201500001I	93.CTR	—	142,473
Pass-through Access to Advanced Health Institute	75N93019C00059	93.CTR	—	179,690
Pass-through Ann & Robert H. Lurie Children's Hospital	75D30122C15605	93.CTR	4,006	21,006
Pass-through Assoc of Schools & Pgms of Public Health	S5033	93.CTR	—	215
Pass-through Duke University	T2HL156812	93.CTR	—	5,245
Pass-through Frontier Science and Technology Res Fdn	PSAWCIEM00	93.CTR	—	214
Pass-through Georgia Institute of Technology	75F40120C00207	93.CTR	—	131,498
Pass-through Georgia Institute of Technology	N6600123C4503	93.CTR	—	55,131
Pass-through Harvard University	1AYSAX000005-01	93.CTR	—	314,751
Pass-through Infectious Disease Research Institute	75N93019C00059	93.CTR	—	(50,717)
Pass-through Massachusetts General Hospital	OT2NS136938	93.CTR	—	7,235
Pass-through Mount Sinai School of Medicine	75N93019C00046	93.CTR	—	543,486
Pass-through Mount Sinai School of Medicine	75N93019C00051	93.CTR	—	1,144,462
Pass-through Mount Sinai School of Medicine	75N9301R00028	93.CTR	—	221,411
Pass-through NORC at the University of Chicago	75D30118F03426	93.CTR	—	(866)
Pass-through Purdue University	AUTM Human Tissue MTA	93.CTR	—	4,937
Pass-through Radiological Society of North America	75N92020D00021	93.CTR	—	25,002
Pass-through Stanford University	75N93022C00052	93.CTR	—	385,777
Pass-through Univ of Arkansas for Medical Services	75N91019D00024	93.CTR	—	29,971
Pass-through University of North Texas Health Sci Ctr	10T20D032581-01	93.CTR	—	356,999
Pass-through University of Alabama Birmingham	HHSN272201300012I/HHSN27200014	93.CTR	—	(2,028)
Pass-through University of Chicago	75N92020D00018/75N92020F00001	93.CTR	—	144,924
Pass-through University of Colorado	NCATS-P00438-B	93.CTR	—	90,038
Pass-through University of Maryland	75N90022C00013	93.CTR	—	239,348
Pass-through University of Maryland, Baltimore	75N930221D00035	93.CTR	—	304,890
Pass-through University of North Carolina Chapel Hill	75N93022C00024	93.CTR	—	51,945
Pass-through University of Pennsylvania	75N93021C00015	93.CTR	—	427,452
Pass-through University of Washington	HHSN272201800008C	93.CTR	—	320,117
Pass-through Vanderbilt University Medical Center	75D30121C11656	93.CTR	—	1,610
Pass-through Vanderbilt University Medical Center	75D30122C14944	93.CTR	—	505,055
Total AL No. 93.CTR			2,271,022	33,469,273
U.S. Department of Health and Human Services Total			140,590,752	709,328,430

EMORY UNIVERSITY AND ITS SUBSIDIARIES
Supplementary Schedule of Expenditures of Federal Awards
Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
U.S. Department of Homeland Security:				
Assistance Listing Program Title:				
Pass-through George Mason University	17STCIN00001	97.061	—	112,607
Total AL No. 97.061			—	112,607
U.S. Department of Homeland Security Total			—	112,607
U.S. Agency for International Development:				
US Aid Foreign Assistance For Programs Overseas:				
Pass-through FHI 360 Llc	7200AA20CA00016	98.001	—	14,249
Pass-through Intl Aids Vaccine Initiative	AID-OAA-A-16-00032	98.001	—	394,975
Pass-through Task Force For Global Health, Inc	AIDOAG1400008	98.001	89,960	137,771
Pass-through Technoserve	7200AA22LE00002	98.001	—	471,554
Total AL No. 98.001			89,960	1,018,549
Cooperative Development Program (CDP)				
Pass-through Georgia Institute of Technology	RF409-G1	98.002	—	(15,099)
Total AL No. 98.002			—	(15,099)
U.S. Agency for International Development Total			89,960	1,003,450
Total Research and Development Cluster			147,425,699	753,421,311
Student Financial Assistance Cluster (notes 2 through 5):				
U.S. Department of Education:				
Federal Work-Study Program		84.033	—	1,834,716
Federal Supplemental Educational Opportunity Grants		84.007	—	1,054,507
Federal Pell Grant Program		84.063	—	9,271,769
Federal Direct Loan Program		84.268	—	80,896,769
Federal Direct PLUS Loan Program		84.268	—	90,972,635
Federal Perkins Loan (FPL)		84.038	—	1,974,766
Total U.S. Department of Education			—	186,005,162
U.S. Department of Health and Human Services:				
Nursing Faculty Loan Program (NFLP)		93.264	—	795,593
Health Professions Student Loans, Including Primary Care Loans and Loans for Disadvantaged Students (HPSL)		93.342	—	533,745
Nursing Student Loans (NSL)		93.364	—	857,948
Total U.S. Department of Health and Human Services			—	2,187,286
Total Student Financial Assistance Cluster			—	188,192,448
U.S. Department of Commerce:				
Cluster Grants	ED20HDQ0200045	11.020	51,570	51,570
U.S. Department of Commerce Total			51,570	51,570
U.S. Department Of Defense:				
Language Grant Program	H98230-22-1-0048	12.900	—	61,547
U.S. Department of Defense Total			—	61,547
U.S. Department of Justice:				
Community-Based Violence Intervention and Prevention Initiative:				
Pass-through Dekalb County	15PBJA22GG04712CVIP	16.045	95,103	122,048
U.S. Department of Justice Total			95,103	122,048
U.S. Department of State				
AEECA/ESF PD Programs	SRB10023GR0085	19.900	26,204	62,244
U.S. Department of State Total			26,204	62,244

EMORY UNIVERSITY AND ITS SUBSIDIARIES
Supplementary Schedule of Expenditures of Federal Awards
Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
U.S. Department of Treasury Coronavirus State and Local Fiscal Recovery Funds Pass-through De Kalb County	SLFRP002	21.027	—	3,000,000
U.S. Department of Treasury Total			—	3,000,000
National Endowment for Humanities: Promotion of the Arts Grants to Organizations and Individuals	1886761-42-21	45.024	—	13,234
Promotion of the Humanities Division of Preservation and Access	PW-285174-22	45.149	—	925
National Endowment for Humanities Total			—	14,159
U.S. Department of Veterans Affairs: Legal Services for Veterans Grants	GA-256-LSV-191-22	64.056	—	67,562
Total AL No. 64.056			—	67,562
Contract	36C24721C0077	64.CTR	—	180,471
Contract	36C24722C0090	64.CTR	—	169,128
Contract	36C24724R0044	64.CTR	—	475,570
Contract	36C24E21D0032	64.CTR	—	6,224
Contract	508-21-2-144-0022	64.CTR	—	616,290
Total AL No. 64.CTR			—	1,447,683
U.S. Department of Veterans Affairs Total			—	1,515,245
U.S. Department of Health and Human Services: National Family Caregiver Support, Title III, Part E: Pass-through Atlanta Regional Commission	2301GAOASS	93.052	—	18,756
Total AL No. 93.052			—	18,756
Maternal And Child Health Federal Consolidated Programs	UC153079	93.110	—	6,285
Maternal And Child Health Federal Consolidated Programs	UH7MC30772	93.110	118,400	629,813
Pass-through Hemophilia of Georgia	H3024046	93.110	—	38,043
Total AL No. 93.110			118,400	674,141
Environmental Health Pass-through Hemophilia of Georgia	H30MC24046	93.113	—	8,227
Total AL No. 93.113			—	8,227
Emergency Medical Services for Children Pass-through Rhode Island Hospital	U0349671	93.127	250,385	464,789
Total AL No. 93.127	U03MC33155	93.127	—	(2,278)
			250,385	462,511
HIV-Related Training and Technical Assistance: Pass-through University of Washington	U1032104	93.145	—	1,272
Total AL No. 93.145			—	1,272
Scaling the National Diabetes Prevention Program to Priority Populations: Pass-through Amer Assoc of Diabetes Educators	NU58DP006361	93.261	—	10,816
Total AL No. 93.261			—	10,816
COVID-19 – Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Systems, Capacity and Security	NU14GH001238	93.318	177,669	1,824,198
Total AL No. 93.318			177,669	1,824,198
Epidemiology and Laboratory Capacity for Infectious Diseases (ELC): Pass-through Georgia Dept of Public Health	NU50CK000529	93.323	—	9,972
Total AL No. 93.323			—	9,972
The Healthy Brain Initiative: Technical Assistance to Implement Public Health Actions related to Cognitive Health, Cognitive Impairment, and Caregiving at the State and Local Levels: Pass-through Alzheimers Association	NU58DP006744	93.334	—	263,074

EMORY UNIVERSITY AND ITS SUBSIDIARIES
Supplementary Schedule of Expenditures of Federal Awards
Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through Alzheimers Association	NU58DP006912	93.334	—	7,641
Total AL No. 93.334			—	270,715
Public Health Emergency Response: Cooperative Agreement for Emergency Response:				
Public Health Crisis Response:				
Pass-through Kentucky Hospital Association	6 NU90TP922182-01-01	93.354	104,271	151,416
Total AL No. 93.354			104,271	151,416
Sickle Cell Treatment Demonstration Program:				
Pass-through University of Alabama Birmingham	U1EMCA42461	93.365	30,565	88,523
Total AL No. 93.365			30,565	88,523
National and State Tobacco Control Program				
Pass-through Georgia Dept of Public Health	NU58DP006828	93.387	—	70,617
Total AL No. 93.387			—	70,617
COVID-19 – Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health	NU50CK000617	93.421	70,646	1,215,892
Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health				
Pass-through Amer College of Preventive Medicine	NU38O3000289	93.421	—	2,126
Pass-through Amer College of Preventive Medicine	NU38OT000289	93.421	189,274	348,447
Total AL No. 93.421			259,920	1,566,465
The National Cardiovascular Health Program:				
Pass-through Kentucky Department for Public Health	NU58DP006612	93.426	—	202,732
Pass-through Minnesota Department of Health	NU58DP006522	93.426	—	3,209
Pass-through Tennessee Department of Health	NU58DP006552	93.426	—	78,774
Total AL No. 93.426			—	284,715
Networking2Save": CDC's National Network Approach to Preventing and Controlling				
Tobacco-related Cancers in Special Populations:				
Pass-through Patient Advocate Foundation	NU58DP006468	93.431	—	40,422
Total AL No. 93.431			—	40,422
The Innovative Cardiovascular Health Program:				
Pass-through Georgia Dept of Public Health	NU58DP006623	93.435	—	19,224
Pass-through Utah Department of Health	NU58DP006609	93.435	—	7,339
Pass-through Wisconsin Department of Health and Family	NU58DP006607	93.435	—	20,550
Total AL No. 93.435			—	47,113
Community-Based Child Abuse Prevention Grants:				
Pass-through Georgia Department of Human Services	42700-040-0000106749	93.590	4,898	66,090
Pass-through Georgia Department of Human Services	42700-040-0000112920-01	93.590	30,403	118,908
Total AL No. 93.590			35,301	184,998
Children's Justice Grants to States:				
Pass-through Georgia Department of Human Services	2201GACJA1	93.643	—	78,034
Pass-through Georgia Department of Human Services	42700-040-0000107717	93.643	—	1,543
Total AL No. 93.643			—	79,577
PPHF: Racial And Ethnic Approaches To Community Health Program Financed Solely By Public Prevention And Health Funds:				
Pass-through Georgia Dept of Public Health	NU58DP006580	93.738	—	8,899
Total AL No. 93.738			—	8,899
Medical Assistance Program (Medicaid Cluster):				
Pass-through Georgia Department of Behavioral Health	2305GA5MAP	93.778	—	360,997
Total AL No. 93.778			—	360,997

EMORY UNIVERSITY AND ITS SUBSIDIARIES
Supplementary Schedule of Expenditures of Federal Awards
Year ended August 31, 2024

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Opioid STR:				
Pass-through Atlanta Harm Reduction Coalition	H79T1083292	93.788	—	10,057
Total AL No. 93.788			—	10,057
COVID-19 - National Ebola Training and Education Center (NETEC)	NU38CK000481	93.825	—	1,899,174
National Ebola Training and Education Center (NETEC)	NU38CK000481	93.825	—	302,536
Total AL No. 93.825			—	2,201,710
Improving Epilepsy Programs, Services, and Outcomes through National Partnerships	NU58DP007543	93.850	—	245,275
Total AL No. 93.850			—	245,275
HIV Emergency Relief Project Grants:				
Pass-through Fulton County	HA89HA00007-32	93.914	—	1,686,322
Total AL No. 93.914			—	1,686,322
Grants To Provide Outpatient Early Intervention Services With Respect To HIV Disease	H7607848	93.918	—	637,593
Total AL No. 93.918			—	637,593
Assistance Programs for Chronic Disease Prevention and Control:	NU58DP007745	93.945	222,269	2,909,760
Total AL No. 93.945			222,269	2,909,760
Block Grants for Prevention and Treatment of Substance Abuse:				
Pass-through Georgia Department of Behavioral Health	B08TI084637	93.959	—	62,687
Total AL No. 93.959			—	62,687
Centers for Disease Control and Prevention Collaboration with Academia to Strengthen Public Health				
Pass-through De Beaumont Foundation	NE11OE000067-01-00	93.967	—	6,560
Total AL No. 93.967			—	6,560
Sexually Transmitted Diseases (STD) Provider Education Grants:				
Pass-through University of Washington	NU62PS924588	93.978	—	50,831
Total AL No. 93.978			—	50,831
Contract	1891136	93.CTR	—	1,321
Contract	75D30120C07672	93.CTR	—	1,300,086
Pass-through Assoc of State & Territorial Denta	5 NU58DP006573	93.CTR	—	1,317
Pass-through Georgia Department of Community Health	2017001	93.CTR	—	287,569
Pass-through North Central Health District	NU58DP007606	93.CTR	—	51,467
Total AL No. 93.CTR			—	1,641,760
U.S. Department of Health and Human Services Total			1,198,780	15,616,905
Total Non-Research and Development Programs			1,371,657	20,443,718
Total Student Financial Assistance Cluster and Non-Research and Development Programs			1,371,657	208,636,166
Total Expenditures of Federal Awards			\$ 148,797,356	962,057,477

See accompanying notes to Supplementary Schedule of Expenditures of Federal Awards and Schedule of Cash Receipts and Expenditures of State of Georgia Awards.

**SUPPLEMENTARY SCHEDULE OF CASH RECEIPTS AND
EXPENDITURES OF STATE OF GEORGIA AWARDS**

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Supplementary Schedule of Cash Receipts and Expenditures of State of Georgia Awards

Year ended August 31, 2024

State of Georgia contract number	State of Georgia Agency	Program title	Cash receipts	Expenditures
15PBJA22GG04712CVIP	DeKalb County	DeKalb County Community-Based Violence Intervention Plan	\$ 37,196	122,048
2017001	Georgia Department of Community Health	Evaluation Services for the Planning for Healthy Babies Family Planning Waiver Program	6,920,776	521,104
2201GACJA1	Georgia Department of Human Services	Summer Child Advocacy Program	25,585	78,034
2305GA5MAP	Georgia Department of Behavioral Health	2022-2023 Emory Neuro Developmental Exposure Clinic (ENEC)	361,000	494,754
2305GA5MAP	Georgia Department of Behavioral Health	2023-2024 Emory Neuro Developmental Exposure Clinic (ENEC)	270,750	494,754
40500-036-22223686	Georgia Dept of Public Health	Operation of the Statewide Georgia Comprehensive Cancer Registry	590,844	791,256
42700-040-0000106749	Georgia Department of Human Services	Center for Family Resilience	33,690	66,090
42700-040-0000107717	Georgia Department of Human Services	Summer Child Advocacy Program	54,319	1,543
42700-040-0000112920-01	Georgia Department of Human Services	Center for Family Resilience	66,523	118,908
69A3752030000405BGAH	Governors Office of Highway Safety	2023 Statewide Seatbelt Use Survey	149,492	42,925
69A3752330000405BGAH	Governors Office of Highway Safety	2024 Statewide Seatbelt Use Survey	66,935	239,126
B08TI084637	Georgia Department of Behavioral Health	2022-2023 Fetal Alcohol and Drug Screening project: MSACD	126,239	130,525
B08TI084637	Georgia Department of Behavioral Health	2023 Opioid Prevention Curriculum	79,879	130,525
HA89HA00007-32	Fulton County	Ryan White HIV/AIDS Treatment	3,826,176	1,686,322
NU50CK000529	Georgia Dept of Public Health	GA DPH NWSS Training	84,061	9,972
NU50CK000626	Georgia Dept of Public Health	Emory University Genomic Survey	18,540	414,173
NU50CK000645	Georgia Dept of Public Health	EIP	2,492,212	5,350,569
NU58DP006352	Georgia Dept of Public Health	Operation of the Statewide Georgia Comprehensive Cancer Registry	55,543	(302)
NU58DP006580	Georgia Dept of Public Health	Evaluation of the REACH Grant	(18,161)	8,899
NU58DP006623	Georgia Dept of Public Health	GA Department of Health_DPP Support_1817	52,619	19,224
NU58DP006828	Georgia Dept of Public Health	BreatheEasy Recognition Program	65,000	70,617
U3REP150546	Georgia Dept of Public Health	Hospital Preparedness Program - HPP Carryover Authorization	76,453	76,453
			<u>\$ 15,435,671</u>	<u>10,867,519</u>

See accompanying notes to Supplementary Schedule of Expenditures of Federal Awards and Schedule of Cash Receipts and Expenditures of State of Georgia Awards.

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Notes to Supplementary Schedules of Expenditures of Federal Awards and Cash Receipts and Expenditures of State of Georgia Awards

Year ended August 31, 2024

(1) Summary of Significant Accounting Policies

The accompanying supplementary schedule of expenditures of federal awards (the Schedule) includes the federal grant activity of Emory University and its subsidiaries (the University) and is presented on the accrual basis of accounting. The Schedule presents all grants, contracts, and similar agreements entered into directly between agencies and departments of the federal government and subawards to the University from nonfederal organizations pursuant to federal grants, contracts, and similar agreements. The Schedule also presents awards passed through from the University to other nonfederal subrecipient organizations. The information in the Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Therefore, some amounts presented in the Schedule may differ from amounts presented in, or used in the preparation of, the consolidated financial statements.

The accompanying supplementary schedule of cash receipts and expenditures of State of Georgia awards includes expenditures incurred by the University and grant revenues received from State of Georgia agencies under various state contracts.

Negative balances represent programs with unfunded expenditures prior to normal closeout procedures, which were subsequently transferred to unrestricted cost centers.

(2) Basis of Accounting

Expenditures for federal student financial assistance programs are recognized as incurred and include grants to students under the Federal Pell Grant and Federal Supplemental Educational Opportunity Grant Programs, student earnings under the Federal Work Study Program, and administrative cost allowances, where applicable. Expenditures for loans related to the Federal Direct Student Loan Programs (FDSLP) are reported in the Schedule when disbursed.

New loans made during the fiscal year and loans from previous fiscal years for which the University has continuing compliance requirements to adhere to are reported in the Schedule. Expenditures for other federal awards are recognized as incurred using the cost accounting principles contained in Uniform Guidance. Under these cost principles, certain types of expenses are not allowable or are limited as to reimbursement.

(3) Federal Loan Programs

Most federal financial assistance is in the form of cash awards. However, there are a number of federal programs that do not involve cash transactions with the University. These noncash transactions in which the University obtains other assistance are the FDSLP and revolving loan programs, such as the Federal Perkins Loan Program.

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Notes to Supplementary Schedules of Expenditures of Federal Awards and Cash Receipts and Expenditures of State of Georgia Awards

Year ended August 31, 2024

The loans advanced and related expenditures are as follows for the various student loan programs:

	<u>AL #</u>	<u>Amount</u>
Federal Direct Student Loan Programs:		
Student loans advanced:		
Subsidized Stafford Loan Program	84.268	\$ 78,366,258
Unsubsidized Stafford Loan Program	84.268	<u>2,530,511</u>
Total Direct Stafford Loan Program		80,896,769
Federal Direct PLUS Loan Program	84.268	<u>90,972,635</u>
Total Federal Direct Student Loan Programs		<u>\$ 171,869,404</u>

The Federal Perkins Loan (FPL) program, Nurse Faculty Loan Program (NFLP), Health Professions Student Loans (HPSL) program, and Nursing Student Loans (NSL) program are administered directly by the University, and balances and transactions relating to these programs are included in the University's consolidated financial statements. The amounts presented on the Schedule include the FPL, NFLP, HPSL, and NSL outstanding as of August 31, 2023 plus any loans issued in the current year and administrative charge, as applicable. FPL, NFLP, HPSL, and NSL outstanding at August 31, 2024 totaled \$1,368,847, \$757,438, \$451,709, and \$709,892, respectively. NFLP, HPSL, and NSL issued \$501,276, \$54,491, and \$114,152 in new loans during the year ended August 31, 2024. No FPL were issued in the current year.

The University is responsible for the performance of certain administrative duties with respect to the FDSLPL. It is not practicable to determine the balance of loans outstanding to students and former students of the University under this program as of August 31, 2024. These loans are not included in the University's consolidated financial statements.

(4) Matching

Under the Federal Supplemental Educational Opportunity Grant Program, the University matched \$196,376 in funds awarded to students for the year ended August 31, 2024 in addition to the federal share of expenditures included in the Schedule.

Under the Federal Work Study Program, the University matched \$416,501 in total compensation to students for the year ended August 31, 2024 in addition to the federal share of expenditures included in the Schedule.

EMORY UNIVERSITY AND ITS SUBSIDIARIES

**Notes to Supplementary Schedules of Expenditures of Federal Awards and
Cash Receipts and Expenditures of State of Georgia Awards**

Year ended August 31, 2024

(5) Administrative Cost Allowance

The University recorded an administrative cost allowance of \$142,945 for the year ended August 31, 2024. This amount is included in the Schedule as federal expenditures under the Federal Work Study Program.

(6) Indirect Costs

For the year ended August 31, 2024, the University did not elect to use the 10% de minimis indirect cost rate permitted by the Uniform Guidance.

UNIFORM GUIDANCE REPORTS



KPMG LLP
Suite 2000
303 Peachtree Street, N.E.
Atlanta, GA 30308-3210

**Independent Auditors' Report on Compliance for Each Major Federal Program;
Report on Internal Control Over Compliance; and Report on Supplementary
Schedules of Expenditures of Federal Awards Required by the Uniform Guidance
and Cash Receipts and Expenditures of State of Georgia Awards**

The Board of Trustees
Emory University:

Report on Compliance for Each Major Federal Program

Opinion on Each Major Federal Program

We have audited Emory University and its subsidiaries' (the University) compliance with the types of compliance requirements identified as subject to audit in the *OMB Compliance Supplement* that could have a direct and material effect on each of the University's major federal programs for the year ended August 31, 2024. The University's major federal programs are identified in the summary of auditors' results section of the accompanying schedule of findings and questioned costs.

In our opinion, the University complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended August 31, 2024.

Basis for Opinion on Each Major Federal Program

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (GAAS); the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. Code of Federal Regulations Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Our responsibilities under those standards and the Uniform Guidance are further described in the Auditors' Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of the University and to meet our other ethical responsibilities, in accordance with relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on compliance for each major federal program. Our audit does not provide a legal determination of the University's compliance with the compliance requirements referred to above.

Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules and provisions of contracts or grant agreements applicable to the University's federal programs.

Auditors' Responsibilities for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on the University's compliance based on our audit. Reasonable assurance is a high level of assurance but is not



absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about the University's compliance with the requirements of each major federal program as a whole.

In performing an audit in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the University's compliance with the compliance requirements referred to above and performing such other procedures as we considered necessary in the circumstances.
- Obtain an understanding of the University's internal control over compliance relevant to the audit in order to design audit procedures that are appropriate in the circumstances and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of the University's internal control over compliance. Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

Other Matters

The results of our auditing procedures disclosed an instance of noncompliance which is required to be reported in accordance with the Uniform Guidance and which is described in the accompanying schedule of findings and questioned costs as item 2024-001. Our opinion on each major federal program is not modified with respect to this matter.

Government Auditing Standards requires the auditor to perform limited procedures on the University's response to the noncompliance finding identified in our compliance audit described in the accompanying schedule of findings and questioned costs. The University is also responsible for preparing a corrective action plan to address the audit finding included in our auditors' report. The University's response and corrective action plan were not subjected to the other auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response or the corrective action plan.

Report on Internal Control Over Compliance

Our consideration of internal control over compliance was for the limited purpose described in the Auditors' Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance and therefore, material weaknesses or significant deficiencies may exist that were not identified. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, as discussed below, we did identify a certain deficiency in internal control over compliance that we consider to be a significant deficiency.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned



functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance. We consider the deficiency in internal control over compliance described in the accompanying schedule of findings and questioned costs as item 2024-001, to be a significant deficiency.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

Government Auditing Standards requires the auditor to perform limited procedures on the University's response to the internal control over compliance finding identified in our audit described in the accompanying schedule of findings and questioned costs. The University is also responsible for preparing a corrective action plan to address the audit finding included in our auditors' report. The University's response and corrective action plan were not subjected to the other auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response or the corrective action plan.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

Report on Supplementary Schedules of Expenditures of Federal Awards Required by the Uniform Guidance and Cash Receipts and Expenditures of State of Georgia Awards

We have audited the consolidated financial statements of the University as of and for the year ended August 31, 2024, and have issued our report thereon dated December 18, 2024, which contained an unmodified opinion on those consolidated financial statements. Our audit was performed for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying supplementary schedules of expenditures of federal awards and cash receipts and expenditures of State of Georgia awards are presented for purposes of additional analysis as required by the Uniform Guidance and the State of Georgia, respectively, and are not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with GAAS. In our opinion, the schedules of expenditures of federal awards and cash receipts and expenditures of State of Georgia awards are fairly stated in all material respects in relation to the consolidated financial statements as a whole.

KPMG LLP

Atlanta, Georgia
May 19, 2025

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Schedule of Findings and Questioned Costs

Year ended August 31, 2024

(1) Summary of Auditors' Results

- (a) The type of auditors' report issued on whether the consolidated financial statements were prepared in accordance with U.S. generally accepted accounting principles: **Unmodified**
- (b) Internal control deficiencies over financial reporting disclosed by the audit of the consolidated financial statements:
 - Material weaknesses: **No**
 - Significant deficiencies: **None reported**
- (c) Noncompliance material to the consolidated financial statements: **No**
- (d) Internal control deficiencies over major program disclosed by the audit:
 - Material weaknesses: **No**
 - Significant deficiencies: **Yes, see finding 2024-001**
- (e) Type of auditors' report issued on compliance for major programs: **Unmodified**
- (f) Any audit findings, which are required to be reported under Section 2 CFR 200.516(a) of Uniform Guidance: **Yes, see finding 2024-001**
- (g) Major programs:
 - **Research and Development Cluster** – various AL numbers
 - **Student Financial Assistance Cluster** – AL# 84.033, 84.007, 84.063, 84.268, 84.038, 93.264, 93.342, 93.364
 - **Coronavirus State and Local Fiscal Recovery Funds** – AL# 21.027
- (h) Dollar threshold used to distinguish between Type A and Type B programs: **\$3,000,000**
- (i) Auditee qualified as a low-risk auditee: **Yes**

(2) Findings Relating to the Consolidated Financial Statements Reported in Accordance with *Government Auditing Standards*

None

(3) Findings and Questioned Costs Relating to Federal Awards

Finding 2024-001: Cash Management

Federal Agency: U.S. Department of Education

Federal Program: Federal Direct Student Loans (ALN 84.268)

Award Year: September 1, 2023 to August 31, 2024

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Schedule of Findings and Questioned Costs

Year ended August 31, 2024

Criteria or Specific Requirement

Per 2 CFR 200.303, a non-Federal entity must establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award.

Per 34 CFR 685.300(b)(50), schools participating in the Direct Loan program are required to perform monthly Direct Loan reconciliations. Electronic Announcements DL-22-07 and GENERAL-22-86 explain that a school must reconcile the funds it received from G5 with actual disbursement records the school submitted to Common Origination and Disbursement (COD). Each month, COD sends the school a School Account Statement, which is the Department of Education's (ED's) official record of the school's cash and disbursement records and identifies the difference between the net draws from G5 and the actual disbursement information reported to COD by the school. The school is required to account for any differences by reconciling ED's records (School Account Statements) with the school's financial and business records.

Condition Found

The reconciliation between ED's records (School Account Statements) and the school's financial and business records were prepared timely throughout the year; however, the differences identified in the reconciliation were not accounted for and no review or segregation of duties was documented as part of that process.

Cause and Possible Asserted Effect

The control to ensure that the reconciliation between the ED's records and the school's financial and business records was performed and reviewed by an individual separate than that who prepared it and that any differences identified were investigated was not operating effectively. As a result and based on the documentation provided, the monthly reconciliations were not reviewed by an individual separate than that who prepared them and any differences identified during the reconciliation process were not investigated.

Questioned Costs

None.

Whether the Sample Was a Statistically Valid Sample

The sample was not intended to be, and was not, a statistically valid sample.

Identification of Whether the Audit Finding Was a Repeat Finding in the Immediately Prior Audit

Not at repeat finding.

Recommendation

We recommend that the University strengthen controls over the management review process over the monthly reconciliations between the ED's records and the school's financial and business records to ensure there is a segregation of duties in the review and approval process, and any differences within management's prescribed level of precision are investigated and documented.

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Schedule of Findings and Questioned Costs

Year ended August 31, 2024

View of Responsible Officials

The finding was primarily caused by an unforeseen staff shortage. This led to one person being the preparer and reviewer with no segregation of duties. Although the differences were identified, they were not documented on the reconciliation form.

To resolve this finding, the Office of Financial Aid (OFA) has hired new employees and implemented a new process. The Financial Operations Team is now fully staffed with two senior accountants and one senior director. As part of our ongoing efforts to strengthen internal controls and ensure the integrity of our processes, we have implemented a segregation of duties framework. This approach will help us clearly define roles and responsibilities, ensuring that critical tasks are divided among different individuals. By doing so, we will meet compliance requirements, reduce errors, and promote accountability within our office. One senior accountant will prepare the monthly reconciliation by the 10th of the following month. The senior director will review the monthly reconciliation by the 15th of the following month. In the absence of the initial preparer/reviewer, the executive director of OFA will take on the reviewer role.

We understand that proper documentation is crucial for clarity, tracking, and future troubleshooting. The differences/discrepancies that are identified in the reconciliation process will be accounted for through proper documentation on the reconciliation form, which will be reviewed/investigated by a second reviewer.

The Financial Operations Team within the OFA will continue to create timely and accurate monthly Federal Direct Student Loan reconciliations that compare OPUS (Emory), General Ledger (Emory), Student Account Statement-SAS (U.S. Department of Education), and GS (U.S. Department of Education).